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Abstract
Opioid dependence has reached epidemic levels in the United States and around the world. With
the increased prescribing of opioid pharmaceuticals and the influx of inexpensive heroin, the
health care cost to society has topped $72.5 billion annually (Murphy et al., 2016). Opioid
overdose deaths have now surpassed motor vehicle deaths and have tripled since 1990. In some
age groups opioid overdose is the leading cause of death. This study seeks to analyze the only
field that directly treats this primary brain disease: medication assisted treatment for opioid
dependence. The three primary participants in this partnership include: (a) doctors and allied
medical providers; (b) substance abuse counselors known in Washington State as Chemical
Dependency Professionals (CDPs); and (c) clients affected by opioid dependence. Together they
combine medical approaches and psychosocial counseling with clients to attain the goal of
recovery. Attitudes and beliefs of these three groups of individuals vary, as do their views toward
the medications currently being utilized in the treatment field. This study measures these
differences and discusses the implications for clients, medical providers, and CDPs. It was
hypothesized that differences in opinions across the three groups about medication assisted
treatment, length of time clients should be on medications, and recovery limit positive outcomes.
Data were collected via survey from more than 250 clients being treated for opioid dependency
and from over 200 professionals (medical and counseling). Descriptive and comparative
ANOVA and t-test statistics were used in the analysis. Results indicate that there remain large
differences in beliefs and attitudes among the medical providers, CDPs, and clients on key issues
related to medication assisted treatment. The gap appears to be especially evident when
comparing the two professional groups who treat clients with opioid use disorder. CDPs and
medical providers are working from a different set of paradigms and approaches especially as
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related to their beliefs about the use of medications. CDPs are generally less supportive of
medication assisted treatment. Medical providers and CDPs disagree about the length of time
clients should be on medications and the long term goals of opioid dependence treatments. In
addition clients in opioid treatment programs that use methadone have significantly different
views on many issues from those who use buprenorphine/naloxone (Suboxone®). Findings from
this study can be used to improve the services provided to clients to increase provider awareness
of the ways that attitudes and perceptions impact treatment outcomes. The electronic version of
this dissertation is at AURA: Antioch University Repository and Archive,
http://aura.antioch.edu/ and OhioLINK ETD Center, https://etd.ohiolink.edu
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Summary Statement
Medication assisted treatment in the field of opioid dependence is a growing field of
major importance to the health of many patients who are addicted to prescription pharmaceutical
narcotics, and/or heroin. The incidence of impairment for those people addicted to opioids has
continued to rise at an alarming rate, with the results being catastrophic for individuals, their
families, and overall public health. The focus of this dissertation project has been on analyzing
the three important individuals involved in the complex process of treating and overcoming this
disease process: the physicians and medical providers, the chemical dependency professionals
(future reference will be CDPs as they are certified in Washington state, however in other states
addiction counselors may be known by other designations), and the patient who is opioid
dependent and most affected by this disease. Together they make up the “three legged stool” of
recovery from this debilitating illness. The importance of these three groups working together for
positive outcomes cannot be overstated. Problems arise when medical providers, CDPs, and
clients have divergent attitudes toward the appropriate use of various medications used in
medication assisted treatment for opioid dependence. This study has collected and analyzed the
attitudes, beliefs, and experience of these individuals as they relate to opioid dependence and the
treatment and recovery process for the purpose of identifying convergences and divergences
among the groups that have the potential to impact both positively and negatively upon treatment
outcomes.
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Chapter I: Introduction
There is both a national and worldwide opioid epidemic occurring today. The record
number of prescriptions being written for painkillers, and the influx of less expensive heroin has
proven to be a deadly combination. Drug overdose deaths have more than tripled in the United
States since 1990, and studies by the Centers for Disease Control and Prevention attribute more
than half of those deaths to prescription painkillers (Paulozzi, Budnitz, & Xi, 2006). Many of
these people are our nation’s most precious resource. Our future leaders in the 15 to 24 age
group remain the highest risk group for death due to overdose. Treatment admission for opioid
dependence has risen in some areas of the country to account for over 50% of all admissions
(Volkow, Frieden, Hyde, & Cha, 2014a).
The problem often begins with easy access to pharmaceutical prescription medications,
mainly opioid based pain relievers. These are easily attained through raiding their parent’s
cabinets, their grandparent’s cabinets or getting it off the street. Opioid dependence, however,
does not just start with unlawful acquisition of prescription painkillers. One of my current clients
reported to me, “I never would have thought that in five years I would be injecting heroin in the
bathroom somewhere, in a bathroom stall, or finding dirty needles off the group and using them
because I couldn’t find any cheaper needles” (personal communication, October 2015.) Many
people with opioid addiction journeys begin with simple back injuries, a trip to the dentist office,
or some physical injury that results in an opioid prescription for their pain. Opioids relieve pain
and fill a medical need during and after surgeries, injuries, or throughout the rehabilitative
process of many medical conditions. However these same opioids that are prescribed for good
intention and aimed at positive outcomes quickly become a trap of addiction from which people
cannot easily escape. Physical and psychological dependence and an increase in tolerance follow
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and soon people become dependent on the opioids just to feel normal because the physical
withdrawal from opioids is one of the worst of all drugs. “I thought for sure I was going to die, I
was puking, had nausea & diarrhea, was experiencing hot and cold flashes, my entire body
ached, and I felt like I had just contracted the worse flu In the world,” Alicia told me last week
when I visited her in detox.
People with opioid dependence speak with certain nostalgia much like a child speaks of
their first puppy, when referring to their use of opioids. They say that opioid dependence is the
hardest habit they’ve had to shake, and it works its way into your soul and has a grip on you in a
way that is difficult to put into words. “Opioid addiction is like no other and it has the ability to
grab a hold of you, not let go, and take control over your life,” Bob, a recovering heroin addict
told me.
Opioid dependence is a major public health concern and remains primarily an untreated
or undertreated medical condition in the United States. It is estimated that in 2012 there were
over 560,000 individuals who used heroin, but an even more alarming 11.4 million Americans
that had non-medical use of prescription opioids (Scheibe & Week, 2016). The economic cost
is estimated to top $21 billion a year and the far reaching human implications are even more
staggering. Opioid dependency is associated with several well-known health risks including
Hepatitis B, & C, along with an increased spread of HIV infection. This appears to be only the
tip of the iceberg from the standpoint of opioid abuse and dependence as this modern epidemic
continues to be on the rise in 2015–2016. Worldwide the scope of the current problem is even
more alarming. The United Nations Office on Drugs and Crime notes that opioids, especially
heroin, are the main problem drugs globally (United Nations Office on Drugs and Crime,
2010). They estimate that there are 15.6 million opioid abusers worldwide. The World Health
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Organization (WHO) estimates that there are 12.6 million injection drug users worldwide.
Injection drug users represent the single highest risk for HIV infection. According to the Joint
United Nations program on HIV/AIDS, injection drug use accounts for up to 80% of HIV
infections in Europe and Central Asia (Mann & Tarantola, 1996).
The medical cost and implications of opioid dependence are outweighed by the
devastating social consequences that accompany this chronic disease process. Broken families,
divorce, parentless children, incarceration, overdose deaths, child abuse/neglect, and
socioeconomic ruin make up but a short starter list of what the opioid dependent individual
experiences with their impulsive and compulsive pursuits. Opioids impact the brain, leading to
temporary feelings of intense pleasure. Dependence to opioids can develop very quickly, even
with minimal use. This opioid dependence can be physical, in that a habitual user’s body
craves the drug. It can also be mental, in that a user consciously desires the drug’s effects. A
person who is dependent on opioids may do whatever it takes to get more of the drug,
regardless of the risks or consequences. The consequences of the opioid dependence are severe
to both the individual who suffers from the disorder and to society. For individuals these
include increased morbidity and overdose deaths, hepatitis C, HIV, liver failure, and infections
and more. Psychosocially the impact is even great as people with opioid addiction lose their
jobs, their families, their homes, and become involved in the justice system because of their
involvement in illegal behaviors in order to support their dependence to opioids. The stories, as
told through the eyes of those who are dependent, tell the true physical, emotional, and mental
toll that their opioid dependence have caused. James told me, “I have no life now, where once
I had a family, a home, a job, and some peace of mind. Now I am just a tortured soul that has
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lost everything. My only hope is that I will get caught ripping off people and put in jail. It may
save my life.”
The relapse rate and treatment outcomes for opioid dependence are very grim. Some
studies suggest a 95% recidivism rate for people with opioid dependence that complete
traditional treatment programs (Center for Substance Abuse Treatment, 2005). Medical experts
and those working in the addictions field recognize the definition for opioid dependence from the
National Institute on Drug Abuse (NIDA)—a chronic, relapsing brain disease characterized by
compulsive drug-seeking and use despite harmful consequences and by long-lasting structural
and functional changes in the brain. Since the problem is so large, the recovery rates so low, and
the lifelong consequences so dire for both the individuals and society as a whole, the importance
of continued research in this area to improve outcomes is paramount. The purpose of this study
was to add to the body of knowledge related to this fast growing societal problem, and work to
identify how the three most important players in this epidemic can work together to improve
outcomes.
Medication assisted treatment for opioid dependence has been around for over half a
century since 1962 when Dole and Nyswander carried out early research with morphine as a
replacement therapy for opioid dependence (Dole & Nyswander, 1980). Researchers quickly
realized that morphine was not a good choice as a medication for opioid maintenance treatment
because of the short half-life, and the decrease in social functioning and the sedating effects to
patients. Methadone was shown to be effective in early trials and by the early 1970s became the
treatment of choice for opioid dependence. Methadone maintenance treatment became a major
public health initiative to treat opioid addiction. Dr. Jerome Jaffe headed the Special Action
Office for Drug Abuse Prevention in the Executive Office of the White House in the early 1970s.
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Dr. Jaffe's office oversaw the creation of a nationwide, publicly funded system of treatment
programs for opioid dependence. Buprenorphine and naltrexone then joined the FDA’s approved
list of medications for treating opioid dependence and along with methadone these now represent
the current “big three” medications used throughout the United States and the world in
medication assisted treatment (Fiellin & O'Connor, 2002).
Even though medication assisted treatment has been around for the past several decades,
the rise in the opioid epidemic problem coupled with the approval of new medications has
combined to substantially increase the number of people being currently treated by private
physicians with buprenorphine/naltrexone and in opioid treatment program clinics that
primarily use methadone throughout the United States. Buprenorphine/naltrexone is known to
the general public as Suboxone®. However, Suboxone® is a brand name. To avoid using a
brand name and for ease of reference and understanding the generic shortened term, bup/nal,
will be used throughout this paper to refer to this medication. By some estimates the number of
clients in methadone maintenance has remained stable over the last 10 years at around 200,000
clients in the United States whereas buprenorphine, which has only been clinically approved
since 2002, now boasts over 650,000 clients engaging in this form of treatment nationwide.
Medication assisted treatment, despite its popularity and efficacy, continues to be challenged by
old attitudes and traditional paradigms of “abstinence based addiction treatment” models. In
2015 we can use all the technology, see the clinical trials of the efficacy of medication assisted
treatment, and addiction counselors, CDPs, social workers, and other health care providers still
want to know when these clients will get off their medications and become truly “drug free.”
The treatment and recovery issues that continue to surface reflect deep-seated attitudes that
clients are not “successful” because they require continuous medications to remain opioid free.
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During data collection at the opioid treatment program that administers bup/nal in October 2015
one client reported, “I think I want to get off suboxone because even though it has changed my
life. I keep being asked by my family and my counselor when I am going to be drug free. Just
when I am feeling stable and having the most time clean I have had ever, it feels like it is not
good enough. I am tired of this and just want to not take it anymore [sic].” Clients have
reported that they still feel stigmatized by being on this accepted form of medications, and that
they get referred to as “weak-willed” or “unmotivated” because they are receiving medication
assisted treatment. CDPs have also made statements that reflect their resistance in supporting
their clients who attend the clinic and are on medications. At a recent workshop with over 200
Washington State CDPs on the pros and cons of medication assisted treatment, the sentiments
were captured in the following questions: Why not teach people how to use drugs safely and
not use pharmaceuticals? What is the long term goal of medication assisted treatment and when
should clients be weaned off the medications? How can medication ultimately end the addiction
process? Do clients really have to stay on these medications and why can’t they be taken off of
them after they are stable? Isn’t the goal to be totally drug-free and don’t you think some of
these clients are just using the medication as a crutch because they are not motivated to be
clean? [Sic] (2014 Washington State Warm Beach Counselor Retreat).
This is only a short list of the treatment issues involved, explaining why more research
is needed in order to bring to light the underlying issues, biases, and attitudes of providers that
are a key link in clients’ successful recovery. The three legs of this important stool are the
(a) medical provider or prescribing physician and mid-level medical providers, (b) CDPs, and
(c) opioid dependent clients who suffer and are looking to overcome the disease and get into
recovery. The clients who suffer are the most important people in this triangle. They are the
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ones that have been impaired and are facing severe life consequences, and they deserve
individualized and professional support to overcome this affliction. If these three parties do not
work closely together and share the same goals then positive treatment outcomes are not
attained. The wide variety of training, professional backgrounds, personal experiences, and
underlying biases represent one of the largest challenges facing these medical providers, CDPs
and their clients.
Positionality
I have been a certified CDP in the state of Washington for the past 28 years. I have also
worked as an addiction specialist and CDP for the Lummi Nation, a Native American sovereign
nation located in the NW corner of the United States. I am currently the program director of the
Lummi nation’s “Healing Spirit Clinic” opioid treatment program. We are a state and federally
certified program that has been open since January 2013. The Healing Spirit Clinic is licensed
to serve up to 500 clients, with a current client load of 356 active participants. All participants
are required to meet criteria for “opioid dependence” based on DSM V criteria and must be
enrolled as a Native American in a federally recognized tribe. We treat patients with
buprenorphine/naloxone (Suboxone®) or naloxone only. We do not treat with methadone. We
are one of the only programs operating this way in the United States. Most opioid treatment
programs operate as methadone maintenance programs and offer only methadone as their
primary medication. There are over 1,200 of these clinics nationwide, yet only three that we
know of offer the modality that the Healing Spirit Clinic does. I am involved as a member of
the Washington State Association for the Treatment of Opioid Dependence. This unique role
that our clinic plays in the opioid treatment field has been recognized by our colleagues. As a
result we have many Native American tribes and other providers consulting and visiting us,
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interested in how we are dealing with the opioid problem on the Lummi Reservation. We have
quarterly meetings with our association and all other state opioid treatment programs to discuss
issues relating to best practice, quality improvement, diversion, overdose, DEA compliance,
current trends, clinical issues, and all other concerns related to our practice as opioid
replacement providers.
Because of this position I am also offered a unique and integral perspective of treatment
and recovery issues as they relate to opioid dependence. My current job offers me a front seat
view of life in the trenches of opioid dependence and treatment, and due to my experience and
background I interact daily with prescribing physicians, dosing nurses, clients, and addiction
professionals (CDPs) that provide the psychosocial support in order to attain the goal of
recovery and abstinence. The issues related to both treatment and recovery are complicated. In
surveying the experiences and attitudes of what I call the big three (medical providers, CDPs,
and clients) and emphasizing the importance of their forming a good working team, I am
drilling down into the deeper core issues that are, in many cases, the barriers to better outcomes
and compassionate care for affected individuals.
I come from a training and experiential background that was philosophically built on a
total abstinence mindset. The foundational beliefs and ways of practicing addiction treatment
for the first 24 years of my Chemical Dependency Professional certification were seriously
challenged. A major paradigm shift was necessary, along with an open mind and continued
study in order to adjust to the challenges and changes that lie ahead. I needed to address current
best practice and adjust to the state of opioid addiction treatment practices. I saw the difficulty
some of my colleagues and fellow addiction treatment specialists were having adapting to the
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new way of thinking. Using an opioid substitute to treat the substance abuse felt like cheating
on a test and challenged the ethical and moral foundation of what I felt “recovery” was.
Medication assisted treatment and traditional methadone treatment carried with it a
stereotype of failed attempts to be clean and sober, and a settled philosophy of harm reduction.
I was challenged to continue to change with the times or face being left behind and stalled with
old ways of thinking. Doing this critical review of literature and research in the opioid
treatment field aided positively to my ever-changing mindset. I learned that the various
treatments were not meant to be in opposition to each other, and that I did not need to find out
which treatment was more effective than the next, but rather how to individualize the treatment
approaches to better serve those affected.
One size does not fit all. I had many personal biases as I set about reading for this
dissertation work and I soon discovered how misdirected my thinking was. I had failed to
realize and understand a basic foundational principle that I now will call “recovery potential.”
Much like the concept of human potential, recovery potential encompasses all that is possible
for individuals in their personal and private journeys on the road to wellness. Dogmatic
approaches that only saw complete and total abstinence from all substances in order to be
successful in recovery were missing the mark. As a result of this research process I am a better
Chemical Dependency Professional, more open-minded and understanding of each individuals
struggle. It has helped me to better serve those who reach out, to have a more emphatic and
compassionate approach, and to celebrate success with individuals who seek to change. I am a
better and more rounded clinician now and have a better grasp on both the questions and
answers when it comes to opioid addiction and treatment.
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Research Questions
There were five research questions for this inquiry:
1. What attitudes, beliefs, and practices do medical providers, chemical dependency
professionals, and clients have related to medication assisted treatment of opioid
dependence?
2. To what degree are the views and practices of each of the three groups different from
those of the other groups?
3. In what ways are the views and practices of medical providers, chemical dependency
professionals, and clients similar or different?
4. What underlying beliefs and philosophies explain the similar or different views of the
three groups?
5. What implications do these differences and similarities have for the opioid
dependence treatment field?
Based on my professional experience my hypothesis is that physicians and their opioid
dependent clients are more accepting of medication assisted treatment than are CDPs. I have
conducted a mixed method research design that utilized surveys that included both quantitative
data and qualitative data collection and analysis. Medical providers and Washington State CDPs
completed voluntary and anonymous surveys on line after being properly identified and invited
to participate. Methadone and bup/nal opioid treatment programs clients were administered paper
and pencil surveys at two participating clinics.
Justification for Study
The most important part of opioid addiction and recovery is providing supportive and
effective treatments to opioid dependent clients so they can free themselves from the
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overwhelmingly strong grip of opioid dependence. The negative impacts of opioid dependence
on one’s life, family, and the community one resides in are well documented. From reduced life
spans, the spreading of communicable diseases, lifelong legal problems, destruction of the
family unit, physical, medical, and moral degradation, just to name a few, opioid dependence
shatters and diminishes lives.
Positive outcomes for opioid dependence continue to be the focus of opioid treatment
centers throughout the United States and the world. Any factors that can aid in the
understanding of this complex addictive dynamic will further positive outcomes. The interplay
that takes place between the medical providers (doctor, physician assistant, and nurse
practitioner), the active opioid dependent client, and the CDPs who provide psychosocial
support is worthy of further study. Most reviews in the opioid treatment field concern
themselves with the “effectiveness” of the medication involved in treating active opioid
dependent individuals and the counseling approaches applied. Studies tend to look at positive
outcomes regarding those patients who remain engaged in treatment services and who cut down
their negative behaviors that are associated with using heroin or other opioids. This study aims
to go a step further to focus on the underlying attitudes, beliefs, and mindsets of the three
groups involved in the recovery process for opioid dependence. It is important that these three
groups of people, who are working toward the common goal of recovery for the suffering
individual, be on the same page on important and key issues regarding opioid recovery. As a
28-year addiction professional and the program director of an opioid treatment program, I often
hear the disparity in approaches and attitudes between these three groups. For instance, CDPs
often express the belief that clients should be taken off medications when they are doing well in
their recovery. The medical providers on the other hand consult with their clients about their
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medications and do not normally urge clients to discontinue medications. The suffering
individuals are often caught in the middle of these divergent views and ultimately have to
negotiate their way through this labyrinth of varying viewpoints.
The field of addiction counseling has its roots and foundation in a paradigm that demands
complete and total abstinence from all substances in order to be considered “in recovery” from
active addiction. This mindset is especially prevalent when it comes to medication assisted
treatment and opioid dependence. My research focuses on the similarities and differences in
perspective about medication assisted treatment. In my role as opioid treatment program sponsor
and addiction specialist, I hear patients relate the mixed message that they encounter when trying
to do what works best for them. Recovering addicts expose the negative beliefs, attitudes, and
opinions that they encounter from a wide variety of people including their families, AA/NA
members, non-medication assisted treatment physicians, and medical providers. Those who have
substance use disorders have lots of experience with others who discriminate against them, put
them down, judge them, and add to their already existing sense of personal shame for “being an
addict.” They are sensitive to how others perceive or treat them, and so when they encounter any
similar treatment from their counselors or doctors, it just becomes one more roadblock to
successful recovery.
The current study was designed to uncover and study the underlying attitudes and
beliefs that are held by medical providers, CDPs, and most importantly recovering opioid
dependent individuals. While much has been studied about the drugs and treatment processes,
the research gap lies in the lack of exploration into how the interaction between medical
providers, CDPs, and those with opioid dependence, and their potentially divergent views,
affect recovering individuals. The quantitative data were used to explore the commonalities and
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differences across groups. The narrative responses to the open-ended survey questions were
analyzed to address both addicts and those who work in concert for their recovery.
Ethical Issues
Strict measures were employed to assure confidentially and compliance with federal
HIPPA laws for all survey participants. This survey was designed with specific focus to do no
harm and to not engage participants with inquiries that might be upsetting or traumatic for them.
The research design was focused on positive outcomes, treatment approaches that have worked
well, areas of feedback for improvement of services, and exploring the underlying attitudes and
beliefs that these three groups have about the dynamics of medication assisted treatment. I have
followed all Antioch University policy and procedures on research design and implementation
including strict review and approval by Antioch’s IRB.
Limitations of the Study
This study is conducted with a small segment of opioid treatment providers and their
clients in the NW section of the United States; demographic and geographic markers of clients
and their providers may not be similar to other populations or other cultural settings. The
expected sample size was relatively small in comparison to the population affected and therefore
could limit the generalization of results. The field of opioid replacement therapy continues to
grow and the issues involved in the treatment of this disorder become increasingly complex.
Thus, longitudinal and in depth quantitative and qualitative studies could potentially yield
important findings, but these approaches to research are outside the scope of this study.
Value of This Research
As stated previously, the epidemic of opioid dependence continues to spread in the
United States and worldwide. The devastating personal and societal consequences caused by
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rising tide of heroin and prescription pain killer dependence is well documented. According to
a recent article published by the Yale school of medicine SBIRT (Screening Brief Intervention
& Referral to Treatment), “Opioid dependence is a major public health concern and remains
primarily an untreated medical condition in the United States” (Schwarz, Zelenev, Bruce, &
Altice, 2012, p. 2). The economic cost is estimated to top $21 billion a year and the far reaching
human implications are even more staggering. Worldwide the scope of the current problem is
even more alarming. The United Nations Office on Drugs and Crime notes that opioids,
especially heroin, are the main problem drugs globally (United Nations Office on Drugs and
Crime, 2010). Any additional or continued research in this important area of public health can
be beneficial to all concerned. Understanding how differing attitudes and beliefs about
medication assisted treatment effects patients recovery from opioid use disorder is crucial to
helping improve client outcomes. The primary parties that I refer to as the “big three”—
medical providers, CDPs, and clients—working together to address and overcome opioid
dependence, require additional information and collaboration in order to be successful and
increase successful treatment outcomes. This research focuses on those areas of cooperation,
collaboration, communication, and attitudes and beliefs between the providers and those they
serve. Information and educational implications of this study are important contributing facts
to the body of knowledge in the opioid treatment field.
Definition of Key Terms
Medication assisted treatment: Utilizing opioid replacement medications along with
psychosocial counseling to gain abstinence and obtain recovery from opioid addiction.
Addiction specialist: A profession who has been trained to counsel and case manage clients
engaged in Opioid addiction treatment services. In Washington State where this study took

15

place, addiction specialists are called Chemical Dependency Professionals, or CDPs.
Naltrexone: A drug that is an endorphin and narcotic antagonist. It is available in both oral
tablet form and subcutaneous injections for the treatment of alcohol and drug addiction. The
brand name of the injectable form is vivitrol and will be used as synonymous for naltrexone.
Methadone: A potent synthetic narcotic drug, that is less addictive than morphine or heroin and
is used as a substitute for these opioid drugs in addiction treatment programs. It is also used for
chronic pain management.
Buprenorphine/naloxone (Bup/nal): A prescription medication containing a combination of
buprenorphine which is a mixed opioid agonist/antagonist, and naloxone a pure opioid
antagonist, used in the treatment of opioid and heroin addiction treatment. Brand names
include Suboxone® , Zubsolv®, and Bunavail®. Generic forms are also available.
Buprenorphine: A partial agonist, partial antagonist, with a “ceiling effect” making it harder to
overdose or abuse than other opioids. Buprenorphine is a prescription opioid used for pain
control and for people addicted to heroin or other opioids that acts by relieving the symptoms
of opioid withdrawal and reducing cravings. Buprenorphine is less addictive and has a lower
risk of overdose than methadone.
Vivitrol: Pharmaceutical company brand name for naltrexone. As previously defined, is an
opioid antagonist used as the hydrochloride salt in the treatment of opioid or alcohol addiction.
Recovery: The return to a normal or health condition. Recovery describes the act and process
of getting off addictive substances. Used in the alcohol and drug addiction treatment field to
describe the process of being “clean and sober” or drug free and functioning well.
Sobriety: The state or condition of being sober. Also a term used to describe the state of being
clean and off all alcohol and drugs.
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Harm Reduction: A range of public health policies designed to reduce the harmful
consequences associated with various human behaviors. In this context the term is used to
describe the philosophy behind methadone treatment and opioid treatment programs.
Journey to Wellness: A philosophy of recovery from addiction as defined by the Lummi tribal
council in 2010. A philosophic approach to treatment that sought better outcomes and higher
functioning that harm reduction philosophies.
Abstinence: The process of abstaining from alcohol and other illicit drugs.
Medical provider: Authorized and trained medical professionals that hold licensure to
prescribe and oversee clients in treatment. Example includes Physician, Physician assistant,
and Nurse Practitioner.
Mid-level provider: Authorized and trained medical professionals that hold licensure to
prescribe and oversee clients in treatment but such as physician’s assistants and nurse
practitioners and who are no physicians.
Client/patient: Identified person who is engaged in treatment services.
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Chapter II: Literature Review
This critical review of literature in the opioid dependency and treatment field covers the
range of research that has been conducted in the field. The literature discussed relates to the
various forms of treatment for opioid dependence as well as well as the attitudes and beliefs
about these treatments affect outcomes.
Treatments
One focus of this literature review looks at the various methods of treatment for opioid
dependence, as well as their effectiveness and implications for the future. These treatments fall
into three broad based categories: (a) no treatment, aging out, or spontaneous recovery;
(b) psychosocial counseling; and (c) medication assisted treatment. This last method is by far
the most cited and researched to date and includes the most up to date and comprehensive
view and philosophy of modern opioid dependence treatment literature. The treatment of
choice for opioid dependence as it stands today usually includes a combination of counseling
with medication assisted treatment in the form of (a) methadone, (b) buprenorphine, and
(c) naltrexone, although there is not a consensus in the medical community on what constitutes
the most effective treatment modalities (Amato et al., 2008).
Natural Recovery or Recovery From Opioid Addiction Without Treatment
Recovery from opioid addiction without any formal intervention or treatment is not a very
popular concept in the opioid dependency field for several reasons. The first reason is the dire
and life threatening consequences of continuing what has been a well-documented downhill
course of the disorder. Some question the ethics of advocating following this course of action.
Given the severity and relapsing tendencies of opioid abuse and dependency, to stand by and
wait for people to “age out” (Biernacki, 1990) can lead to permanent damage and premature
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death. Alternatively, some researchers suggest that opioid addicts simply cannot maintain the
lifestyle and that the constant stress and energy it takes to continue this behavior will eventually
lead to negative effects and untreated remission.
Biernacki’s (1986) work summarizing recovery from opioid addiction is possibly
outdated. Much has been discovered over the past 27 years, particularly in the field of
neurobiology, including brain scans and the science behind how opioids change the brain
pathways. Biernacki (1986) cites even older work by Winick (1962) that suggests that young
adults become addicted as a way to deal with life problems encountered during the turbulent
time of adjustment to young adulthood and that their maladaptive response in the form of using
opioids was merely a phase that most were able to stop on their own. Robins (1973) in her
widely cited research on Vietnam War veterans, lent support to this line of reasoning as well.
Robins was able to demonstrate that most Vietnam veterans that met criteria for opioid
dependence (20%) were able to return to pre-war rates of societal opioid dependence of less
than 1% without formal intervention and treatment. Robins made a case for the environmental
and stress factors that led to the disorder, and showed how once veterans return to their home
communities where opium was not accessible, where they had the support of family and friends,
that their opioid dependence disorder went into spontaneous remission. Biernacki’s (1990) work
was retrospective in nature, included no quantitative information and only three citations,
possibly limiting its value. The researcher himself noted the limitations of his “relatively small
sample size” (which was never quantitatively identified) and that the people located for
discussion on these points came from the “snowballing method.” In other words the researchers
sought names of potential study participants from other self-identified opioid addicts who had
quit using. There were also no methods in place to verify self-reports.
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Another prominently cited researcher in this field is Waldorf. In the 1980s he published
several articles where he spoke to the social and psychological process of untreated addiction
and recovery and coined the term “natural recovery.” He also cited Robins’ (1973) research with
returning Vietnam era opioid dependent soldiers. Waldorf (1983) cites social surveys with larger
random samples (e.g., Odonelle et al., 1976; Brunswick, 1979) along with evaluations of
chemical dependency treatment programs (e.g., Burt Associates, 1977; Macro Systems, 1975).
Waldorf interviewed and surveyed 201 ex-addicts and addressed both the sample selection
process and the inability to claim that his data were definitive in nature. His sample was not
randomly selected and therefore caused him to reflect on what population, if any, his findings
might represent. He spoke of three types of addicts: (a) ghetto or barrio street addict, (b) middle
class addict, and (c) situational addict. Waldorf did not expand on these definitions nor did he
classify the types of interview participants that he was citing in his research. Thus, the
“maturing out” idea postulated by Winick (1962) was not systematically tested and there were
only three studies (i.e., Ball & Snarr, 1969; Snow, 1973; Vallant, 1966) that offered any type of
empirical support to this idea and even these studies found the concept inconclusive.
Maddux and Desmond (1979) followed up Winick’s (1962) work and made the argument
that the maturing out thesis was based solely on records from the Federal Bureau of Narcotics
and was “certainly unrealistically optimistic” (Vaillant, 1973). The general approach to research
was exploratory and was not set out to test well-defined hypotheses with random samples of ex
addicts. Data from Waldorf’s (1983) work was garnered from a combination of quantitative and
qualitative methods. Half (i.e., 100) of the participants were treated addicts while the other half
(i.e., 101) of them were untreated addicts. The sampling method was snowballing and
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participants were paid $20 to participate. Results showed six patterns of why people quit their
opioid use that was contrary to the aging out theories that were being hypothesized.
Opioid Dependence Recovery With Psychosocial Counseling
“Drug rehabilitation” is the term commonly associated with the process of recovery from
dependence on psychoactive substances. The term was coined in the 1960s with the formation
of residential treatment programs, the origins of which date back to the 1930s with the
publishing of the original self-help twelve step recovery approach used in Alcoholics
Anonymous (AA). This original mutual aid support network helped lay the foundation for many
of the concepts utilized in the drug/alcohol rehabilitation centers. These early approaches to
addiction treatments did not address the medical nature of addictions and were fairly dogmatic
in their philosophies of a total abstinence model of recovery. This AA phenomenon has spread
worldwide and is credited by many, including well-respected researchers, to be the most
effective therapy known for alcoholism and drug dependence (Seiberling, 1985).
However, when it came to harder drugs, and substances that had a stronger
physiological dependence like heroin and other opioid narcotic drugs, the positive outcomes of
traditional approaches such as abstinence-only and non-medical counseling were not as well
supported by research. The phenomenon of opioid dependence has been widely studied. In a
search of Psycho INFO, over 18,000 articles were related to the topic (Mayet, Farrell, Ferri,
Amato, & Davoli, 2004). The need to address the more complex dynamics and severity of
addiction as it relates specifically to opioid dependence has brought about the entire field of
medication assisted treatment. Psychosocial approaches of counseling and support toward a
totally abstinence-based lifestyle have not shown good outcomes for opioid dependence
(Flynn, Joe, Broome, Simpson, & Brown, 2003). Recidivism rates for opioid addiction have

21

been sometimes reported as high as 95%; however, some abstinence-based approaches that
include psychosocial interventions have shown evidence of support for their effectiveness
(Amato et al., 2008).
Electronic searches of the Cochrane Library, MEDLINE (1966–2003), LILACS
(1982–2003), EMBASE (1980–2003), and Psycho INFO (1872–2003) databases found over a
thousand articles with these subject lines. The articles were identified and screened to meet
criteria that conform to modern day treatments for opioid dependence. It was a difficult task
to separate pure counseling approaches since many of these studies included both a mixture of
medication assisted approaches along with counseling and support. Adding to the difficulties
in trying to make proper comparisons was the heterogenic nature of the population studied
(inpatient, outpatient, jail settings, etc.). The most comprehensive and up-to-date meta-analysis
of psychosocial approaches to opioid dependence was undertaken by “The Cochrane
Collaboration” in 2010. Their review, found through an exhaustive search of past and current
literature on this subject matter, produced over 1,024 articles and references; however, using
the criteria they selected for low bias and adequate allocation concealment, they ultimately
settled on 16 articles. Their conclusion was that it was unclear if psychosocial treatments alone
were an effective intervention or better than other approaches that offered both counseling and
support along with pharmacological interventions. In addition, the diversity of psychosocial
interventions available in the field of drug and alcohol dependence makes it very challenging to
draw specific conclusions on the absolute effectiveness of these approaches. Psychosocial
components of treatment and therapy have long been thought to be a major component of the
holistic treatment approaches provided in both inpatient and outpatient drug treatment centers.
However these therapies vary in nature and scope and are applied in a variety of differential
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settings, making the challenge of isolating effectiveness of the psychological therapy approach
very difficult to evaluate. The current trend of opioid dependence treatments to involve
pharmacological approaches is an impediment to evaluating treatments using only traditional
psychosocial approaches.
Treatment of opioid dependence is very complex and the range of treatment
interventions is extensive. Research reviews addressing a combination of pharmacological
approaches along with psychosocial therapies are far and away the most plentiful (Dawe et al.,
1993; Goldstein, Deren, Kang, Des Jarlais, & Magura, 2002; Gruber, 2000; Katz, Chutuape,
Jones, & Stitzer, 2002; Zanis, 1996). The results of these studies cannot be pooled or
summarized as they were very heterogeneous in nature.
Since the onset of medication assisted treatments it is no longer ethically viable to
conduct research on counseling-only approaches. With the outcomes so poor, there are serious
ethical considerations in conducting research where only psychosocial interventions are
explored. Therefore the following studies of psychosocial approaches were conducted with
re-engaging or outreaching to dropouts from a methadone maintenance treatment program.
As previously noted, heroin dependence is a chronic, relapsing illness where
approximately 70% of all methadone maintenance treatment program clients relapse within one
year following discharge (Alterman, 1996). Many clients who have been discharged and
constitute out of treatment patients resume high risk for various health issues like Hepatitis C,
HIV infection, as well as criminal behaviors and a host of other dangerous behaviors. It is
prudent that psychosocial approaches to re-enroll these high-risk users be employed. The
methods employed in the Alterman article were to identify and reach out to 110 discharged
clients one year after discharge from methadone maintenance treatment. The study included
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identifying 110 former patients from a VA Medical Center’s methadone program that were
categorized in four discharge types: (a) completed treatment, (b) transferred to other treatment
programs, (c) voluntarily dropped out of treatment, and (d) involuntarily discharged. Subjects
who were not re-enrolled in methadone maintenance treatment program services and were deemed
eligible for the program (41) were randomly assigned to two treatment groups of either enhanced
outreach counseling, or standard intervention conditions. The study found that after one year
10% were deceased, 39% were already re-enrolled in treatment, and 7% did now require
intervention or treatment. Results were favorable for the enhanced outreach-counseling program
where 67% were re-enrolled in the program within 2 weeks of the intervention, whereas only 7%
of those in the standard referral condition were re-enrolled in treatment services. Based on a chisquare analysis, and adjusted for Yates correction for continuity, the results showed a statistically
significant difference between the two groups. The limitations of this study affected the ability to
generalize the findings because of small sample size (110 screened for the study and only 40
assigned to the two treatment groups). Most in the sample were male veterans who generally
have greater access to health insurance and treatment services. There also was no evidence to
demonstrate the effectiveness this enhanced outreach program approach had at follow-up points.
The enhanced outreach group was supported as a more effective form of getting clients engaged
back into methadone medication treatment programs than the standard intervention conditions.
However the “success” involved patients in forms of medication assisted treatment as well as
psychosocial forms of opioid dependency treatment. Thus, again there were few, if any,
applicable research studies that solely identified and evaluated psychosocial approaches to
treating opioid dependency.
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The Katz et al. (2002) study described opioid dependence in the state of Maryland.
Their study reported that a third of the admissions to substance abuse treatment programs
were for opioid use. Also noted in this important and often cited psychosocial treatment
literature was the acknowledgement of the difficult and often-fruitless efforts of treating
opioid addiction in a drug free modality because of poor retention and frequent relapse. A
nationwide Drug Abuse Treatment Outcome Study (DATOS) reviewed retention data from 14
outpatient drug free programs and showed that clinics only retained 50% of clients for the
first 90 days, and an even lower 20% over 180 days (Simpson et al., 1997). In an effort to
address these poor retention rates, the researchers enacted a monetary supported voucher
system that would offer financial incentives for participating clients. Voucher systems had
been used extensively for treatment of cocaine abusers (Higgins et al., 1994) and in
methadone maintenance programs (Silverman et al., 1996). Since these voucher incentive
programs were effective in previous trials, it was hypothesized that this approach could also be
effective when used with psychosocial treatment modalities to increase both retention and
successful outcomes for opioid dependent individuals. The financial incentives were
significant in that individuals in the voucher treatment group could earn upwards of $1,807
over three months for submitting urine negative for both opioids and cocaine. The results
were somewhat disappointing as the researchers found no significant differences between the
voucher group and non-voucher group on mean days retained in treatment, mean number of
opioid and cocaine negative urine submitted, duration of continuous abstinence, or for
percentage of participants abstinent for four weeks. Several rationales were theorized to
explain the lack of successful outcomes, including that this study targeted users of both
cocaine and opioids, whereas in previous studies using vouchers incentives had been focused
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on single drug use stoppage. In addition, the lapse and relapse dynamics that affect heroin
addicts are different from those that affect cocaine abusers. Heroin users find it more difficult
to abstain because of post-acute withdrawal effects and prolonged physiological cravings for
the drug. Discussion continued in reference to drug positive urine samples at intake and how
they were associated with program failure, suggesting that the voucher incentive program may
be better suited for reinforcing motivation to stay clean, and not for becoming drug free.
Dawe et al. (1993) also evaluated approaches of psychosocial counseling to opioid
dependence and looked at a controlled randomized study that followed 186 subjects that
employed a cue exposure technique. Their research was conducted in a residential treatment
setting where controls were more tightly administered and controlled. Subjects were randomly
assigned to one of two treatment settings, one with a drug dependence unit with a special
10-week program and the other to a 4-week general behavioral treatment unit (control group),
without cue exposure. Cue exposure is the introduction to stimuli associated with drug activity
that is designed to elicit reactions that potentially lead to relapse. In each setting subjects either
had cue exposure for six sessions over the last three weeks or a control condition. Even though
both groups did show significant decrement in cue-elicited cravings, withdrawal responses, and
negative mood, the results did not support the cue exposure treatment modality and the authors
expressed major reservations that this form of psychosocial treatment was an effective and/or
practical form of intervention for opioid dependent individuals.
Mattick, Breen, Kimber, and Davoli (2009) conducted research that attempts to
validate psychosocial treatments and interventions without adjunctions to medication
assisted forms of therapy. Retention in methadone maintenance treatment programs is
predictive of abstaining from opioids and having other positive benefits as well (Mattick
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et al., 2009). The study attempted to re-engage methadone maintenance treatment program
patients in treatment using psychosocial approaches employed three approaches: (a) street
outreach, (b) cognitive behavioral groups, and (c) individual counseling over a 3-month
period. This study analyzed the impact these three alternative programs had on treatment
re-entry (Goldstein et al., 2002). The most important study findings suggest that those
individuals who attended two or more groups of the three interventions (street outreach,
cognitive behavioral groups, and individual counseling) were more likely to return to
methadone maintenance treatment programs during the six month follow up, and that it
was possible to engage 87% of the dropout sample in some portion of the psychosocial
intervention. The limitations however were that these re-engagement approaches were
designed to get subjects back into medication assisted treatments using the opioid
agonist methadone. Even though the designs were psychosocial in nature, the incentive
and goal was to get subjects back onto a powerful opioid substitution medication, hence
not a solely psychosocial form of treatment.
As the comprehensive Cochrane collaboration (Mayet et al., 2004) review of
psychosocial treatment effectiveness for opioid dependence points out, there is a lack of
evidence suggesting that this type of approach is effective for a disorder that has been
described in the medical literature as a “brain disorder”(Koob & Le Moal, 2008). In the
plain language summary Mayet et al. (2004) stated
Despite its wide use in clinical practice, no systematic review of effectiveness has
ever been carried out. My review demonstrates that there is inadequate evidence
available to prove the effectiveness of psychosocial interventions alone for the
treatment of opioid dependence or that they are superior to any other type of
treatment. (p. 2)
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It appears that psychosocial interventions are an important strategy and a critical
component of opioid dependence treatments, but only when combined with medications
(Chambless et al., 1998). In critical analysis of the multitude of opioid treatment
literature, counseling approaches, along with medication, continue to be considered best
practice.
Medication Assisted Treatments for Opioid Dependence
It is well established that opioid dependence has (Louria, Hensle, & Rose, 1967) many
destructive consequences that include not only medical complications, but also huge
disruptions to a normal life course. Physiological, psychological, emotional, mental, family,
and social consequences of this brain disorder (Leshner, 1997) are well documented and well
researched. The bleak outcomes of traditional counseling approaches have demonstrated the
unacceptable outcomes that traditional psychosocial counseling alone has provided to those
afflicted. As a result researchers, doctors, and other healthcare professionals sought more
effective treatment modalities. The long-term treatment goals began to shift away from the
total abstinence paradigm toward a more practical, pragmatic, and effective way of treating
opioid dependence. Outcomes started to become more focused on the importance in reducing
negative health and social consequences and to improving the well-being and social
functioning of those affected (Riley et al., 1999).
Medication assisted forms of treatment were introduced (Batki, Kauffman, Marion,
Parrino, & Woody, 2008), originally in a very crude format as compared with the advanced
therapies of today, back in the early 1900s when physicians used morphine and even heroin to
alleviate cravings and withdrawal in a doctor supervised setting. The difficulties with these
early forms of medication assisted treatments were the short half-lives of both heroin and
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morphine. Afflicted patients needed to get a dose of medication every 8 hours. These forms of
medication assisted treatments did reduce both drug cravings and physiological withdrawal
symptoms for clients, but faced practical limitations since clinics and their staff could not be
available 24 hours a day, 7 days a week. Searches for longer acting medications resulted in the
use of methadone for that purpose. Methadone was developed in Germany back in 1937 in
WWII because of the need to maintain a reliable source of opioid analgesic (Gerlach, 2004).
Methadone was introduced into the United States ten years later in 1947 by drug
manufacturers Eli Lilly and Company. Methadone is a synthetic opioid and acts on the same
mu opioid receptor sites as heroin and other opioids and mimics the same effects. Methadone
was found to be useful in the managing of severe and chronic pain because of its long duration
of action, powerful effects, and very low cost. These three factors led to methadone becoming
the widely used medication to assist in what is known today as medication assisted treatment.
Additional and significant literature in the field of opioid dependence is focused on the
chemistry of the brain and lays the foundation for scientists and medical specialists to call
opioid use disorder a “chronic brain disease” (Koob, 2009). The field of neurobiology
continues to produce studies that demonstrate support for this theoretical orientation that seeks
to uncover the mechanisms in the brain that are most effected by the use of opioids. Koob’s
work in the field of neurobiology of emotions works to define what he refers to as the “dark
side” of compulsivity in addiction. He has written and published numerous articles that help
explain and understand the opioid dependent individual’s compulsion, obsession, and loss of
control over their use of opioids. Koob describes the body’s homoeostatic process, where the
neurological system always attempts and defaults to a place of normalcy. Examples of this
include the body’s blood pressure, body temperature, as well as the brain’s neurobiology that
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has been disrupted by the addiction process. His theories include how the use of medications
used to assist the opioid dependent person feel within this homoeostatic range. Koob’s
theories are considered at the leading edge of today’s current views of opioid dependence and
advocate the use of medications to assist in the recovery process to satiated and repair these
damages neuro pathways (Koob & Le Moal, 2005; Koob & Volkow, 2010). Another
recognized leader in the field of opioid dependence treatment and a researcher that lends
support for the use of medication to assist in the treatment and recovery process is Volkow
whose body of work includes strategies for identifying and treating opioid use disorder
(Compton & Volkow, 2006b). Volkow discusses the nature of addiction and points to recent
advances in neurosciences that offer insight into the biological nature of the disease model
(Baler & Volkow, 2006) and lends evidence to refute that addiction is simply a moral
dilemma. The belief that people with opioid use disorder can simply “quit” using if they have
determination and self-will to recover represents the moralistic view that many people hold as
true. McLellan’s work also focuses on mood states, and the underlying triggers for cravings
and relapse with opioid dependence (CHILDRESS, McLellan, & O'BRIEN, 1986). Effective
medical treatment for opioid use disorder must contain a component that includes current best
practice the utilization of medications to assist in the recovery process.
Today the evolution of additional medications beyond methadone has advanced to a
more sophisticated and very well researched body of knowledge. Relapse rates of those who
suffer from opioid dependence are cited at almost 95% with traditional psychosocial
treatments. Those treated with opioid replacement therapy have shown rates of
40–65% for maintaining complete abstinence from opioids. There are four medications used
in today’s treatments that supplement all of the counseling and psychosocial support efforts
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that all modern day opioid treatment programs around the globe adhere to. These opioid
treatment program medications include: (a) methadone, (b) LAMM (Levo-alpha acetyl
methadol), (c) naltrexone, and (d) buprenorphine/naloxone (bup/nal).
Methadone. Methadone is a pure opioid agonist. It is classified as a synthetic opioid
and as such is easily produced in a laboratory setting. Of the four medications listed as FDA
approved for the treatment of opioid dependence methadone is the one that has been studied
the most. The history of this medication is intriguing as it was synthesized in WWI and came
into vogue as the preferred method of treatment for the burgeoning heroin addiction epidemic
from the mid-1960s into the early 70s and spanned several administrations including the
Kennedy and Nixon presidencies. As stated earlier, the early treatments for this affliction
were to dose patients on heroin or morphine, but because of the short half-life of the drug, the
demonstration of increased tolerance to patients, and the perceived public perception of the
threat to the abstinence based treatments of the time; these trials and clinics were shut down
by the U.S. Treasury Department through legal pressure, and inspections (Center for
Substance Abuse Treatment, 2005). The early rationale for research into methadone was born
out of the societal concerns in the areas of public health and safety, as well as the social
ramifications of continuing to ignore the negative impact of the growing opioid dependency
problems. Dr. Vincent P. Dole received a grant to establish the early research and investigate
the feasibility of opioid maintenance treatment approaches. In preparing for this research,
Dole read “The Drug Addict as a Patient” (Nyswander, 1956). Nyswander was one of the first
of her medical colleagues that asserted these patients could be treated under a medical
treatment modality typically used for patients with chronic diseases. She also forwarded the
notion that this was not an acute condition in which patients could be treated and put into a
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remission state in a short period of time, but rather that they would be more successful if
maintained on opioid replacement therapy for extended periods. This was born out of her
experience and work with opioid users who chronically relapsed and failed to make gains
toward recovery without medication. Other chronic diseases responded to a continued
reliance on medication, so why not extend that to the treatment of opioid dependence?
Nyswander joined Dole’s research staff in 1964 and, along with clinical investigator Kreek,
found that morphine was not a good medication of choice to treat patients because of the
negative impact on social functioning due to the side effect of sedation, the short half-life of
the drug that required several injections per day, and the onset of tolerance, thus increasing
the dosage with no stable platform (Dole & Nyswander, 1980). This early research paved the
way for methadone since the shorter acting options were eliminated and the focus became a
longer acting substitute. Methadone also has the benefit of being effectively administered
orally. The very first study was conducted on two patients who were previously maintained
on morphine. Once baseline tolerance was established, patients demonstrated the ability to
function normally without the anxiety of drug cravings, and the absence of self-reported
withdrawal. The most important findings from the early methadone trials (Dole &
Nyswander, 1980) were:
x

Patients did not experience euphoric, tranquilizing, or analgesic effects. Thus, they
were able to more effectively socialize and work normally without incapacitation.

x

At the appropriate dosage methadone reduced or blocked euphoric and
tranquilizing effects of opioid drugs (morphine, heroin, meperidine, and opium)
even if patients tried to smoke or inject the drugs.

x

Unlike morphine, no tolerance was noted in long-term administration of
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methadone. Therefore, a therapeutic dose could be held constant for extended
periods of time.
x

Methadone was effectively administered orally, eliminating the need for needles
and demonstrating that patients could administer it one time a day.

x

Methadone took away opioid cravings, which were thought to be a major
component of most relapses, and eliminated the physiological symptoms of opioid
withdrawal, which most addicts would go to great lengths to avoid.

x

Methadone caused minimal side effects and researchers indicated that it was
medically safe and non-toxic.

The importance of this early and pioneering research cannot be overstated. By 1965 the
initial research on methadone safety and efficacy was transferred to the Manhattan General
Hospital in New York. Dole realized that his research would need to be independently
evaluated and tested. Gearing (1970) was able to verify some of the early finding on methadone
medication treatment by also demonstrating that once patients were stabilized on a dose of 80
to 120 mg/day their social functioning improved, and they demonstrated improved
employment, school attendance, homemaking, and decreased recidivism of legal difficulties.
The positive effects to the community and larger society by having opioid addicts participate
in the newly supported forms of medication assistance did not go unnoticed.
Methadone maintenance treatment was the first widely used opioid replacement therapy
to treat heroin dependence and remains the best-researched treatment for this purpose (Mattick
et al., 2009). Even though it is the most widespread treatment in many countries, it remains a
controversial treatment whose effectiveness has been disputed. The controversy swirls mainly
around the attitudes associated with viewing heroin addiction as a brain disease like most
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medical providers do, or as a form of weak self-willed moral deficiency as many still prefer to
view it. The Cochrane Collaboration conducted the most comprehensive critical review of the
methadone treatment research literature in 2009. They concluded that the use of methadone for
treatment of opioid dependence was effective and represented best practice in the primary
treatment process for opioid use disorder.
LAAM. Longer acting alternatives to methadone were also explored and subject to
critical review. LAAM (Levo-alpha acetyl methadol) was much like methadone in that it was
classified as an opioid agonist and also classified as a DEA schedule II controlled substance.
Thus it was under the same intense scrutiny and regulation for the handling, prescribing, and
distribution as other schedule II narcotic drugs. LAAM was first developed in 1948 by German
chemists as an analgesic (Finn & Wilcock, 1997). LAAM mimicked much of the positive
effects that had been demonstrated by methadone in that it blocked the euphoric effects of
opioids, suppressed the withdrawal effects, eliminated hunger/cravings for the drug, but also
had the additional benefit of a longer effective schedule. LAAM can achieve the same effects
as methadone but maintain that for 48 to 72 hours longer. This longer acting effect captured the
excitement and imagination of those researching LAAM since its practical application had an
obvious upside. LAAM demonstrated a longer biological half-life. Medications with a longer
half-life remain in a patient’s system longer and allow clients to dose less often. This dynamic
appeared to benefit clients and practitioners. Patients could reduce their daily visits to clinics,
as required on the primary treatment regime of methadone medication treatment, replace that
with LAAM, and only be required to come in for dosing three days a week. This had benefits
for both providers and patients alike; it reduced the dependence around the clinical model and
helped increase compliance with treatment while at the same time reducing risk in the
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community by eliminating “take home” dosing as is popular in most methadone clinics. By the
late 1960s research interest in LAAM rose as clinicians saw it as a new alternative to
methadone maintenance treatment. Between 1969 and 1981, more than 27 studies with over
6,000 participants established LAAM’s safety and efficacy (Finn & Wilcock, 1997). These
studies demonstrated LAAM as an effective alternative to methadone maintenance treatment
and led to FDA approval for treatment in opioid replacement therapy in 1993 (Ducharme &
Abraham, 2008).
The entire body of evidence in LAAM research showed that this medication is as
effective as, or even more effective than, methadone in maintaining abstinence amongst opioid
addicts (Blaine et al., 1981). LAAM then became the first FDA approved medication that gave
clinicians and patients a choice between methadone and LAAM as a form of treatment for those
who were opioid addicted. Since LAAM differed from methadone, clinicians felt this new form
of opioid treatment program medication could help those that could not be helped by methadone.
Even though it was not thought of as the treatment of choice for affected patients, clinicians
could now increase their success rates by identifying people who would benefit most from
LAAM’s advantages. LAAM and methadone are metabolized differently. The most noticeable
difference is the delay before the effects of LAAM can be detected and that LAAM remains in
the body for much longer than methadone does (Fraser & Isbell, 1952). Since this became the
first new research and discovery in the field of methadone maintenance treatment up until 1993
for opioid dependency, it is important to note the advantages and disadvantages of LAAM as
compared to methadone.
Advantages of LAAM to methadone. There are several advantages to LAAM, including:
● LAAM reduces the number of clinic trips. This is an advantage to those
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experiencing commuting problems to the clinic, and frees patients from daily
dependence on the clinic.
● LAAM gives a more stable dose across time, thus promoting a more normal
feeling state than both heroin and methadone. LAAM does not produce the effects
of euphoria from opioids, while at the same time blocking effects of both cravings
and withdrawal which are thought to be one of the main precursors to relapse.
● Federal regulations prohibit take-home privileges for LAAM, and thus it
eliminates the negotiations between clinician and clients over that privilege.
● LAAM reduces diversion opportunities. The clinic has tighter controls over the
medication, which reduces potential harm to the community via abuse or overdose.
Disadvantages of LAAM to methadone. There are several disadvantages to
LAAM including:
x

LAAM can be difficult to adjust to as it can take up to two weeks for patients to
reach a steady state. This discomfort can lead to treatment non-compliance and
relapse.

● Since it is a long acting opioid agonist, it should never be given more than every
other day. If LAAM is taken more often than this, the drug will accumulate in the
body and lethal overdose can occur.
● Lack of daily contact can be seen as an advantage to some clients, but some
clients need and benefit from daily contact and structure and for them less than
daily contact becomes a disadvantage in their treatment outcomes.

36

● Since LAAM was a new and unfamiliar medication, anxiety at first is increased and
some clients will need additional support and counseling in order to deal with this
dynamic.
● LAAM cannot be given to pregnant women as can methadone and also is forbidden
for clients under the age of 18.
Despite its advantages over the shorter acting and preferred treatment of choice,
methadone, widespread usage was short-lived for LAAM. Even though it still remains an FDA
approved therapeutic agent for opioid dependence, LAAM was discontinued in Europe in 2001
due to concerns over life threatening cardiac dysrhythmias (arrhythmia or irregular heartbeat)
(Jaffe, 2007). The manufacturer Roxane Laboratories discontinued LAAM, branded as Orlaam,
in the United States in 2003. It was of interest that even though it passed many clinical trials in
the years 1969–1980, LAAM was ultimately a very short lived alternative, and initial trials
missed the longer term effects that became evident later. LAAM is no longer being used in
opioid treatment programs.
Naltrexone. The two most popular and widely researched medications for treating
opioid dependence remain methadone and buprenorphine. However, naltrexone, a
lesser-known medication, is also a form of medication assisted treatment. Researchers picked
up an interest in naltrexone in the early 1970s and began clinical trials for efficacy and safety
(Resnick et al., 1991). Naltrexone is an opioid receptor antagonist, meaning that this mediation
occupies the opioid receptor sites in the brain without activating them. This effectively blocks
all euphoric effects from the ingestion of opioids, making it meaningless to ingest heroin,
morphine, demerol, and other narcotics. Naltrexone is the only pure opioid antagonist of those
discussed here and was approved for use as an opioid treatment by the FDA in 1984 (Washton,
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Pottash, & Gold, 1984). The primary use of naltrexone never caught on as a mainstream
treatment due to several notable limitations. Some opioid treatment providers have found that
naltrexone is useful for highly motivated patients who are detoxified, or no longer under the
effects of opioids, and in need of additional support. This medication offers some relief from
drug cravings, but is not helpful for withdrawal, and simply blocks the effects of opioids.
Treatment compliance has been poor with long-term naltrexone therapy because it offers no
relief of active symptoms of cravings and withdrawal (Mark, Kranzler, & Song, 2003).
Naltrexone was also subsequently approved by the FDA in 1995 as a preventative treatment for
relapse in alcohol dependent individuals (Malerich, 1999), and its use for alcoholics could
actually be more beneficial than for opioid addiction (Haile, Kosten, & Kosten, 2008). A
review of more recent research suggests that more studies are needed in order to show
naltrexone’s effectiveness in treating opioid dependence and to compare it to the more popular
and widely accepted opioid treatment program medications of methadone and buprenorphine
(Minozzi et al., 2011). One of the drawbacks and limitation of naltrexone is that with oral
administration it requires daily dosing. Clients that experience opioid cravings can simply skip
a day’s dosage before they resume abusing their drug of choice. Clients best suited for this
medication must be screened and followed carefully. Clinicians found that those who have the
best chances of success with naltrexone are clients who have a very stable social/living
situation and are highly motivated to quit the lifestyle and pursue recovery (Tucker & Ritter,
2000). A critical review of the research on naltrexone was completed in 2000, and published as
“Naltrexone in the Treatment of Heroin Dependence: A Literature Review” (Tucker & Ritter,
2000). The review found 649 articles published in English, however 326 were animal studies
and 67 were articles related to uses of naltrexone other than alcohol and opioids. Of the total
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number of articles located, 91 were review papers while 29 reported on opioid withdrawal (12
of them research trials). Thirty-seven naltrexone outcome studies, 12 of them controlled and 25
open trials were found and reviewed. Noted by the authors were the absence of articles that
dealt with actual patients and data. In addition, concerns were also noted regarding how this
small amount of research generated so many “review” papers. Review of this literature found
several noteworthy issues and concluded that naltrexone is not widely accepted as a form of
medication assisted treatment for opioid treatment programs and is underused for this purpose
(O'Brien, Greenstein, & Woody, 1978) and as an opioid antagonist treatment it may only
appeal to 5-10% of the opioid-dependent population (O'Brien, 1996). Explanations for poor
patient acceptance rates include fear of withdrawal or the inability to withdraw from opioids,
the need for an opioid free period prior to dosing of naltrexone, fear of the new drug and
possible aversive effects, inability to cope with depression during the opioid-free period
required before active dosing, lack of euphoria-producing properties, and lack of any sincere
motivation to pursue a drug free lifestyle (Schecter, 1980; Schuckit, Schuckit, & Schuckit,
1984). Retention rates in drug dependence programs are historically low with the exception of
methadone maintenance treatment and are described in terms of initial reactions (first 2 weeks).
Early attrition rates with naltrexone were found to be quite high (Fram, Marmo, & Holden,
1989). Between 39% and 74% of participants left treatment by the end of the second week.
Finally, abstinence rates were calculated and varied widely across studies depending on
treatment regime and were measured by opioid positive urine tests (Hollister, Schwin, &
Kasper, 1977; Judson, Carney, & Goldstein, 1981). Results and comparisons to other forms of
methadone maintenance treatment were varied and difficult to ascertain given that the majority
of the studies conducted did not randomly assign clients to treatment. The trend, however, does
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lean toward positive outcomes as compared with the other three medications reviewed and
supports more randomized clinical trials for further research. New methods of administration
and a longer acting form of naltrexone, given to clients with a monthly injection, showed
promise with the branded “vivitrol” (Krupitsky & Blokhina, 2010), new to treatment specialists
since 2005. Research is limited and leans toward preferable treatment for alcohol dependent
clients (Garbutt et al., 2005); however, some methadone maintenance treatment and opioid
treatment programs are now examining the efficacy of using this long acting form of naltrexone
in their treatment programs (Comer et al., 2006). Opioid substitution treatment will continue to
employ naltrexone as a treatment option both now and in the future. Continued clinical trials
are indicated and direction should be toward comparison studies with both methadone and
buprenorphine employing randomized control groupings.
Buprenorphine. Buprenorphine is a semi-synthetic opioid that was first indicated for
use to control moderate pain in non-opioid tolerant individuals. Chemists in Britain in 1958
began working to develop an over-the-counter analgesic through the simulation and
formulation of a variety of opioid compounds. After years of work by chemists and animal
trials a compound known as RX6029 began human trials in 1971, and by 1978 buprenorphine
was released as an injection for pain in the UK with a sublingual pill to follow in 1982 (Martin,
1979). Widely utilized in Europe as an opioid substitution treatment model in the 1990s
(Fatseas & Auriacombe, 2007), the newest of the four medications reviewed for opioid
substitution therapies gained huge and unprecedented support and growth initially in Europe.
One of the proving grounds for the use of buprenorphine in opioid agonist pharmacotherapy
was in France. Because of the combination of their open health care system and attitudes
toward designating opioid addiction as a “chronic” illness and the universal medical insurance
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which covered 100% of the cost of treatment, France become very fertile ground to
demonstrate the safety and efficacy of buprenorphine. The spike in overdose deaths prompted a
national response to the offering of buprenorphine treatment by general practitioners. Studies in
the United States were also noting a significant decline in overdose deaths due to heroin (Olsen &
Sharfstein, 2014; Schwartz et al., 2013). Since opioid addiction has become such a widespread
phenomenon worldwide and many of those afflicted are not receiving or engaged in treatment
services, ranging by some estimates from 70–85%, (Domingo-Salvany, Hartnoll, Maguire,
Suelves, & Anto, 1998; Tang, Zhao, Zhao, & Cubells, 2006) any new discoveries in
medication assisted treatment methods represent progress. By contrast methadone maintenance
treatments have been in place for over 45 years and the number of patients being treated in
specialized clinics has remained stagnant while the problem of opioid dependence has
burgeoned (Inciardi & Harrison, 1999). With the onset of this newest medication the number of
opioid addicts receiving formalized help has grown by some estimates to 65% of those affected
(Bickel & Amass, 1995).
Clinical trials for buprenorphine began in the European bloc countries as an opioid
substitution therapy over 30 years ago in the 1980s. Since the introduction of buprenorphine the
increased access to a less restricted form of medication fueled further interest and clinical trials
in France, and other European communities (Resnick et al., 1991). Researchers recognized the
potential to those afflicted by this chronic disease, and the advantages that buprenorphine has
over methadone maintenance treatment, naltrexone, and LAAM (Reed, Glasper, Cornelis,
Bearn, & Gossop, 2007). The initial and very positive trials on buprenorphine and the
experiences of many office-based doctors in Europe pushed buprenorphine to the forefront in
the battle by clinicians to overcome this worldwide health problem. By 1995 all registered
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medical doctors in France were being allowed to prescribe buprenorphine for opioid agonist
treatment without any specialized training. This trend began to challenge the long held and
preferred method of pharmacological medication using methadone. Buprenorphine offered the
advantage of being less dangerous for overdose deaths. Since buprenorphine was not a full
opioid agonist and contained a partial mu antagonist it had a built-in ceiling effect that
prevented overdose. Since it was also a less controlled medication and was widely and readily
available, access for opioid addicts to this new form of medication-assisted treatment
resulted in the number of clients being treated increasing from 15–30% to nearly 65% (San,
Tremoleda, Olle, & de la Torre, 1989). A medication that was less dangerous to prescribe,
more accessible to the masses affected by opioid dependence, coupled with favorable outcome
studies (Giacomuzzi, Kemmler, Ertl, & Riemer, 2006) helped build a body of evidence to
support buprenorphine as the medication of choice for many doctors, clinicians, and researchers
(Auriacombe, Fatséas, Dubernet, Daulouède, & Tignol, 2004).
Advancement and acceptance of buprenorphine in the United States for the treatment
of opioid addiction was 7–10 years behind the progress of its international colleagues.
American researchers however were taking note and began clinical trials of their own (Fiellin
& O'Connor, 2002) that led to the FDA’s approval of buprenorphine for the treatment as an
opioid substitution treatment in 2002. Another important decision and legislation in the United
States that cleared the way for the method by which most buprenorphine is prescribed today
was the Drug Addiction Treatment Act of 2000 (DATA 2000), that allowed the Secretary of
Health and Human Services to grant waivers to physicians with specific training to prescribe
and administer Schedule III, IV, or V narcotic drugs for treatment of addiction or
detoxification (Fiellin & O'Connor, 2002). Buprenorphine was designated as a Schedule III
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drug, whereas the more tightly regulated methadone is a Schedule II narcotic. The designation
asa Schedule III medication is very significant; it entails less stringent guidelines, controls,
and prescribing ability, as well as increased access to use buprenorphine in both an office
based and specialized clinic treatment setting. By some estimates the number of clients in
methadone maintenance has remained stable over the last 10 years at around 200,000 clients in
the United States whereas buprenorphine, which has only been clinically approved since
2002, now boast over 650,000 clients engaging in this form of treatment nationwide (Center
for Substance Abuse Treatment, 2005).
A critical review of the research demonstrates that buprenorphine is as effective if not
more so than methadone, LAAM, or naltrexone (Amato et al., 2008; Batki et al., 2008; Bickel
& Amass, 1995). It represents the newest advancement in the field of medication assisted
treatment for opioid dependent clients. Buprenorphine has undergone multiple clinical trials,
double blind studies, and randomized trials beginning in 1986 and continuing today. The body
of evidence continues to be demonstrated by researchers and clinicians and drug treatment
policy has reflected this trend. It remains under some debate and scrutiny whether methadone
or buprenorphine holds the most advantages and is most effective. Research continues to bear
out the advantages and disadvantages of each approach and when each medication is best
indicated for individual clients.
Literature Summary
Table 2.1 shows the major categories of treatment modalities for opioid dependence as
outlined (no treatment, psychosocial counseling, and medication assisted treatments—
naltrexone, LAAM, methadone, and buprenorphine), the research authors, publication date,
article title, research method and theme of article.
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Table 2.1
Research Studies Addressing the Four Opioid Addiction Treatment Modalities
Type of Treatment

Author

Title

Methods/Findings

No Treatment “Ageing
out”

Waldorf, D. 1983

Natural Recovery from
Opioid Addiction: Some
social-psychological
processes of untreated
recovery

Exploratory “in depth”
study. Combination of
Qualitative and
Quantitative approaches
with 201 ex-addicts.
Selected via the snowball
approach, exploratory
research. Not
representative of any
population, restrictive
generalization with no
specific theories or
hypothesis. Findings are
“maturing out” concept is
not sufficient to explain
variations of opioid
addiction and subsequent
results

Psychosocial Counseling

Katz EC, Chutuape MA,
Jones HE, Stitzer ML

Voucher reinforcement for
heroin and cocaine
abstinence in an outpatient
drug free program

Quantitative and
Qualitative study involving
52 participants who were
Opioid Dependent.
Randomly assigned to
voucher or no voucher
groups and enrolled in an
outpatient drug free
program. Participants were
stratified on three
variables. All participants
recently completed
Inpatient Detox. Findings
did not improve retention
or abstinence outcomes.

Naltrexone (Vivitrol) oral
or injection Opioid blocker

Cornish, J. Metzger, D.
Woody, G. Wilson, D.
McLellan, T Vandergrift,
B. O’Brien, C.

Naltrexone
Pharmacotherapy for
Opioid Dependent Federal
Probationers

Quantitative study with 51
volunteers randomly
assigned to 2 groups.
Limited sample size and
sampling group. Good
design, methods, & internal
validity. Limitation for
generalization due to
sampling population being
respondents on federal
probation. Results indicate
that naltrexone (oral) and
counseling are effective in
cutting down positive
Urine drugs screens, and
re-arrest.

LAAM (Levomethadyl
Acetate or Long acting

Johnson, Rolley E;
Chutuape, Mary Ann;

A comparison of
levomethadyl acetate,

Quantitative study with
N = 220 respondents
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Methadone)

Strain, Eric C; Walsh,
Sharon L; Stitzer, Maxine
L; Bigelow, George E

Buprenorphine, and
methadone for opioid
dependence

participating in a single site
randomized controlled
study with four treatment
groups. LAAM as
compared to Methadone
(low and high dose) and
Buprenorphine. Stratified
according to gender, age,
marital status, &
personality. Reviewed and
cleared by IRB committee.
Results LAAM along with
Buprenorphine, and high
dose Methadone
substantially reduced use
of illicit Opioids.

MMT (Methadone
Maintenance Treatment)

Gunne, Lars-M;
Grönbladh, Leif

The Swedish methadone
maintenance program: a
controlled study

Quantitative and
Qualitative research study
of Chronic IV Heroin
addicts. Small sample size
N = 34. Randomly
assigned, however not a
blind study. Ages of
respondents only 20-24
years old, limited ability to
generalize results. Controls
were loose. Results
demonstrate support for
Methadone for efficacy in
treating Opioid addiction.

Buprenorphine (Bup/nal)

Mattick RP, Ali R, White
JM, O'Brien S, Wolk S,
Danz C

Buprenorphine versus
methadone maintenance
therapy: A randomized
double-blind trial with 405
opioid-dependent patients

Quantitative and
Qualitative study, mixed
design. N = 405
respondents in a 13 week
randomized controlled
double blind double
dummy trial. Study took
place outside US in
Australia a different
cultural/geographic
context. Findings support
Buprenorphine in its ability
to suppress Heroin use and
did not differ in the more
popular medication
Methadone, however
retained 10% fewer
respondents in the
Buprenorphine group.

Conclusion
The literature that covers treatment for opioid dependence dates back over 60 years and
covers three main themes: (a) No treatment, aging out, or spontaneous recovery;
(b) Psychosocial counseling approaches (cognitive behavioral treatments with no medications);
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and (c) Medication assisted treatment. The field has been evolving since its inception in the
1940s to the present state it is today. The early forms of intervention, treatment, and research
included the argument that opioid dependent people would recover on their own with no formal
intervention. Noted in the research literature of aging out or spontaneous recovery (Biernacki,
1990) cited earlier work by Winick (1962) that suggested that opioid use was simply a
maladaptive response and only represented a phase where most people were able to stop on their
own. In today’s landscape doing nothing and waiting for people who have this brain disorder to
simply deteriorate represents an unethical practice now that modern literature has noted the use
of medications to assist in the treatment and recovery process as best practice.
The second and most popular mode of treatment for opioid dependent individuals was
the traditional counseling and cognitive behavior treatments (CBT). These treatments become
popular in the 1960s and did not address the medical nature of opioid dependence. Psychosocial
approaches of counseling and support via 12-step support groups originally held great promise as
had previously happened in the alcoholism recovery movement, however these treatment that
were based on a totally abstinence-based lifestyle did not produce good outcomes (Flynn et al.,
2003).
The most well studied of all treatment approaches for opioid dependence included the
use of medications to assist in the treatment and recovery process. LAAM (long acting
methadone) is a medication that is no longer being used, is discontinued and not being
manufactured due to severe and life threating side effects, The first and most studied medication
was methadone which has been studied in many clinical trials since its’ first use in 1947.
Methadone became the primary medication utilized in the field of medications assisted treatment
until a more recent medication (buprenorphine/naloxone), often known under a brand name of
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Suboxone® (bup/nal), underwent clinical trials and was approved for use in 2004 in the United
States. Together methadone and buprenorphine/naloxone, or the term used in this study, bup/nal,
represents the current accepted practice within the opioid treatment field. Medication assisted
treatment as it has become known is no longer just a treatment option, but a widely accepted and
utilized adjunct to most of today’s treatment of opioid dependence. The literature clearly shows
an evolvement from earlier paradigm’s that did not demonstrate good client outcomes, to the
current state of medication assisted treatment that utilizes methadone, buprenorphine/naloxone,
and naltrexone.
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Chapter III: Methodology
This research project was a comparative mixed methods study with data collection
focused on attitudes, beliefs, and practices of three groups of participants. These participants
make up what is referred to as the “three legged stool” in the field of opioid addiction and the
field of medication assisted treatment (MAT)—the prescribing medical providers, chemical
dependency professionals (CDPs), and opioid addicted clients in treatment at methadone and
bup/nal attitudes, beliefs, and practices in the opioid dependence treatment field. Analysis
includes descriptive and comparative ANOVA statistics with post hoc analysis. Quantitative and
qualitative data were collected via a survey, and covered a range of research questions that the
study has formally addressed. The method of research and how data were collected, as well as a
deeper look into the participants, the survey itself, and how survey responses were analyzed are
explored below.
Study Design
A mixed method design was utilized for this review as both quantitative and qualitative
data were collected and analyzed. Mixed methods research designs offer several important
advantages, particularly that combining both qualitative and quantitative paradigms strengthen
the research and creates a stronger theoretical framework by providing two pathways of thought
and a more robust design. This design also ensures that questions are answered in ways that a
pure qualitative or qualitative approach would not allow for. The mixed method design is a more
practical approach and fit for this study because it allows for information on both the frequency
of beliefs and practices as well as the stories underlying them.
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Research Questions
There are five research questions for this inquiry:
1. What attitudes, beliefs, and practices do medical providers, chemical dependency
professionals, and clients have related to medication assisted treatment of opioid
addiction?
2. To what degree are the attitudes, beliefs, and practices for the three groups different from
those of the other groups?
3. What is the variability on views related to treatment options within each group?
4. What underlying beliefs and philosophies explain the similar or different views of the
three groups?
5. What implications do these differences have for each group of participants in the opioid
addiction treatment field?
Participants and Sample Size
The population that is the focus of this study included medical providers, CDPs, and
clients in both a methadone and bup/nal opioid treatment program in Washington State. The first
category of respondents was medical providers, including prescribing physicians and physician’s
assistants who are working in the field of opioid dependency treatment and medication assisted
treatment settings throughout Washington State. Traditional training of medical providers leans
toward a natural tendency to support medication assisted treatment. The scope of medical
providers’ practice includes prescribing and adjusting medications, and advising clients about
them. Providers have expressed concern that patients being treated under the current model are
being negatively influenced by attitudes and perceptions of clients, their peers, and their CDPs.
Some of these attitudes include beliefs that clients don’t need medication and they are
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marginalized because they are not seen as being in recovery when they are on medications. Or,
that they are inherently weak because these have to rely on medications to assist them in the
recovery process. The medical providers for this study were those who worked in Washington’s
certified opioid treatment programs, and outpatient office based practices that were credentialed
under the Federal DATA 2000 program to provide office-based medication assisted treatment.
These providers are identified through several available databases that include membership in
Washington state association of opioid treatment professionals, state board certified ASAM
(American Society of Addiction Medicine) physicians, bup/nal and buprenorphine locater
websites, and staff that work in methadone and buprenorphine clinics. There are over 400
medical providers statewide, with an expectation of between 50 and 75 responses to the survey.
The second category of respondents were the CDPs, also known as certified addiction
counselors, that professionally counsel and oversee each opioid dependent client as well as
clients with other addictions. Many CDPs were trained in an abstinence-only paradigm and this
study was designed to measure and analyze their current attitudes, beliefs, and practices related
to medication assisted treatment. The CDPs in the study were certified in the state of
Washington and credentialed through the Washington State Department of Health. They are the
only certified professionals that are recognized and licensed to deliver addiction counseling and
recovery services to any and all clients enrolled in chemical dependency treatment programs
throughout the state. A CDP must be working under the auspices of a state certified chemical
dependency program as per Washington State Department of Behavioral Health and Recovery
(DBHR) requirements. There are currently over 1000 credentialed CDPs in Washington State.
Washington Department of Health (DOH) provided a list of all CDPs licensed in the State of
Washington through the state’s public disclosure law. The list sent to me included the name,
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status, and email contact information of all Washington State licensed CDPs. This list was used
to contact CDPs and invite them to take part in the voluntary and anonymous survey sent to their
email addresses and filled out on line utilizing Survey Monkey. The goal for this study was to
have at least 100 CDPs respond and I received over 200 survey responses from this group.
The third category of respondents was those clients who had been diagnosed as opioid
dependent and who were participating in one of two opioid treatment programs in Washington
State. The first was a methadone clinic where I spent two days collecting over 200 paper and
pencil surveys. The second was a bup/nal clinic where I also spent two days collecting over 130
paper and pencil surveys. Clinic participants were an important element of this study. Other
studies have focused on treatment staff and addiction providers, while those that they serve have
been left out of the study design. Few studies have sought to collect and analyze data from
opioid dependent clients about their medication assisted treatment attitudes and beliefs. At the
time of the study, there were 4,500 clients who were participating in opioid treatment programs
statewide.
Instrument of Measurement Population Survey
The data collection instrument used for this research projects was a 21- (client) and
29- (medical provider/CDP) question survey that covered the topics of: perception/attitudes
toward current medications, perceived effectiveness of medications, short and long terms goals
of medication assisted treatment, length of treatment, views on weaning off medication,
potential drawbacks of the three primary medications (methadone, bup/nal, vivitrol) utilized in
opioid treatment, preferred practices, and challenges facing providers and recovering opioid
dependent individuals.
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Statements related to attitudes, beliefs, and practices about medication assisted treatment
had 6-point Likert-type response scales, including “strongly disagree” to “strongly agree,” “not
at all effective” to “very effective,” and “not at all helpful” to “extremely helpful.” Specifically,
the issues covered were : respondents’ attitudes toward medication assisted treatment, how
strongly they believe in the efficacy of current opioid treatments, which medication is more
effective, how long treatment should last, the drawbacks of each therapy, long and short term
treatment goals, which approaches respondents find most helpful, and whether those receiving
treatments experience shame, judgment or continued marginalization. There were also several
open-ended questions designed to encourage respondents to share their stories related to their
attitudes, beliefs, and practices about medication assisted treatment for opioid dependence.
Although the same core questions were asked of survey respondents from all three respondent
groups, additional questions were also asked of each individual group. The survey also collected
some demographic information, including age, gender, lengthy of time working in the opioid
addiction field, type of treatment modality, and length of time in recovery. This survey
instrument was not limited to the most studied medication, methadone, but also included
questions related to the most popular medications used currently—methadone, buprenorphine,
and naltrexone (vivitrol).
Data Collection Procedures and Participants
Collection of survey data was completed in one of two ways, either a paper and pencil or
online version. Methadone and bup/nal clinic participants were surveyed at their opioid
treatment clinic locations with paper surveys that were then entered into the statistical database.
Electronic online surveys were used for both the medical providers and CDPs. Medical
provider and CDP survey participants were asked to identify themselves as belonging to one of

52

the two groups. The survey instrument utilized an automated “skip logic” function to
differentially move survey respondents into either medical provider or CDP specific questions
depending on how they responded to this survey item. In order to utilize electronic collection
methods survey participants were sent an email with an embedded link giving them the context
of the survey and inviting them to participate.
Survey Monkey was used as the electronic collection method for medical providers and
CDPs. The medical providers and their emails are listed on a Suboxone® (bup/nal) physician
locater websites http://www.buprenorphine-doctors.com/suboxone-doctors/Washington-WA.cfm
and
http://www.opiateaddictionresource.com/treatment/suboxone_treatment_directory/wa_suboxone.
In addition, email contacts for medical directors of all Washington State certified opioid
treatment programs were provided by the Washington State Opioid Treatment Providers
Association. The names and email addresses were downloaded unduplicated into an Excel
spreadsheet and online surveys were sent to all available utilizing Survey Monkey.
The CDPs were located by contacting the Washington State Department of Health
utilizing the public disclosure laws. The health systems quality assurance public disclosure unit
of the Washington State Department of Health provided a full database of all CDPs that were
currently licensed and registered within the State of Washington. The Department of Health
provided me the list under their public disclosure policy and gave me permission to use the
names and email to contact interested participants to fill out the survey. These CDPs were
contacted in the same way as medical providers, through an email that includes an embedded
link that directed them to the electronic survey in survey monkey.
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Buprenorphine physicians were located through a public list as noted on the Substance
Abuse and Mental Health Services Administration (SAMHSA) website locater list. Medical
providers at state methadone clinics were also listed publicly through a common website and
were located and contacted through an email survey introduction. I also followed up with direct
phone calls to each Washington State certified opioid treatment program clinic and their medical
providers to further inform them of this research project and invite them to participate in the
online survey.
The third group of participants was active clients in two identified state-certified
chemical dependency programs. The two opioid treatment programs supported the collection of
paper surveys at their clinic sites—one was a methadone treatment center and the other one was
a bup/nal treatment clinic. Agency directors were contacted in order to obtain permission for the
survey to be distributed and collected at each site. Strict confidentiality of all data was ensured as
no client identifying information were collected or used in this research. Confidentiality and
anonymity statements were also posted on the survey collection tables and embedded in each
survey. All agency IRB policies were followed throughout the collection process. Collection of
paper surveys from the clinic clients occurred in each clinic’s waiting room area where clients
were waiting to be called in to take their medication. A work station with information about the
research study and informed consents was set up in each clinic starting at 8 a.m. on the data
collection days. I spent two full days at each clinic collecting surveys, as my target collection
was a minimum of 100 responses from each clinic. Clinic clients were asked to volunteer to
complete the survey [as they were passing through the waiting room area both before and after
they received their daily medication.] Procedures were established and followed that allowed
for confidential completion of the surveys and return of the survey directly to the researcher
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without routing it through a third party. The researcher provided chairs, clipboards, and pencils
so that volunteers were allowed the time and ease to complete their surveys. Surveys collected by
the researcher were stored in a locked storage cabinet. Paper and pencil survey data was
manually entered into a Survey Monkey data file and then downloaded to Statistical package for
the Social Sciences (SPSS) for analysis.
This survey was tested by consulting with the Antioch Survey Research Group for clarity
and general level of reading and understanding. A pilot study was also conducted with three
participants in each research group. An email was sent to three identified medical professionals,
and three CDPs. Paper client surveys were piloted by three staff members who are recovering
from opioid dependence and were fully informed as to the purpose of the pilot study and signed
an informed consent.
Data Analysis
Data analysis of all collected responses was undertaken utilizing a concurrent
triangulation design (Creswell, 2014). The quantitative and qualitative data collection occurred
concurrently through the survey and analysis began during the data collection phase. Field notes
were also recorded during the four days of data collection at the two opioid treatment program
sites. Clinic participants were very vocal and outspoken in the waiting room areas as they
awaited their daily medications while filling out surveys. The data were collected in the same
instrument, but the quantitative analysis was conducted before the qualitative analysis. The
qualitative data were used to help interpret the quantitative findings. Descriptive data were
presented and analyzed for all closed-end survey questions. The descriptive statistics included
frequency and percentage distributions, as well as mean scores and standard deviations. In
addition to the descriptive quantitative data, across group comparisons using ANOVA with post
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hoc analysis and t-tests were made for: treatment settings, type of medication utilized in
treatment, beliefs/attitudes toward medication assisted treatment, long/short term goals of
treatment, length of time on medications, attitude on recovery status of clients, what forms of
treatment are considered most effective, and measures of judgment/criticism and marginalization
of clients receiving medication to assist in opioid dependence treatment and recovery.
There were three groups in the study—medical providers, CDPs, and clients. Clients
were either methadone or bup/nal medication assisted treatment. Responses from methadone
clients frequently differed significantly from bup/nal clients. For this reason, their responses are
reported separately on the tables. A one way ANOVA with Tukey post hoc analysis was used to
compare means scores for the medical providers, CDPs, methadone clients, and bup/nal clients.
For some variables only two groups were compared; in this case a t test was used to test for
significant differences across means. The tools used to collect and subsequently analyze data
were Survey Monkey and SPSS.
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Table 3.1
Analysis Plan

Topic

ANOVA
with Post
Hoc

t-tests

Survey Question (#)

Medical
providers
& CDPs

[#2] Current state of affairs in
treating opioid dependency.

X

X

Medical
providers
& CDPs

[#3] Variety medications
available to treat opioid
dependency.

X

X

All Groups

[#15] How each of the groups is
responding to the need of
people with opioid
dependency.

Overall

Medication

Descriptive
Statistics

Group(s)

X

X

X

X

All Groups

#12 (item #3) Long term goal of
medication assisted treatment

All Groups

[#8] Narrative analyses -Thoughts on medication
assisted treatment

Medical
providers
& CDPs

[#16] Opinions on medication
assisted treatment

X

Medical
providers
& CDPs

[#3] How effective is each
medication?

X

All Groups

[#4] How long stay on each
medication?

X

All Groups

[#6a] Narrative analysis Downsides and benefits of
methadone
[#6b] Downsides and benefits
of bup/nal

All Groups

[#6c] Downsides and benefits
of naltrexone (vivitrol)

X

X
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Decision
Making

All Groups

Decision
Making

All Groups

[#10] Treatment components

Opioid
Dependent
Experience

All Groups

[#18] Narrative Analysis -Thoughts on medication
assistance

All Groups

[#13] Narrative Analysis –
Challenges in medication
assisted treatment

All Groups

[#14] Narrative Analysis -What recovery means

Client
groups

[#2] Response to treatments
by three groups in survey

X

All Groups

[#17] Age category

X

All Groups

[18] Gender

X

Recovery

Demographics

CDP
counselor

Opioid
treatment
client

Pressure

Opioid
treatment
client

[#9] Who should make
decisions about weaning off
medication?

[#26] Type of treatment
setting

X

X

X

X

X

[#27] length of time as CDP/
experience in the field of study

X

[#3] type of medication
currently taking

X

[#4] Length of time on
medication

X

[#20] pressure to get off
medication

X

[#21] Narrative analyses Additional client thoughts

X
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Qualitative data were used to help describe and explain the nuances of the similarities
and/or differences across groups. Narrative responses to the open-ended questions were coded to
reflect the major themes. I coded in six phases in order to create established and meaningful
patterns. These phases include (a) familiarizing myself with the data, (b) generating codes,
(c) searching and identifying categories represented by the codes, (d) reviewing the categories
for themes, (e) naming and defining the themes, and (f) produce the final report of findings. The
Survey Monkey text analysis tool was used to assist in the narrative analysis.
Key narrative data that add meaning and depth to the quantitative findings are shown in tables
for each of the open-ended questions. Data were collected in October and November 2015.
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Chapter IV: Findings of the Study
This study investigated the attitudes, beliefs, and opinions of the three primary groups
involved in the opioid dependence treatment process. Those answering surveys were medical
providers in both office based practice and state certified (opioid treatment programs, chemical
dependency professionals (CDP), and clients who were participating in an outpatient methadone
or bup/nal opioid treatment program. Specifically, this study sought to understand the difference
in attitudes and beliefs that these three groups held in regards to several key variables in the
opioid addiction treatment and recovery process.
The three groups surveyed were (a) medical professionals (N = 43), including physicians
and mid-level providers (physicians assistants and nurse practitioner); (b) CDPs licensed in
Washington State (N = 199); and (c) active clients in either an outpatient methadone clinic
(N = 199) or an outpatient bup/nal clinic (N = 137).
Data Preparation
Client surveys collected at the methadone and bup/nal clinic sites were sorted and
reviewed for completeness. Twenty-three (23) methadone client surveys and 14 bup/nal client
surveys were only partially filled out and were therefore eliminated from the analysis. The online
surveys submitted by CDPs included 56 that were only partially completed; these CDP surveys
were also eliminated. All online surveys collected from medical providers were complete.
One variable required some recoding. CDPs were asked to best describe the treatment
program where they currently worked. Six surveys were recoded from “other” to the category of
outpatient treatment with no medication assisted treatment. These six surveys were
re-categorized based on their narrative responses that indicated they worked in some form of
outpatient treatment programs that did not utilize medications as a part of their treatment
regimes.
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The client surveys were keyed into a digital database from the paper and pencil format.
Thus, there were two databases—a medical provider and CDP database and a client database that
included both methadone and bup/nal clients. ANOVA analyses required having responses to
similar questions from the different databases in one file. Thus, data were moved into one
master file for analysis.
Demographics
The demographic data collected from all three respondent groups included their age

category and gender. Other demographic data collected varied by group. Medical providers were
asked how long they had been providers in the opioid treatment field, their work settings, and the
types of medications they utilized in their medication assisted treatment practice. CDPs were
asked how long they had been practicing in the addiction field as well as their work settings.
Clients were asked the length of time they had been on methadone or bup/nal and in recovery.
Age and gender for all three respondent groups. Medical providers were older than
any of the other groups with over half (54%) reporting their age as 51 years of age or older.
Medical providers also had a high percentage (28%) in the 60 or older category as compared
with CDP’s (16%), methadone clients (5%) and bup/nal clients (4%). None of the medical
providers were under the age of 30 and 46% were between the ages of 31–50 (see Table 4.1).
The CDPs were somewhat younger than the medical providers, with 61% under age 51, 13%
between the ages of 21 and 30, 24% between 31 and 40, and 24% between 41 and 50. About
39% were age 51 or older, with 16% age 61 or older (see Table 4.1).
The methadone clinic clients were fairly evenly spread across the 21 and 60 years old age
groups, with 21% between 21 and 30, 30% between 31 and 40, 20% between 41 and 50, and
24% between 51 and 60. A few (5%) methadone clinic clients were 61 or older (see Table 4.1).
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The bup/nal clinic clients were largely younger with 2% under age 21 and 87% between the ages
of 21-50. Only 11% were over age 51 (see Table 4.1).
Table 4.1
Age Group Percentage Distributions for Medical Providers, CDPs, and Methadone and Bup/nal
Clients
Age Group

18-20 years old
21-30 years old
31-40 years old
41-50 years old
51-60 years old
61 or older

Medical
Providers
%
N = 43

30.2
16.3
25.6
27.9

CDPs
%
N = 199

13.4
23.7
23.7
23.2
16.0

Clients
Methadone
Bup/nal
%
%
N = 199
N = 137
1.5
20.7
36.5
30.1
32.1
20.2
19.0
23.8
7.3
5.2
3.6

The respondent groups also varied by gender distribution. The medical providers were
predominately male (74%), with the other 26% female. The CDPs were more predominately
female, with 66% females and 34% males. Both the methadone and bup/nal outpatient client
groups had more female participants (58% and 56% respectively) than males (42% and 44%
respectively). Based on clinic statistics, this is a percentage distribution that closely reflected the
gender spread at the methadone (50% females and 50% males) and bup/nal (54% female and
46% male) clinics (see Table 4.2).
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Table 4.2
Gender Percentage Distributions for Medical Providers, CDPs, Methadone and Bup/nal Clients
Gender

Female
Male

Medical
Providers
%
N = 43
25.6
74.4

CDPs
%
N = 199
66.5
33.5

Clients
Methadone
Bup/nal
%
%
N = 199
N = 137
58.0
55.9
42.0
44.1

Medical provider and CDP professional demographics. Medical providers were
asked how long they had been in the opioid treatment field, while CDPs were asked how long
they had been practicing in the addiction counseling field. CDPs reported a higher number of
professionals practicing for less than one year (12%), however, in all other categories of
experience the percentages were very similar between the two groups (see Table 4.3).
Table 4.3
Percentage Distributions for Length of Time as a Medical Professional in Opioid Treatment
Field or as a CDP
Time as OTP or
medical provider

Less than 1 year
1 to 5 years
6 to 10 years
11 to 20 years
21 years or more

Medical
Providers
%
N = 43
7.0
30.2
16.3
25.6
16.3

CDPs
%
N = 199

Clients
Methadone

Bup/nal

12.4
34.0
19.1
18.6
16.0

Medical professionals were asked what type of opioid treatment setting they were
currently working in. They worked in a cross section of opioid treatment settings, with some
providers working in more than one setting. Medical professionals often work in more than one
setting; thus, they were encouraged to “check all that apply.” The diversity of settings included
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outpatient methadone clinic (14%), outpatient bup/nal clinic (62%), detox unit (24%), and other
settings (23%), such as hospital addiction programs, family practice, residential treatment, pain
management, and hospital emergency room (see Table 4.4).
Table 4.4
Percentages for Medical Provider Respondent Places of Work
Medical providers
Work setting

Medical Providers
%
N = 43
14.3

CDPs

Clients
Methadone
Bup/nal

Methadone Clinic OTP (Opioid
treatment program)
Office based practice
61.9
Bup/nal/Buprenorphine
Bup/nal program with Physician
23.8
in an outpatient chemical
dependency program
Bup/nal Clinic OTP (Opioid
26.2
treatment program)
Detox unit
23.8
Other
23.8
Note. Medical Providers often had more than one place of work.
Medical providers were also asked to list all the medications used in their current
practice. A large majority utilized bup/nal (92%), subutex (81%), and naltrexone/vivitrol (69%),
while the minority (21%) used methadone in their medication assisted treatment. Only a few
medical providers (9%) identified other medications they used in their medication assisted
treatment practice, such as Zubsolv®, Bunavil®, Butrans®, and Campral® for alcohol abuse.
(See Table 4.5.)

64

Table 4.5
Percentages for Medications That Medical Providers Use in Their Medication Assisted
Treatment Practice
Medications used in
Medication Assisted Treatment
Bup/nal
(buprenorphine/naloxone)
Buprenorphine (subutex)
Naltrexone (oral or injection),
vivitrol
Methadone
Other

Medical Providers
%
N = 43
95.2

CDPs

Clients
Methadone
Bup/nal

81.0
69.0
21.4
9.5

CDP respondents worked in a variety of settings and were not limited to traditional
methadone/bup/nal opioid treatment programs. The majority (89%) of CDPs were not currently
employed in a methadone/bup/nal clinic. They either worked in an outpatient treatment program
with no medication assisted treatment (29%), in an outpatient center that had a medical provider
that prescribes bup/nal (30%), or in another chemical dependency treatment setting (31%), such
as long and short term inpatient chemical dependency treatment programs, detox centers,
outpatient agencies with co-occurring caseloads, drug courts, private practice, outpatient mental
health centers, juvenile justice centers, and even school settings (see Table 4.6).
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Table 4.6
Percentage Distributions for CDP Respondent Place of Work
Treatment Program
Description. *

Medical
Providers

CDPs
%
N = 199

Methadone Clinic
Bup/nal Clinic
Outpatient Treatment with NO
Medication Assisted Treatment
Outpatient Treatment with
medical provider that prescribes
bup/nal
Other
* Note. A few CDPs had more than one place of work.

Clients
Methadone
Bup/nal

9.6
2.0
28.8
29.8
30.8

Client demographics. Clients that were actively attending and participating in the
medication assisted treatment for opioid dependency were asked about the length of time they
had been receiving help from their particular clinics. Methadone clients were more than twice as
likely to have been participating in treatment less than 1 year (56%) as compared with bup/nal
clients (27%). The highest percentage (42%) of bup/nal clients had been receiving treatment at
their clinic for 2–3 years. About one-third of both methadone and bup/nal clients had been
receiving treatment at their clinics for more than three years, 32% and 31% respectively (see
Table 4.7).
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Table 4.7
Percentage Distributions for Length of Time as an Active Client in Methadone and Bup/nal
Treatment Programs
Time in clinic

Medical
Providers

CDPs

Less than 1 year
A few years (2-3)
More than 3 years

Clients
Methadone
N = 199
%
56.3
12.1
31.7

Bup/nal
N = 137
%
27.0
42.3
30.7

Methadone clients (30%) were much more likely than bup/nal clients (7%) to be taking the
medication for 6 or more years. Methadone maintenance treatment has also been used to treat
opioid dependence for over 45 years. Bup/nal was approved by the FDA in 2004 for use in
opioid treatment. However, bup/nal clients (35%) were more likely than the methadone clients
(20%) to be on their medication for 3-5 years (see Table 4.8).
Table 4.8
Percentage Distributions for Length of Time Methadone and Bup/nal Clients Have Been Taking
Medication for Opioid Dependence
Length of time on medication

0–5 months
6 months to 2 year
3 year to 5 years
6 years or more

Medical
Providers

CDPs

Clients
Methadone

Bup/nal

%
16.8
32.2
20.2
30.3

%
21.5
37.0
34.8
6.7

The majority of clients in both the methadone (88%) and bup/nal (98%) clinics identify
themselves as being in recovery. The methadone clients were more likely to be only somewhat
sure (25%) about being in recovery. Methadone clients were also more likely than their bup/nal
counterparts to report they are not in recovery, 9.7% compared 1.5%. Methadone clients
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appeared less clear and certain about their recovery status than did bup/nal clients (see
Table 4.9).
Table 4.9
Percentage Distributions for Clients Belief They Are in Recovery From Opioid Dependency for
Methadone and Bup/nal Clients
In recovery

Yes, definitely
Yes, somewhat
No

Medical
Providers

CDPs

Clients
Methadone
Bup/nal
%
%
N = 199
N = 137
61.9
85.2
26.5
13.3
11.6
1.5

Methadone clinic and bup/nal clinic clients were asked about the length of time they had
been in recovery from opioid dependence. Bup/nal clients reported being in recovery for longer
periods of time, with 64% in recovery for one year or more compared to 52% of methadone
clients. All bup/nal clients reported themselves to be in some time linked stage of recovery,
whereas over 5% of methadone clients did not view themselves as in recovery at all (see
Table 4.10).
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Table 4.10
Percentage Distributions for Length of Time Methadone and Bup/nal Clients Believe They Have
Been in Recovery From Opioid Dependence
Length time in recovery

Medical
Providers

CDPs

0–5 months
6 months to 1 year
1 to 2 years
3 years or more
Not in recovery

Clients
Methadone
Bup/nal
Clients
Clients
%
%
N = 199
N = 137
21.8
18.9
20.8
17.4
17.8
29.5
34.5
34.1
5.08
0.00

A large majority (79% and 92% respectively) of methadone and bup/nal clinic clients saw
the treatment services they were receiving as having helped a lot. No bup/nal participants rated
the treatment as not helpful and only a small percentage (1.4%) of the methadone clients saw the
treatment as not helpful at all. Overwhelmingly all clients surveyed viewed their medication
assisted treatment services as helpful (see Table 4.11).
Table 4.11
Percentage Distributions for Methadone and Bup/nal Client Perception of How Helpful
Treatment Services
Has treatment helped

Helped a lot
Somewhat helped
Helped a little
Not helped at all

Medical
Providers

CDPs

Clients
Methadone
%
N = 199
79.5
14.1
4.8
1.4

Bup/nal
%
N = 137
92.7
7.3
0.0
0.0
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As expected, almost all (99% and 98% respectively) clients in the methadone and bup/nal
clinics surveyed self-reported being exclusively on the medication that their particular clinic
endorsed.
Attitudes Toward Medication Assisted Treatment
All three respondent groups were surveyed on a variety of opioid treatment issues in
order to understand the similarities and differences in their attitudes toward medication assisted
treatment. The attitudes explored included important treatment issues related to progress in the
OTP field, effectiveness of medications, length of time clients should be on medications, helpful
components of treatment, and a variety of other issues as listed in the tables below.
The quantitative responses to the survey addressed three research questions about
attitudes toward medication assisted treatment for opioid addiction. These were:
1. What attitudes, beliefs, and practices do medical providers, CDPs and opioid
dependent, addiction counselors, and clients have related to medication assisted
treatment of opioid dependence?
2. To what degree are the attitudes, beliefs, and practices for the three groups different
from those of the other group?
3. What is the variability on views related to treatment options within each group?
There were significant differences across respondent groups for most variables. Within
the client group, the methadone and bup/nal clients also frequently had significantly different
responses. Thus, client group responses were broken out in the analyses by methadone and
bup/nal client group.
Overall progress. Medical providers and CPDs were asked about their views on the
progress being made in addressing the opioid addiction problem within the treatment field.
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Medical providers (M = 6.33) on a response scale of 1 (no progress at all) to 10 (great deal of
progress) had a statistically significant more positive view of the progress being made in
addressing opioid addiction than the CDPs (M = 5.32), t(1,235) = 3.15, p = .002. Medical
providers and CDPs were also asked about the effectiveness of the medications currently being
utilized in the opioid addiction treatment field. Again, on a scale of 1 (not at all effective) to 10
(very effective), medical providers (M = 7.55) rated the effectiveness significantly higher than
the CDPs (M = 6.08), t(1,235) = 5.8, p = .000 (see Table 4.12). Methadone and bup/nal clients
were not asked these two overall rating questions. Results were statistically significant that CDPs
rated both progress in the field and effectiveness of medications lower than the medical
providers.
Table 4.12
Mean, Standard Deviation, and t-Test Results for Overall Progress and Medication Effectiveness
in Addressing Opioid Dependence Problems for Medical Providers and CDPs

Overall…

…Progress in addressing opioid
addiction problem within opioid
addiction treatment field
…Effectiveness of currently
available medications utilized in
the opioid addiction treatment
field.

Medical
Providers
(N = 43)
M(SD)

CDPs
(N = 199)
M(SD)

6.33

5.32

(1.90)

(1.86)

7.55

6.08

(1.61)

(2.07)

Clients
Methadone

T-test

Bup/nal

.002

.000

Supporting group response to opioid dependence issues. Medical providers, CDPs,
and methadone and bup/nal clients were asked to assess how well various supporting groups
were doing in responding to the needs of opioid dependent individuals. Response options were

71

1(not at all well), 2(somewhat okay), 3(okay), 4(well), and 5(extremely well). ANOVA results
showed there were statistically significant differences across respondent groups for each
supporting group, F(3,557) = 33.2, p = .000. Post hoc analysis identified the specific respondent
group differences at the p < .05 level. With respect to how the physicians were doing in
responding to needs of clients, bup/nal clients (M = 3.89) were most likely to see this group as
doing well as compared to methadone clients, CDPs, and physicians.
Respondent groups were also asked how the counselors were doing at responding to the
needs of opioid dependent individuals. ANOVA results showed there were statistically
significant differences across groups F(3,545) = 18.3, p = .000. Post hoc analysis showed that
when it came to rating the counselors on the same response scale at the p = .000 level of
significance the bup/nal clients (M = 4.03) were again more likely to view them as doing well
compared to the methadone clients responses (M = 3.31) and the medical providers responses
(M = 3.21). At the same time, medical providers (M = 3.21) were significantly less likely than
CDPs (M = 3.83) and bup/nal clients (M = 4.03) to see counselors as doing well. Medical
providers did not rate the counseling as effective as did other groups, this has implications
toward integrated care.
Respondent groups were also asked how they felt their local communities were doing in
responding to the needs of opioid dependent individuals. The mean scores for support from local
communities for all groups were lower than for any other supporting group. ANOVA results
showed there was also a statistically significant difference across respondent groups
F(3,550) = 13.0, p = .000. Post hoc analysis showed that at the p < .05 level both methadone
(M = 2.24) and bup/nal (M = 2.29) client groups responded more positively than either CDPs
(M = 1.78) and medical providers (M = 1.83) in regards to how their local communities were
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responding to their needs. Medical providers and CDPs did not have a good regard for how their
local communities were doing in responding to the needs of affected individuals, suggesting a
need for improvement in shared responsibility.
Respondent groups were also asked how the clients themselves were doing at responding
to the needs of opioid dependent individuals. ANOVA results showed there was statistically
significant across groups F(3,544) = 32.7, p = .000. Post hoc analysis again showed at that the
p = .000 level of significance methadone (M = 3.06) and bup/nal (M = 3.42) clients were more
likely to see clients responding better to the problem of opioid dependence as compared to the
hired professionals.
Respondent groups were also asked how family and friends were doing at responding to
the needs of opioid dependent individuals ANOVA results showed there was a statistically
significant difference across respondent groups F(3,551) = 50.5, p = .000. Post hoc analysis
showed that at the p = .000 level of significance bup/nal (M = 3.46) clients reported higher mean
scores on the family and friends response to the needs of opioid dependent individuals, than
medical providers (M = 2.39), CDPs (M = 2.07), and methadone (M = 2.81) clients were less
positive about the support of family and friends. Methadone clients were also significantly more
positive about the support of family and friends than medical providers and CDPs. The medical
providers and CDPs did not differ on this item. It appears that both sets of paid professionals
underrated the helpfulness of the client’s family members and friends (see Table 4.13).
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Table 4.13
Mean, Standard Deviation, and ANOVA Results for Overall Progress in Addressing Opioid
Dependence Problems for Medical Providers, CDPs, and Methadone and Bup/nal Clients
How Supporting Group
Meeting Needs of
Opioid Dependent
Clients
Physicians/physician
assistants/nurse
practitioner
Counselors
Local communities
Addicts themselves
Families and friends of
addicts

Medical
Providers

CDPs

Clients

(N = 199)

Methadone

Bup/nal

2.49
(1.20)

M(SD)
2.56
(1.29)

N = 199
2.95
(1.32)

N = 137
3.89
(1.05)

3.21
(1.44)
1.83
(.82)
2.50
(1.25)
2.39
(1.09)

3.83
(1.42)
1.78
(1.01)
2.52
(1.23)
2.07
(.89)

3.31
(1.06)
2.24
(1.20)
3.06
(1.11)
2.81
(1.12)

4.03
(.97)
2.99
(1.12)
3.42
(1.07)
3.46
(.99)

(N = 43)

ANOVA
Results

.000

.000
.000
.000
.000

Length of time clients should use methadone or bup/nal. Respondents were also
asked about the length of time clients should use methadone or bup/nal to assist in the recovery
process. Medical providers, CDPs, and methadone clients were asked this question with respect
to methadone. Response options ranged from detox (less than 1 week) to as long as needed.
Methadone clinic participants that were actively taking methadone as part of their treatment for
opioid dependence, overwhelmingly (84%) responded that they should be allowed to take
methadone for as long as needed. Only (3%) of methadone respondents answered that it was
appropriate to take the medication less than 6 months. Medical providers also largely (70%)
supported that clients should be allowed to take methadone as a part of their treatment regime for
as long as it was needed. A much lower percentage (26%) of CDPs felt that methadone should
be used for as long as it was needed. Unlike the medical providers and the methadone clients,
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the majority of CDPs (63%) thought methadone should be used for a shorter period of time, such
as detox, or less than 1 week (13%), or stabilization, 1 week to less than 6 months (26%). CDPs
consistently favored the use of medications for stabilization purposes only, whereas both the
clients and their medication provider’s felts medications should be used for as long as needed
(see Table 4.14).
Table 4.14
Percentage Distributions for Length of Time Clients Should Be on Methadone to Assist in Opioid
Treatment for Medical Providers, CDPs, and Methadone Clients
Length Time on methadone

Detox (1 week or less)
Stabilization < 6 months
6 months to 2 years
3 to 5 years
For as long as needed
No Experience

Medical
Providers
%
N = 43
7.0
2.3
7.0
4.7
69.8
9.3

CDPs
%
N = 199
13.4
25.8
24.2
5.7
25.8
5.2

Clients
Methadone
Bup/nal
%
N = 199
1.0
2.0
9.2
4.1
83.7
0

Medical providers, CDPs, and bup/nal clients were asked the same length of time
question with respect to bup/nal treatment of opioid dependence. Again the response categories
ranged from detox (1 week or less) to “for as long as needed.” Both medical providers (81%),
and bup/nal clinic participants (83%) felt that it would be appropriate to utilize bup/nal to assist
in opioid dependence treatment for as long as needed. A much lower percentage (27%) of CDPs
felt that bup/nal should be used for as long as needed. CDPs were more likely to suggest bup/nal
should be used for 6 months to 2 years (31%), stabilization—less than 6 months (25%), or
detox—one week or less (10%). When the detox, stabilization < 6 months, and 6 months to 2
years were combined, this accounted for 16% of medical professionals’ responses, 16% of
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bup/nal clinic participants’responses, and 57% of CDP responses. CDP responses again favored
stabilization only, whereas medical providers and clients felt medication use should be for as
long as needed (see Table 4.15).
Table 4.15
Percentage Distributions for Length of Time Clients Should Be on Bup/nal to Assist in Opioid
Treatment for Medical Providers, CDPs, and Bup/nal Clients

Length Time on Bup/nal

Detox (1 week or less)
Stabilization (less than 6 months)
6 months to 2 years
3 to 5 years
For as long as needed
No Experience

Medical
Providers
%
N = 43
2.3
0
14.0

CDPs
%
N = 199

2.3
81.4
0

1.5
26.8
4.6

10.3
25.4
31.4

Clients
Methadone
Bup/nal
%
N = 137
0
4.5
10.7
1.5
83.3
0

Medical providers and CDPs were also asked about vivitrol, an opioid blocker, a third, but less
frequently used medication in the treatment of opioid dependence treatment. Medical providers
and CDPs were asked about the length of time vivitrol should be used. Methadone and bup/nal
clinic participants were not expected to have a working knowledge of vivitrol. The same five
categories were given as possible survey responses, ranging from detox—1 week or less to for as
long as needed. About 12% of the medical providers and 21% of the CDPs indicated that they
had no experience with vivitrol. Of those with experience with vivitrol, medical providers were
most likely to support its use for longer periods of time, with 31% responding that 6 months to 2
years was appropriate, and 52% indicating they indicating that it could be used or as long as
needed. A much smaller percentage of CDPs thought the longer time periods of 6 months to 2
years (17%), and for as long as needed (26%) were appropriate. Therefore, not surprisingly,
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CDPs were more likely than medical professionals to respond that vivitrol should be used for
less than 6 months, (34%) compared to (5%). Even for naltrexone (vivitrol) that is a non-opioid
medication that blocks the effects of opioids, CDPs did not favor its use for other than
stabilization purposed. Medical providers and clients again felt that this medication like all
others should be used for as long as needed in the treatment and recovery process (see
Table 4.16).
Table 4.16
Percentage Distributions for Length of Time Clients Should Be on Vivitrol to Assist in Opioid
Treatment for Medical Providers and CDPs
Length on Vivitrol

Medical
Providers
%
N = 43
0
4.8

CDPs
%
N = 199

6 months to 2 years

31.0

17.0

3 to 5 years
For as long as needed

0
52.4

1.5
26.8

No Experience

11.9

20.6

Detox (1 week or less)
Stabilization (less than 6 months)

Clients
Methadone

Bup/nal

6.2
27.8

The fourth medication that both medical professionals and chemical dependency
professionals were asked to rate was buprenorphine (subutex). Subutex is basically the same
medication as bup/nal without the mu partial agonist “naloxone” added. Not surprisingly, since
buprenorphine and bup/nal are very similar compounds, the results for this medication mirrored
the responses groups gave about bup/nal. CDPs were more likely to agree to shorter use for
detox (9%), for stabilization (29%) and for 6 months to 2 years (23%), compared to 5%, 12%,
and 19% respectively of medical providers. At the same time, medical providers were more
likely to indicate that clients should be allowed to stay on the medication for long as needed
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(65%) whereas only 23% of CDPs thought that for as long as needed was appropriate. All
medical providers had experience with buprenorphine (subutex), while 14% of CDPs indicated
they had no experience with this medication. Again identical results as compared to the other
three medications surveyed, CDPs favored stabilization only. These consistent results have major
implication in the treatment field (see Table 4.17).
Table 4.17
Percentage Distributions for Length of Time Clients Should Be on Buprenorphine (Subutex) to
Assist in Opioid Treatment for Medical Providers and CDPs
Length time on buprenorphine
(subutex)

Medical
Providers
%
N = 43
4.7
11.6

CDPs
%
N = 199

6 months to 2 years
3 to 5 years

18.6
2.3

22.7
2.1

For as long as needed

62.8

22.7

0

14.4

Detox (1 week or less)
Stabilization (less than 6 months)

No Experience

Clients
Methadone Bup/nal

9.3
28.9

Effectiveness of medications. Medical providers and CDPs were also asked to rate the
effectiveness of the four medications that are currently being utilized in medication assisted
treatment for opioid dependence. The response scale was: 1(not at all effective), 2(not to
effective), 3(somewhat effective), 4(effective), 5(very effective). Medical providers were more
likely than CDPs to view the two most frequently utilized medications, methadone (M = 3.98)
and bup/nal (M = 4.44), higher in effectiveness. Medical providers (M = 3.98) were significantly
more likely than CDPs (M = 2.99) to view methadone as effective, t(1,235) = 2.8, p = .000.
Medical providers (M = 4.44) were also more likely than CDPs (M = 3.67) to view bup/nal as
effective, t(1,234) = 13.6, p = .000. CDPs viewed the effectiveness of all opioid based
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medications lower than did the medical providers. The only medication that CDPs were more
likely than medical providers (M = 3.86) to view as effective was also the only opioid antagonist
(blocker) and non-opioid medication, vivitrol, but the differences were not statistically
significant. CDPs did not rate the currently available and widely used medications as effective
compared with all other groups (see Table 4.18).
Table 4.18
Mean, Standard Deviation, and t-Test Results for Drug Effectiveness for Medical Providers and
CDPs
Medication
effectiveness

How effective is:
Naltrexone (Vivitrol)
How effective is:
Methadone
How effective is:
Bup/nal
How effective is:
Buprenorphine
(subutex)

Medical
Providers
(N = 43)
M(SD)

Chemical
Dependency
Professionals
(N = 199)
M(SD)

Clients
Methadone
Bup/nal

T test

3.86 (1.21)

4.15 (1.38)

.171

3.98 (1.28)

2.99 (1.31)

.000

4.44 (0.82)

3.67 (1.20)

.000

4.21 (0.80)

3.86 (1.42)

.126

Who should be involved in decision to get off medications? Survey respondents were
asked how much they agreed that physicians, counselors, clients, or families should be involved
in decisions related to getting off medications. The response scale was: 1(strongly disagree),
2(disagree), 3(somewhat disagree), 4(somewhat agree), 5(agree) and 6(strongly agree). There
were statistically significant differences of opinion about whether each of these supporting
groups—physicians, counselors, clients, and family—should be involved in decisions about
stopping a client’s medications. ANOVA results showed statistically significant differences
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across responding groups about whether physicians should be involved in the decision,
F(3,551) = 21.1, p = .000. Post hoc analysis showed that at the p < .01 level of significance
methadone clients (M = 3.35) had the statistically lower level of agreement about whether
physicians should be involved in the decision to stop medications when compared to the other
respondent groups—medical providers (M = 4.95), CDPs (M = 4.42), and bup/nal clients
(M = 4.11). Methadone clients felt that they should be the ones to determine when they
discontinue the use of methadone (see Table 4.19).
With regard to counselors’ input into the decision to get a client off medications, there
were again statistically significant differences across groups, F(3,535) = 12.3, p = .000. Post
hoc analysis showed that at the p = .000 level of significance the methadone clients (M = 3.42)
were less likely than bup/nal clients (M = 4.20), medical providers (M = 3.85) and CDPs
(M = 4.28) to agree that counselors should be involved in the decision to stop medication. Again
methadone clients were most likely to favor their own input in deciding when to discontinue the
use of methadone (see Table 4.19).
Medical providers (M = 5.02), CDPs (M = 4.57), methadone (M = 5.20), and bup/nal
(M = 5.07) clients groups all had their highest level of agreement that clients should be involved
in the decision to stop medications. Although they all agreed that clients should be involved in
the decision, ANOVA results again showed statistically significant differences across groups,
F(3,546) = 6.5, p = .000. Post hoc analysis showed that at the p < .01 level of significance
CDPs (M = 4.57) were less likely than the methadone (M = 5.20) and the bup/nal (M = 5.08)
clients to agree that clients should be involved in the decision to stop medications. CDPs agreed
that clients should be involved in the decision to discontinue medication but as statistically
significantly lower level than all other group (see Table 4.19).
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Medical providers (M = 2.60), CDPs (M = 2.34), methadone (M = 2.35) and bup/nal
(M = 3.20) clients all tended to disagree that family members should be involved in the decision
to stop medication. Again, however, ANOVA results showed statistically significant differences
across groups, F(3,506) = 9.6, p = .000 . Post hoc analysis showed that at the p = .000 level of
significance bup/nal clients (M = 3.20) were more likely than the other groups to agree that
family should be involved in the decision. Bup/nal clients demonstrated a higher level of trust
involving their families in decision about their medications (see Table 4.19).
Table 4.19
Mean, Standard Deviation, and ANOVA Results for Who Should Be Involved in Decision to Get
Client Off Medications for Medical Providers, CDPs, Methadone and Bup/nal Clients
Decision to taper off

Physician
Counselors
Clients in treatment
Family members

Medical
Providers
(N = 43)
M(SD)
4.95 (1.13)
3.85 (1.45)
5.02 (1.30)
2.60 (1.36)

CDPs
(N = 199)
M(SD)

4.42 (1.39)
4.28 (1.33)
4.57 (1.42)
2.34 (1.25)

Clients
Methadone
Bup/nal
(N = 137)
(N = 199)
M(SD)
M(SD)
3.35 (1.74)
3.42 (1.63)
5.20 (1.56)
2.35 (1.59)

4.11 (1.59)
4.20 (1.31)
5.07 (1.36)
3.20 (1.58)

ANOVA
Results

SIG
.000
.000
.000
.000

Helpfulness of treatment options. Attitudes of all survey respondent groups about their
perceptions of various components of the treatment process and their helpfulness was collected
and summarized. The scale included the response options of: 1(not at all helpful), 2(not helpful),
3(somewhat helpful), 4(helpful), 5(very helpful), and 6(extremely helpful). ANOVA results
showed there were statistically significant differences in opinions across respondent groups
about how they viewed the helpfulness of various components of the opioid treatment process,
F(3,555) = 25.4, p = .000. Post hoc analysis identified which groups had significantly different
views on the helpfulness of the treatment components.
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Medical providers rated medications (M = 5.11) and a combination of medications, urine
analysis, and counseling as very or extremely helpful (M = 5.53). Medical providers also viewed
involvement with 12 step support (M = 4.34) and counseling (M = 4.40) as helpful components.
CDPs viewed counseling (M = 5.05) and the combination of counseling, medications, and urine
analysis (M = 5.50) as very or extremely helpful. CDPs rated medications alone (M = 4.44) a bit
lower, but still helpful. Methadone (M = 5.29) and bup/nal (M = 5.35) clients rated the use of
medications as the single most helpful component of their treatment programs, followed by
counseling, M = 4.13 and M = 4.97 respectively, and combinations of medications and
counseling, M = 4.64 and M = 4.98 respectively. Methadone clients rated the 12 step (M = 2.83)
support as the least helpful.
Looking at each of the treatment options, with respect to counseling, overall ANOVA
results showed there was a statistically significant difference across groups, F(3,563) = 22.9,
p = .000. Post hoc analyses showed there were several significant between group differences at
the p < .01 level of significance. Methadone (M = 4.13) clients rated counseling as less helpful
than the CDPs (M = 5.05) and bup/nal (M = 4.97) clients. Medical providers (M = 4.40) viewed
counseling as less helpful than the CDPs (M = 5.05). Bup/nal (M = 4.97) clients rated counseling
as more helpful than the medical providers (M = 4.40). Bup/nal clients and CDPs did not differ
significantly with respect to the helpfulness of counselling. Medical providers and methadone
clients saw the counseling components of treatment as less helpful than the counselors
themselves.
Medication. Overall, ANOVA results showed a statistically significant difference across
groups on the helpfulness of medication, F(3,555) = 25.4, p = .000. Post hoc analysis
demonstrated that at the p < .01 level of significance medical providers (M = 5.11), bup/nal
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(M = 5.35), and methadone (M = 5.2) clients groups all rated the use of medications in the
treatment process as more helpful than did the CDP (M = 4.44) group at the p < .01 level of
significance. There were no significant differences between the medical providers and their
clients with respect to the helpfulness of medications. CDPs again saw the use of medications as
less helpful than the medical providers and the clients who used them to assist in treatment and
recovery. Results are consistent with CDP attitudes and beliefs against the use of medications
(see Table 4.20).
Twelve step support and urine analysis drug screens. Overall, ANOVA results showed a
statistically significant difference across groups on the helpfulness of 12-step supports,
F(3,530) = 45.1, p = .000. Post hoc analysis showed that at the p = .000 level of significance
methadone clients (M = 2.83) viewed 12 step supports as a less helpful treatment component than
medical providers (M = 4.34), CDPs (M = 4.45), and bup/nal clients (M = 4.13). Post hoc
analysis ratings on helpfulness of the urine drug screens were identical to the results noted for the
12 step support. Methadone (M = 3.51) clients rated the drug screens statistically significantly
lower in the helpfulness than did the medical providers (M = 4.79), CDPs (M = 4.75), and
bup/nal clients (M = 4.71). Methadone clients did not see accountability via urine drug screens or
attendance at 12 step support group meetings as helpful components of treatment (see Table
4.20).
Combination of counseling and medication. Overall, ANOVA results showed a
statistically significant difference across groups on the helpfulness of the combination of
counseling and medication F(3,545) = 8.1, p = .000. Post hoc analysis showed that at the p < .05
level of significance methadone clients (M = 4.04) had a less favorable view of the combination of
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counseling and medication than medical providers (M = 5.09), CDPs (M = 5.20), and bup/nal clients
(M = 4.98) (see Table 4.20).
Combination of counseling, medication, and urine drug screen. Overall, ANOVA results
showed a statistically significant difference across groups on the helpfulness of the combination
of counseling, medication, and urine drug screens, F(3,542) = 50.1, p = .000. Post hoc analysis
showed that at the p < .05 level of significance both medical providers (M = 5.53), and CDPs
(M = 5.50) viewed the combination of medication, counseling and accountability as more helpful
than did both the methadone clients (M = 4.04), and bup/nal clients (M = 4.94). The paid
professionals see the combination of all forms of the treatment process as more helpful than did the
clients who were the receivers of these services (see Table 4.20).
Table 4.20
Mean, Standard Deviation, and ANOVA Results for Components of Treatment That Are Helpful
to Clients in Opioid Treatment for Medical Providers, CDPs, and Methadone and Bup/nal Clients
Treatment
components

Counseling
Medication
Accountability
UA
12 Step support
Combination of
counseling &
medication
Combination of
counseling,
medication, &
UAs

Medical
Providers
(N = 43)
M(SD)
4.40 (1.03)
5.11 (.73)
4.79 (.91)

CDPs
(N = 199)
M(SD)
5.05 (.99)
4.44 (1.25)
4.75 (1.14)

Clients
Methadone
Bup/nal
(N = 199)
(N = 137)
M(SD)
M(SD)
4.13 (1.53) 4.97 (1.02)
5.29 (1.09) 5.35 (.87)
3.51 (1.52) 4.71 (1.27)

ANOVA
Results

4.34 (1.15)
5.09 (.72)

4.45 (1.27)
5.20 (1.50)

2.83 (1.67)
4.64 (1.33)

4.13 (1.30)
4.98 (1.02)

.000
.000

5.53 (.70)

5.50 (.936)

4.04 (1.57)

4.94 (1.13)

.000

.000
.000
.000
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Other client issues. All survey respondents were asked about clients who are involved
in the treatment process being negatively judged or not, being seen as not motivated. The rating
scale was as follows: 1(strongly disagree), 2(disagree), 3(somewhat disagree), 4(somewhat
agree), 5(agree), and 6(strongly agree).
Negatively judged. The respondent groups demonstrated a high level of agreement that
people on medication for opioid dependence are negatively judged by others. While there was
concurrence that clients were negatively judged, there was also a statistically significant
difference across respondent groups, F(3,565) = 15.2, p = .000. Post hoc analysis showed that at
the p < .05 level of significance methadone clients (M = 5.16) were more likely than medical
providers (M = 4.65), CDPs (M = 4.61), and bup/nal clients (M = 4.30) to strongly agree that
they were negatively judged. Methadone client’s felts more negatively judged than all other
groups, and this is consistent with narrative responses as well.
Opioid dependence a chronic disease. ANOVA analysis showed a statistically
significant difference across respondent groups on the issue of whether opioid dependence is a
chronic disease, F(3,565) = 5.4 p = .001. Post hoc analysis showed that at the p < .01 level of
significance medical providers (M = 5.83) were statistically significantly more likely than the
CDPs (M = 5.32), methadone clients (M = 5.31), and bup/nal clients (M = 5.11) to strongly agree
that opioid dependence is a chronic disease. All groups had strong agreement with this item,
however medical providers strongly agreed at a higher rate.
Client motivation to get clean. All groups disagreed that people on medication for
opioid dependency are not motivated to get clean. ANOVA results showed statistically
significant differences across respondent groups on the issue of motivation to get clean,
F(3,561) = 3.1, p < .05 . Post hoc analysis showed that at the p < .05 level of significance
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medical providers (M = 1.74) more strongly disagreed that people on medications are not
motivated than CDPs (M = 2.43). CDPs appear to question clients motivation to get clean more
so than the medical professionals and clients themselves (see Table 4.21).
Table 4.21
Mean, Standard Deviation, and ANOVA Results Feeling Judged for Being on Medications for
Medical Providers, CDPs, Methadone and Bup/nal Clients
Attitudes judgment,
motivation,
chronic/acute
People on medication
are negative judged
Opioid addiction is a
chronic disease
People of medication
are not motivated

Medical
Providers
(N = 43)
M(SD)
4.65 (1.04)

CDPs
(N= 199)
M(SD)
4.61 (1.12)

Clients
Methadone
Bup/nal
(N = 137)
(N = 199)
M(SD)
M(SD)
5.16 (1.20)
4.30 (1.33)

ANOVA
Results

5.83 (.43)

5.32 (.98)

5.31 (1.12)

5.11 (1.04)

.001

1.74 (1.07)

2.43 (1.30)

2.21 (1.54)

2.36 (1.44)

.026

.000

Issues related to medication assisted treatment. There were also a variety of issues
addressed related to the process of medication assisted treatment and recovery from opioid
dependence. The response scale for this set of statements was: 1(strongly disagree), 2(disagree),
3(somewhat disagree), 4(somewhat agree), 5(agree), and 6(strongly agree).
Whether clients receiving medication assisted treatment are clean. ANOVA results
showed statistically significant differences across respondent groups on the issue of whether
clients on medication assisted treatment are clean, F(3,557) = 9.7, p = .000. Post hoc analysis
demonstrates that at the p < .05 level of significance CDPs (M = 3.91) were less likely to agree
that clients who are on medication assisted treatment are clean when compared to the medical
providers (M = 4.67), methadone clients (M = 4.46), and bup/nal clients (M = 4.62). CDPs did
not see clients in medications assisted treatment as “clean” as compared to all other groups, and
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reflects a consistent belief about the role of medications in the process of opioid treatment and
recovery.
Whether medication assisted treatment should be time limited. All groups were asked
to rate their level of disagreement or agreement on the view that medication assisted treatment
should be time limited. The rating scale was as follows: 1(strongly disagree), 2(disagree),
3(somewhat disagree), 4(somewhat agree), 5(agree), and 6(strongly agree). ANOVA results
showed statistically significant differences across respondent groups on the issue of whether
medication assisted treatment should be time limited, F(3,554) = 68.9, p = .000. Post hoc
analysis showed that at the p<.05. level of significance medical providers (M = 2.11), methadone
clients (M = 2.12), and bup/nal clients (M = 2.90) were more likely to disagree and the CDPs
(M = 4.27) were more likely to agree with the notion that medication assisted treatment should
be time limited. CDPs as in other survey responses to items related to length of time on
medications, again validated their belief that medications should be time limited and used for
stabilization purposes only.
Whether the long-term goal of medication assisted treatment should be to be off all
drugs and medications. The next statement asks for level of disagreement or agreement that the
long term goal of medication assisted treatment should be to be off both illicit drugs and all
medications. The rating scale was as follows: 1(strongly disagree), 2(disagree), 3(somewhat
disagree), 4(somewhat agree), 5(agree), and 6(strongly agree). ANOVA results showed
statistically significant differences across respondent groups on the issue of the long term goal of
medication assisted treatment, F(3,548) = 22.4, p = .000. Post hoc analysis shows that at the
p < .01 level of significance medical providers (M = 2.48) were more likely to disagree with this
assertion when compared to CDPs (M = 4.53), methadone clients (M = 3.70), and bup/nal clients
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(M = 3.93). There was also a statistically significant difference at the p<.01 level between
methadone clients (M = 3.70) and bup/nal clients (M = 3.93) as compared to CDPs (M = 4.53).
Similarly, CDPs were also much more likely to agree with the assertion that the long term goal
of medication assisted treatment is to be off both all illicit opioids and the medications used to
assist in the treatment process. Methadone and bup/nal clients were are more likely to agree that
the long term goal should be to be off medications as well, however at a significantly lower rate
than the CDPs. Medical providers (M = 2.48) stand alone in their disagreement that the long term
goal should be to be off all medications.
Whether it is okay to stay on medication assisted treatment for life. All groups were ask
their agreement/disagreement on the statement that it is ok for clients to stay on medications for
life if need be. The rating scale was as follows: 1(strongly disagree), 2(disagree), 3(somewhat
disagree), 4(somewhat agree), 5(agree), and 6(strongly agree). ANOVA results showed
statistically significant differences across respondent groups on the issue of whether it is okay to
stay on medication assisted treatment for life, F(3,560) = 30.0, p = .000. Post hoc analysis
showed that at the p<.01 level of significance medical providers (M = 5.20) that oversee and
prescribe the use of medications for the treatment of opioid dependency agree that clients should
be able to stay on medications for life if they need it as compared to CDPs (M = 3.64).
Methadone clients (M = 4.92), and bup/nal clients (M = 4.37) also differed statistically
significantly from CDPs (M = 3.64) on whether clients should be able to stay on medications for
life if need be. Medical providers lead the way when it comes to beliefs about the use of
medications and utilizing them for as long as needed and even for the rest of the client’s lives if
necessary, whereas CDPs demonstrated consistent and contrary attitudes about this notion.
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Whether they support medication assisted treatment. All groups were asked their
disagreement/agreement about the assertion that they support medication assisted treatment. The
rating scale was as follows: 1(strongly disagree), (disagree), 3(somewhat disagree), 4(somewhat
agree), 5(agree), and 6(strongly agree). ANOVA results showed statistically significant
differences across respondent groups on the issue of whether they support medication assisted
treatment, F(3,557) = 22.1, p = .000 . Post hoc analysis showed that at the p<.01 level of
significance medical providers (M = 5.74), methadone clients (M = 5.66), and bup/nal clients
(M = 5.32) agreed on their support of medication assisted treatment as compared to the
somewhat lower level of agreement from the CDP group (M = 4.88). CDPs demonstrated less
overall support for medication assisted treatment. These results continue to point to major
differences in beliefs and philosophies between the CDPs and all other groups.
Whether clients should be considered clean if they are off all medications. Another
survey item was rating the attitudes of all respondents on their opinions of clients in medication
assisted treatment programs and whether those clients should be considered clean only if they are
off ALL medications. The rating scale was as follows: 1(strongly disagree), (disagree),
3(somewhat disagree), 4(somewhat agree), 5(agree), and 6(strongly agree). ANOVA results
showed statistically significant differences across respondent groups on the issue of whether
clients should be considered clean if they are off all medications, F(3,555) = 3.1, p < .05. Post
hoc analysis showed that at the p < .01 level of significance the bup/nal client group (M = 3.12),
as compared to medical providers (M = 2.21), CDPs (M = 2.89), and methadone clients
(M = 2.90).
Whether clients should be given a chance to get clean without medication. The last
measure that groups were asked to share views on was if clients who seek treatment for opioid
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dependence should be given the chance to get clean with the use of medications. The rating scale
was as follows: 1(strongly disagree), (disagree), 3(somewhat disagree), 4(somewhat agree),
5(agree), and 6(strongly agree). ANOVA results showed statistically significant differences
across respondent groups on the issue of whether clients should be given the chance to get clean
with the use of medications, F(3,547) = 26.2, p = .000. Post hoc test results indicate that at the
p < .05 level of significance CDPs (M = 4.83) had a higher level of agreement that clients should
be given the chance to get clean without medication than medical providers (M = 4.18),
methadone clients (M = 3.68), and bup/nal clients (M = 3.67). CDPs again appear to favor
treatment approaches that do not include the use of known and effective medications (see
Table 4.22).
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Table 4.22
Mean, Standard Deviation, and ANOVA Results Attitudes on Issues Related to Clients in Opioid
Treatment for Medical Providers, CDPs, and Methadone and Bup/nal Clients
Attitudes/opinions

Clients in MAT are
clean
MAT should be time
limited
Long term goal is to be
off illicit opioids AND
all medications
Okay for clients to stay
on medications for life
I support medication
assisted treatment
Clients should only be
considered clean if off
ALL medications
Clients who seek
treatment for opioid
dependence should be
given chance to get
clean without meds

Medical
Providers
(N = 43)
M(SD)
4.67 (1.20)

CDPs
(N = 199)
M(SD)
3.91 (1.54)

Clients
Methadone
Bup/nal
(N = 137)
(N = 199)
M(SD)
M(SD)
4.46 (1.38)
4.62 (1.08)

ANOVA
Results

2.11 (1.36)

4.27 (1.75)

2.12 (1.42)

2.90 (1.46)

.000

2.48 (1.46)

4.53 (1.65)

3.70 (1.68)

3.93 (1.34)

.000

5.20 (.88)

3.64 (1.66)

4.92 (1.39)

4.37 (1.36

.000

5.74 (.53)

4.88 (1.26)

5.66 (.78)

5.32 (.95)

.000

2.21 ((1.56)

2.89 (1.72)

2.90 (1.82)

3.12 (1.58)

.026

4.18 (1.38)

4.83 (1.26)

3.68 (1.64)

3.67 (1.43)

.000

.000

Challenges faced by clients. Respondents were also asked about their perceptions of the
challenges faced by those who are involved in the treatment and recovery process for opioid
treatment. There were six possible responses: 1(not at all a challenge), 2(not too much of a
challenge), 3(somewhat of a challenge), 4(a challenge), 5(a big challenge), 6(a huge challenge).
Dependence on medication. ANOVA results showed statistically significant differences
across respondent groups on the issue of being dependent on medication, F(3,562) = 18.1,
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p = .000. Post hoc test indicate that at the p<.05 level of significance CDP’s (M = 4.71) saw being
dependent on the medications as more challenging that both clients groups, methadone (M = 4.22)
and bup/nal (M = 3.62), and medical providers (M = 4.16).
Feeling shame. Feeling shame by clients is an important factor in the opioid treatment and
recovery process, so all groups were asked how much of a challenge shame is for clients on
medication assisted treatment. The rating scale was as follows: 1(strongly disagree), 2(disagree),
3(somewhat disagree), 4(somewhat agree), 5(agree), and 6(strongly agree). ANOVA results
showed statistically significant differences across respondent groups on the issue of whether
clients feel shame, F(3,555) = 40.9, p = .000. Post hoc analysis showed that at the p < .01 level of
significance methadone clients (M = 3.52) and bup/nal clients (M = 2.97) saw shame as less
challenging than both the medical providers (M = 4.32) and the CDPs (M = 4.58).
Not being trusted. Respondent groups were also asked about how much of a challenge not
being trusted was for clients on medications assisted treatment. The rating scale was as follows:
1(strongly disagree), (disagree), 3(somewhat disagree), 4(somewhat agree), 5(agree), and
6(strongly agree). ANOVA results showed statistically significant differences across respondent
groups on the issue of clients feeling of being trusted, F(3,555) = 25.4, p = .000. Post hoc
analysis, again showed that at the p<.01 level of significance both groups of clients, methadone
(M = 3.60) and bup/nal (M = 3.07), rated not being trusted as less challenging than did their
medical providers (M = 4.16) and CDPs (M = 4.45). Further analysis revealed that bup/nal
clients (M = 3.07) saw not being trusted as less of a challenge than methadone clients (M = 3.60),
medical providers (M = 4.16), and CDPs (M = 4.45), p < 000.
Not being understood. Respondent groups were also asked about how much of a challenge
not being understood was for clients on medications assisted treatment. The rating scale was as
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follows: 1(strongly disagree), (disagree), 3(somewhat disagree), 4(somewhat agree), 5(agree),
and 6(strongly agree). ANOVA results showed statistically significant differences across
respondent groups on the issue of clients not being understood, F(3,556) = 23.2, p = .000. Post
hoc analysis showed that at the p = .000 level of significance methadone clients (M = 4.11) and
bup/nal clients (M = 3.32) were less likely than medical providers (M = 4.33) and CDPs (M = 4.64)
to agree with this statement. Bup/nal clients (M = 3.32) also differed at significant than did medical
providers (M = 4.37), CDPs (M = 4.64) and methadone clients (M = 4.11) (see Table 4.23).
Being criticized. The last statement that respondent groups were asked about was how much
being criticized was a challenge for clients on medications assisted treatment. The rating scale was
as follows: 1(strongly disagree), (disagree), 3(somewhat disagree), 4(somewhat agree),
5(agree), and 6(strongly agree). ANOVA results showed statistically significant differences
across respondent groups on the issue of clients being criticized, F(3,553) = 16.2, p = .000. Post
hoc analysis again showed that at the p < .05 level of significance bup/nal clients (M = 3.63)
were less likely to agree that being criticized was as much of a challenge when compared to the
methadone group (M = 4.09) and the CDPs (M = 4.73). Both clients groups, methadone
M = 4.09, and bup/nal (M = 4.09) were less likely than CDPs (M = 4.73) to agree about the
challenge of being criticized.
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Table 4.23
Means and Standard Deviations for Challenges That Participating Clients in Opioid
Dependence Recovery Face for Medical Providers, CDPs, and Methadone and Bup/nal Clients
Medication Assisted
Treatment Clients
Challenges
.

Medical
Providers
(N = 43)
M(SD)

CDPs
(N = 199)
M(SD)

Being dependent on
medication
Feeling shame

4.16 (1.15)

Not being trusted
Not being understood
Being criticized

Clients

ANOVA
Results

Methadone
(N = 199)
M(SD)

Bup/nal
(N = 137)
M(SD)

4.71 (1.10)

4.26 (1.41)

3.62 (1.18)

.000

4.32 (1.01)

4.58 (1.08)

3.52(1.60)

2.97(1.50)

.000

4.16 (1.21)
4.37 (1.15)
4.28 (1.11)

4.45 (1.21)
4.64 (1.15)
4.73 (1.09)

3.60 (1.67)
4.11 (1.60)
4.09 (1.66)

3.07(1.50)
3.32 (1.48)
3.63 (1.56)

.000
.000
.000

Sig

Views on medication assisted treatment. Medical provider and n CDP respondents
were also asked about their views on medication assisted treatment. A few (5%) CDPs stated
they were against it. The starkest difference however is that the CDPs have a much higher
percentage of reservations (36% versus 13%) than the medical providers and medical providers
have a much higher rate of complete support (80%) compared to the CDPs (43%). Medical
providers support medication assisted treatment at a much higher rate than CDPs (see Table
4.24).
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Table 4.24
Percentage Distributions for Level of Support for Medication Assisted Treatment for Medical
Providers and CDPs
Statements on MAT

I am against using medications to
assist in treatment
I used to be against MAT but now
mildly support it
I used to be against MAT but now
strongly support it
I am still unsure if I support the use of
methadone/bup/nal for opioid
dependence treatment
I support MAT but still have
reservations
I totally support MAT for treatment
of opioid dependence

Medical
Providers
%
N = 43
0.00

Chemical
Dependency
Professionals
%
N = 199
5.53

0.00

3.02

6.67

6.53

0

5.03

13.33

36.18

80.00

43.72

Clients
Methadone Bup/nal

Consistent with this view, CDPs also encourage their clients who are engaged in opioid
dependence treatment to get off medications at higher rates than the medical providers that
administer and/or prescribe these medications. More than one-third of the CDPs (38%) almost
always or usually encourage clients to get off all opioid replacement medications. Conversely,
almost two-thirds (65.91%) of the medical providers only occasionally or almost never
encourage their patients to stop their medications. CDPs encourage clients to consider
discontinuing medications at much higher rates that those who are responsible for the medication
decisions-the medical providers. Medication decision is outside the scope of the CDPs practice
(see Table 4.25).
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Table 4.25
Percentage Distributions for Encouraging Clients to Get Off Medication for Medical Providers
and CDPs
Encourage clients to taper
off medications

Yes, I almost always do this
Yes, I usually do this
Yes, I sometimes do this
Yes, I occasionally do this
No, I almost never do this

Medical
Providers
%
N = 43
11.36
4.55
18.18
18.18
47.73

CDPs
%
N = 199

Clients
Methadone

Bup/nal

16.58
21.11
13.07
16.58
32.66

Pressure to get off medication. Getting off of medications is a very central issue in the
treatment process for bup/nal clients. Clients were asked if they experienced pressure to get off
their medications. The rating scale was as follows: 1(strongly disagree), (disagree), 3(somewhat
disagree), 4(somewhat agree), 5(agree), and 6(strongly agree).
Pressure Bup/nal clients felt pressure to get off medication. Bup/nal clients agreed on
some level that they experienced pressure to get off their medications from family members
(54%), followed by their medical providers (43%), friends (43%), and counselors (37%), They
reported less pressure to get off medications by their CPS workers (36%) and probation officers
(34%) when applicable. Bup/nal clients faced significant pressure to get off their medications by
all groups (see Table 4.26).
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Table 4.26
Mean, Standard Deviations, and Percentage Distributions for Bup/nal Clients Experiencing
Pressure to Get Off Their Medications

Pressured by…
My Medical
Provider
N = 126
My Counselor
N = 127
Family
Member
N = 128
Probation
Officer
N = 87
CPS Worker
N = 89
Friends
N = 111

Strongly
Disagree

Disagree

Somewhat
Disagree

Somewhat
Agree

Agree

Strongly
Agree

3.20
(1.40)

12.7

23.8

19.8

24.6

11.9

7.1

3.28
(1.50)

18.4

35.6

9.2

16.1

13.8

6.9

3.40
(1.50)

13.3

18.8

14.1

31.3

14.1

8.6

2.80
(1.50)

25.3

23.0

17.2

18.4

12.6

3.4

25.8

23.6

14.6

21.3

7.9

6.7

18.0

23.4

15.3

21.6

12.6

9.0

M(SD)

2.82
(1.50)
3.14
(1.60)

Pressure methadone clients felt to get off of medications. Methadone clinic participants
were asked if they had experienced pressure to get off their medication that was aiding them in
the recovery process. Methadone clients agreed on some level that they felt pressure to get off
their medications from family members (66%), followed by their friends (52%). To a lesser
degree methadone clients also felt some pressure from medical providers (46%) and their
counselors (37%) as well. About half of the methadone clients had a probation officer (52%) or
CPS worker (47%) and of those who did have these service workers about half (49% and 46%
respectively) agreed on some level that they felt pressure from them to get off their medication.
Experiencing pressure to discontinue the medication (methadone) that is helping them gain and
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maintain abstinence from opioids is noted by the majority of methadone clinic participants. It is
of interest that the two groups that have no input into the client’s treatment, family (66%) and
friends (52%) are rated as the most likely to pressure methadone clinic participants to get off
their medication. Methadone clients faced significant pressure to get off their medications by all
groups (see Table 4.27).
Table 4.27
Mean, Standard Deviation, and Percentage Distributions for Methadone Clients Experiencing
Pressure to Get Off Their Medications
Pressure by…
My Medical
Provider
N = 174
My Counselor
N = 174
Family
Member
N = 166
Probation
Officer
N = 90
CPS Worker
N = 82
Friends
N = 162

M(SD)

Strongly
Disagree

Disagree

Somewhat
Disagree

Somewhat
Agree

Agree

Strongly
Agree

3.19
(1.60)

15.1

29.7

6.9

21.7

12.6

12.0

2.92
(1.50)

18.4

35.6

9.2

16.1

13.8

6.9

3.97
(1.70)

9.6

19.3

4.8

19.3

24.1

22.9

3.29
(1.70)

20.0

20.0

11.1

20.0

17.8

11.1

22.0

26.8

4.9

12.2

26.8

7.3

11.1

24.7

12.3

21.0

19.8

11.1

3.17
(1.70)
3.47
(1.60)

Pressure medical providers felt to get their clients off medication. Medical providers
are the central figure that coordinate care and provides for methadone and bup/nal to be
administered to clients who are in treatment for opioid dependence. They appear as the most
qualified to consult with their patients about the taking of the medications, however they agree
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they experience a significant pressure from clients (69%) as well as family members (81%),
counselors (42%), CPS workers (39%), and insurance providers (78%) to get patients off
methadone and bup/nal. Of interest is that medical providers feel the most pressure from family
members and insurance providers to get their clients off medications. Medical provides faced
significant pressure to get their clients off medications that were helping them in the treatment
and recovery process by all outside non clients groups (see Table 4.28).
Table 4.28
Mean, Standard Deviation, and Percentage Distributions for Medical Providers Experiencing
Pressure to Get Their Patients Off Medications That Assist in the Treatment of Opioid
Dependence (Methadone, Bup/nal, Vivitrol)
Groups That
Pressure
Clients
Counselor
Family
Member
CPS Worker
Financial
Insurance
Providers

Strongly
Disagree

Disagree

Somewhat
Disagree

Somewhat
Agree

Agree

Strongly
Agree

2.4

9.5

19.0

52.4

16.7

0.0

9.8

22.0

26.8

22.0

14.6

4.9

4.27
(.95)

0.0

4.9

14.6

34.1

41.5

4.9

3.25
(1.30)

5.1

28.2

28.2

20.5

10.3

7.7

4.28
(1.40)

4.8

14.3

2.4

19.0

45.2

14.3

M(SD)
3.71
(.94)
3.24
(1.30)

Philosophies and Beliefs on Medication Assisted Treatments
Methadone has been a longstanding medication for treating opioid dependence and dates
back to approval for use in the United States in 1947. There remain both downsides and benefits
of the use of this well-known and well researched medication for its use in the opioid treatment
field. This section addresses research questions four and five,
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4. What underlying beliefs and philosophies explain the similar or different views of the
four groups?
5.

What implications do these differences have for each group of participants in the
opioid dependence treatment field?

Downside of medication assisted treatment. Narrative responses shed light on the
respondent group views on each medication. There is some overall consensus on the harmful
side effects, including the dependency caused by daily dosing and safety issues like overdose.
Methadone. With respect to the downsides of methadone, medical professionals’ focus
is related to safety issues, side effects and difficulty in withdrawing the medication. One medical
doctor summed it up by stating, “Most methadone patients are dosed daily at clinics with clientele
who are frequently involved in drug abuse and crime, and they display drowsy and drugged behavior
and it is very hard to taper them off.” CDPs express more concern for its long term use, lack of
plans to taper clients off, impairment, functioning level, and lack of what they believe is true
“recovery.” CDPs overall reported more negative attitudes toward methadone. A CDP reported,
“I have not seen clients achieve much of anything except staying high. Methadone is a joke and I
have not seen one client at these clinics that wasn’t using.” Methadone clients focus mostly on the
detrimental physical/medical effects, and on how it impacts them personally as they have the
most firsthand knowledge of methadone’s side effects. They also felt the dependence on both the
medication and the clinics made them feel like they were in a “Liquid handcuffs, I don’t feel like I
am in recovery and it is more addictive than heroin.” Bup/nal clients have minimal respect for
methadone and rate it as ineffective when they did express their opinions on methadone it was
presented in a negative way. For example, one bup/nal client stated, “It is the same as using
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heroin except I know what is in it, and the withdrawal is worse than heroin. I don’t think it works and
to me it is just a free high” (see Table 4.29).
The themes identified below are a result of content analysis, grouping responses and that
included word repetitions and searching for key-words-in-context (KWIC). The resulting
grouping of responses were then categorized and recorded in the table below.
Table 4.29
Narrative—Downsides of Methadone for Medical Providers, CDPs, and Methadone and Bup/nal
Clients
Medical
Providers

CDPs

Clients
Methadone

Bup/nal

Rigidity/daily
dosing

Dependent on clinic &
medication

Weight gain

Makes you sleepy

Lethargy

Withdrawal
effects

Cognitive impairment

Constipation

Very difficult to get
off methadone
Withdrawal

Diversion

Sweating

Weight gain

Makes sleepy

Overdose risk

Intoxicating effects

Cognitive impairments

Not recovery

Cross addiction

Decreased libido

Not as effective.

Clients should taper off

Loss of teeth

Safety factors

Not treatment or
recovery

Memory loss

Medical
complications

Harm reduction vs
wellness

Abuse
Overdose
potential
Social stigma

Loss of teeth

Difficulty getting off —
withdrawal
Feeling judged
Stigma.
Not in recovery
Ball and chain dependency
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On the positive and beneficial side of the methadone spectrum, medical providers cite
wealth of research data, best practice and the benefits of methadone in keeping patients alive,
and engaged in treatment services. They appeared more scientific in the explanation of
methadone’s benefits by reporting “Methadone maintenance is well established and has shown
clear evidence of its effectiveness. It helps people stay clean and avoid relapse. It gives them their
lives back.” CDPs see some similar benefits in that it cuts down the death rate, keeps clients
engaged in treatment and cuts the spread of communicable diseases while being under medically
managed care. They do understand and list the benefits of methadone maintenance treatment and
recognize its place in their field of practice. A CDP displayed the reality that “Methadone
maintenance is well established and has shown clear evidence of its effectiveness. It helps people
stay clean and avoid relapse. It gives them their lives back.” Methadone clients report gratitude for
how medication has positively impacted them, as some see it as a lifesaving service. It came as
little surprise that the methadone clients surveyed were overall the most positive about the
medication as they were participating in something that many felt not only improved their
situations, but actually saved their lives. There were many positive sentiments expressed by
methadone clients including, “I don’t use anymore, it has helped me out a lot and I would be dead
without it,” and “It saved my life, I don’t use heroin or inject myself. I don’t have to wake up sick or
be in the rat race that is heroin addiction.” Bup/nal clients do not report many positives in regards
to methadone nor did they see the value of methadone. As one bup/nal client stated “To me there
are NO positives to methadone” (see Table 4.30).
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Table 4.30
Narrative—Benefits of Methadone for Medical Providers, CDPs, and Methadone and Bup/nal
Clients
Medical
Providers

CDPs

Clients
Methadone

Bup/nal

Structure

Inexpensive

Gets me off streets

Stabilization

Reduces relapse

Access Accountability

Stop overdose

Effective

Stabilizes

Reduces criminal
activity

Best practice

Medically managed

Well researched

Cuts heroin use

Manages craving

Stops spread of Hep C and HIV

Gives hope

Inexpensive

Decreases ER visits

Decreases
infectious
disease.

Reduces crime

Normal
functioning

Decreases crime.

Reduces relapse
Evidenced based

May help some

Saves money
No overdose

Provides structure
Saves lives

Lowers death rate
Keeps clients engaged in treatment
Saves lives

Bup/nal. Bup/nal has only been used for opioid dependence in the United States since it
received FDA approval in 2004. Since that time this newer medication has been widely utilized
in the field of opioid dependence and is now a more widely used medication than methadone.
Medical providers, CDPs, methadone clients, and bup/nal clients gave narratives on their views
of both the downsides and benefits of bup/nal as used to combat opioid dependence.
Medical providers were mostly concerned with the diversion, cost, and access to bup/nal,
while promoting positive views on its effectiveness, safety, and the growing body of evidence
that demonstrates how it is a very helpful tool in helping afflicted patients transform from a
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destructive lifestyle to recovery. A bup/nal doctor said “It’s not perfect, but it is far and away the
best we’ve got, it is too bad there are not more doctors willing to get on board with this needed
treatment.” While another pointed out “there is just a growing body of evidence for bup/nal
effectiveness and I am really amazed at the transformative effects it has on my clients.”
CDPs report more negative views than the other three groups, and are quick to point out
the issues of lack of recovery, the inability of clients to taper off medications, poor collaboration
between themselves and medical providers, and what they feel is just switching one drug for
another or cross addiction. “Some people think it is a panacea and addiction is deeper and more
complex than just taking a pill to make you feel okay. People get hooked on bup/nal too, and so
it just becomes another substance that my patients get addicted to.” CDPs do see the benefits of
bup/nal treatment and rate it higher than methadone maintenance therapy in the areas of
functioning level, safety, and ability to fit nicely with CDP treatment services. “Bup/nal fits
nicely with treatment” stated one CDP and he went on to say, “I have seen the greatest benefit
with bup/nal. People are able to engage in employment, counseling, parenting, etc. without
being as sedated as with methadone.”
Methadone clients mostly did not respond to the open ended question about bup/nal, but
did note some drawbacks related to bup/nal use, including cost, taste, and ineffectiveness, while
also reporting that bup/nal did help by blocking the opioid effects and being a safe and
manageable medication. One respondent stated, “I don’t trust Suboxone® [bup/nal] . . . it makes
me sick, terrible side effects, it’s like poison.” On the positive side, however, current methadone
clients like the notion of getting more flexible take home privileges, and how bup/nal helps with
cravings and withdrawals. A methadone medication treatment client reported “[With Suboxone®] I
didn’t have to come to the clinic every day and it took away my withdrawal and cravings.”
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Bup/nal clients noted some minimal negative side effects, including daily dependence on
the medication and that it blocks the opioid effects, but they also touted the benefits, for example
saying, “It’s great I can’t even get high if I wanted to, but with Suboxone® I don’t even think
about using. I really don’t believe there are any downsides, what took them so long to discover
this drug.” Most bup/nal clients touted the benefits that they have experienced in being on the
medication. These benefits included a more normalized life, where they were able to get back to
a functioning life that included important things like family, jobs, and freedom from the stress of
“chasing the dragon” (see Table 4.31).
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Table 4.31
Narrative—Downsides and Benefits of Bup/nal for Medical Providers, CDPs, and Methadone
and Bup/nal Clients
Medical
Providers

CDPs

Clients
Methadone

Bup/nal

Downsides
Diversion

Cost & access

Lack of education

NO drawbacks to
bup/nal

Misuse

Street value

Expensive

Black marker

Diversion

Bad taste

No behavior
change

Lack of counseling Short
term fix

Crutch

Minimal
counseling

Band aid

Habit forming
Withdrawal

Lacks Accountability

Nausea

Bad taste

Withdrawal
Dependence

Lacks acceptance in CDP
field

Don’t like the way it
makes me feel

Stool blocker
(constipation)

Cost & access

Stigma

Withdrawals

Not enough
providers

CDPs won’t work with
clients on bup/nal

No relief from
cravings and
compulsions

Helps with cravings
and withdrawal

Normal functioning

Being dependent on
clinic & meds
Having to take daily
Effects on teeth

Nausea.

Poor collaboration with
medical providers
Clients not motivated
Harm reduction is not
treatment
Withdrawal--trading one
addiction for another cross
addiction
Treats symptoms not cause
Benefits
Helps with
cravings

Helps with detoxing
Cravings

Better recovery
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Reduce high

Prevents overdose

Can get from doctor
without clinic

Keeps me off hard
drugs

Safe—ceiling
effect

Works well with treatment
Flexibility/freedom no daily
visits

Don’t have to come to
clinic daily

Stabilizes

Less stigma than
methadone

Feel normal

Freedom

Safety- can’t
overdose

Higher functioning level

Blocks opioid
effects

Stabilizes

Can’t get high
Blocker

Relieves obsession &
compulsion to use

Easier to kick

Not sick

Reduces relapses

Easier
withdrawal Low
side effects
Flexibility
Take homes
carries privilege
Growing
evidence of
effectiveness

Better treatment and success
Medically managed
Ease of dosing
Cuts down criminal behavior
Good for pregnant women
and mothers
Effective
Transformational

Clean mind
Employable
Saved my life
Reduces relapse
Overall health
improved
Gratitude/thankfulnes
s comments (lots of
those)

Naltrexone Injectable (Vivitrol). Although naltrexone is not an opioid like its
methadone and bup/nal counterparts, it is used in both oral and injectable forms to occupy the
opioid receptor sites and block the effects of opioid ingestion. As such vivitrol is also used as a
medication to assist in opioid dependence treatment. Vivitrol is starting to gain some traction in
the opioid treatment field, but as noted in the narrative responses lags in the shadows of the more
popular methadone and bup/nal medications. All three respondent groups were asked about the
downsides and benefits of vivitrol.
Medical providers cited painful shots, possible tissue injury, as well as the lack of
research literature on efficacy as their main concerns about vivitrol. They reported that “Most of
my patients just don’t like this option, it costs a lot and I just have not experienced the success
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using it as I have when I use suboxone.” Providers did embrace the positive sides of this once a
month opioid blocking injection, pointing out that “It’s great and there is little risk of abuse or
diversion, and its opioid free so I don’t have to concern myself with withdrawals or overdosing.”
Medical providers also liked the benefits of once a month injections, the non-addictive nature,
and the absence of any withdrawal effects.
All groups cited the lack of information, knowledge and experience with vivitrol as a
current hindrance to full acceptance and use in the opioid treatment field. CDPs saw difficulties
with patients being off opioids long enough as a barrier, along with lack of follow through, and
the absence of counseling/treatment services to coincide with the monthly shots. “There just is
not enough evidence to justify the cost and I have just not experienced that much success with
those that got the shot.” CDPs did embrace the lack of diversion potential, blocking of opioid
effects, and the removal of opioid cravings as positives. Vivitrol is viewed more positively by
CDPs as compared to both the medical providers and active clients on methadone and bup/nal.
Some CDPs felt “it is the best treatment out there, and it really helps with cravings as well as
taking away the option to use opioids.” This mindset by CDPs that vivitrol is preferred
medication to its opioid counterparts most likely reflects the consistent and persistent mindsets
that CDPs adhere to in abstinence-based paradigms that reflects their education and training.
Methadone and bup/nal clients were mostly unknowledgeable or inexperienced with vivitrol as a
medication assisted treatment. There were only a few narrative responses focused on this drug.
Overall there appears to be a lack of both education and experience related to vivitrol by current
client participants in the opioid treatment programs that provide methadone and bup/nal (see
Table 4.32).
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Table 4.32
Narrative—Downsides and Benefits of Vivitrol (naltrexone) for Medical Providers, CDPs, and
Methadone and Bup/nal Clients
Medical Providers

CDPs

Clients
Methadone

Bup/nal

Downsides
Painful shots

Side effects

Tissue injury at injection
site

Cost
Lack of research

Risk of OD once off

Poor follow through/no
Difficulty in starting due to second shot
window off opioids needed Switch to non-blocked drugs
Patients don’t like

(meth, cocaine)

Not effective

Increased chance of over dose
when discontinued

Lacking evidence to
support
Cost
Patients not as committed
to recovery process
Poor follow up on shots

Lack of
knowledge or
experience with
this medication

Few responses
Nothing to
report
Lack of
knowledge or
experience with
this medication

Not popular with clients
Doesn’t address addiction
issues
Not effective or popular
Can’t get clean long enough to
take

Benefits
Non addictive

Good after detox

No diversion potential

Removes cravings

No high Infrequent dosing- Blocks opioids
once a month
Once a month dosing
Prevents relapse
Cannot be manipulated
Minimal side effects

No street value

Patients more committed
and motivated

Low diversion potential
Reduces OD Stabilizes
Best option/best treatment
out there

Blocks opioid
high
No withdrawal
Safe

Stabilizing
Once a month
dosing
Good as a backup
plan
No side effects
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Medication assisted treatment. Medical providers, CDPs, and methadone and bup/nal
clients also addressed questions about their beliefs, philosophies, and feelings about the use of
medications to assist in the treatment of opioid dependent people. There was some agreement
that more needs to be done to help those affected. The bup/nal client group reported a more
positive experience and outlook than did their methadone counterparts who felt more judged,
criticized and looked down upon. The methadone clients reported more marginalization of their
lives and circumstances by all involved. Medical providers appeared to embrace medication
assisted treatment as an effective and viable evidence based practice, while the CDP were more
critical of medications, and their use in the treatment process. CDPs were very outspoken in
both their cynicism and criticism of the opioid treatment process that utilizes methadone and
bup/nal (see Table 4.33).
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Table 4.33
Narratives––Other Thoughts About the Use of Medications to Assist in the Treatment of Opioid
Dependence for Medical Providers, CDPs, and Methadone and Bup/nal Clients
Medical Providers

CDPs

Clients
Methadone

Wish I had magic bullet
Need public education
Access and ease to
treatment
Counseling not effective
MAT effective so treat
as a CHRONIC disease
Medications good,
access and delivery lag

Bup/nal

Use heroin legally

Need to expand access

Need counseling for
best outcomes

Feel judged, losers,
homeless junkies,
uneducated, stigma

Saves lives, brings
families together

Substituting, not
getting to cause

Cure is worse than
addiction

Must Taper off

Can still get high

Works, stops cravings,
blocks opioids

Against methadone,
no success

Dependence on
medication

Need a timeline to get
off medication

Medications should
be time limited

Internal motivation
important.

Safe alternative

Outpatient treatment
program legalized
drug dealing,

Side effects bad

Medications are
short term solutions

Pharmaceutical
companies are
getting rich

Has helped with alcohol
and other drugs

Educate public more

long term effects
unknown
Gratitude, saved my
life, would be dead
without it

Medications not the
answer, must be
abstinent.

Recovery. All survey participants were asked to define what “recovery” meant to them
as it relates to opioid dependence. There were a lot of similarities and differences across groups.
Medical professionals and CDPs tended to have lengthier definition that included better overall
functioning level and reaching unrealized human potential. They did not oversimplify the
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complexities of the recovery process and they included a variety of holistic and individualized
set of circumstances that included wellness, and functionality. The methadone and bup/nal
clients who were involved in the process of recovery, saw things on a more personal and intimate
scale. Their answers were much shorter and succinct and included many of the very basic tenants
of recovery of being clean and rebuilding their broken spirits and self-worth. Several methadone
clients noted that some use of opioid was acceptable (see Table 4.34).
Table 4.34
Narrative––What Does “Recovery” as It Relates to Opioid Dependence Mean for Medical
Providers, CDPs, and Methadone and Bup/nal Clients
Medical Providers

CDPs

Client
Methadone

Having a happy,
productive life

Living life without
illicit drugs

Free from illicit drugs,
working steps, recovery

Functioning to best of
ability, reach
individual potential

Job, education, family
higher functioning
Control cravings, stabilizes
life medically
Acceptance of medications
Need more than
medications

Process of change in
all areas
Self-improvement
Having an
individualized
recovery program

Returning to healthy,
Behavioral adaptation,
stable life, without
spiritual journey with love,
obsession &
forgiveness, and discovery.
compulsion
No one right answer

Bup/nal

Off heroin

Honesty

Of streets, no illegal

Being a normal civilized
human, not using any
opioids

Harm reduction, so
irregular use is
recovery
Path of progress and
change, not 100%
clean, just moving
forward
Freedom, not
dependent
Happy, less
successful,
Get life back on track,
family, job
Balanced and
functional life
Staying alive

Getting my life back, able
to function
Family, job, no legal
problems.
Self-worth and growth in
all life areas.
New lifestyle, values,
morals, attitude
Free and less stress
Change in all areas of life
Being clean, body, mind,
and spirit.
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Any additional thoughts. A final open ended question asked for any additional thoughts
about medication assisted treatment. Medical providers had very thoughtful comments about
their reflection on where the field is at, the limitations, and the areas of needed expansion. They
acknowledge that they are a long way from effectively treating all of those in need or negatively
impacted. CDPs also clearly saw the limitation of medication assisted treatment, some embraced
the help it produces, while other remained skeptical about using an opioid to address the
problem. CDPs see this as an epidemic and report the need for more resources and tools to help
their clients overcome this chronic disorder. Methadone clients add in a mix of complaints about
the negative effects of the medications and the methadone medication treatment process, while
also seeing how methadone absolutely saved their lives and helped them on their road to
recovery. Bup/nal clients appeared much more positive about the help they were receiving and
the progress they had made in recovery from opioid dependence that all the other groups. They
expressed much less concern and reported fewer negative opinions they did their methadone
counterparts (see Table 4.35).
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Table 4.35
Narrative—Additional Thoughts About Medication Assisted Treatment for Medical Providers,
CDPs, and Methadone and Bup/nal Clients
Medical Providers

CDPs

Clients
Methadone

Good success for some
not a silver bullet

U.S. behind advances
in other countries.

Trying to find the best
option for everyone,
but it is a huge
challenge

MAT needs to be
between the provider
and client &
individualized

Educate, stop
moralizing

New paradigms that
include MAT

Access and capacity is
huge challenge

Counselors under
resourced and pay

Fulfilling work,
patients grateful

Need FULL MAT
acceptance, still new

Only a start, more
advances needed
Cost and insurance is a
limitation.
Expand research on
vivitrol, and newer
medications.
Office based MAT
good option with other
treatment components

Positive experience
Policies need to
work toward treating
Support and
illness not punish
understanding great.
No time limits on
Never felt Judged
treatments/meds
Hope and success
Methadone is a bad
drug.
Opioid addiction is
complex

MAT works, and its
evolving, keep
Epidemic, treat earlier innovating.
and as chronic
Internal motivation
to change is key
MAT works well if
done correctly, but
pros and cons
Need public education
and acceptance

Bup/nal

More help, people in
family still dying
Never let MAT stop.
MAT has helped many
in community
Internal motivation
important
Need medications,
support and counseling
all together for best
outcomes.
New clean and sober
life, bup/nal saved my
life.

Get tougher on
clients,
Medications do not
work

Table 4.36 presents a quick overview of the detailed findings discussed above. The table
below is a crosswalk of the survey questions and the findings. These represent the typical
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medical provider, CDP, methadone and bup/nal client respondent. That is, where over half of
the responses were in the stated category. A discussion of findings follows in Chapter V.
Table 4.36
Summary—Typical Responses for Medical Providers, CDPs, Methadone and Bup/nal Clients
Summary
Age
Gender
Work setting

Time in field

Medical
CDPs
Providers
Majority older, Younger group,
no under 30,
most 31-50 age
Majority male

Methadone
Clients
Evenly spread
middle age

Bup/nal Clients

Majority female Majority female

Majority female

Majority
outpatient
bup/nal

Youngest
group, under 50

N/A

N/A

Majority over
10 years

Majority under
10 years

N/A

N/A

N/A

N/A

Majority less
than 1 year

Majority 2-3
years or more

N/A

Majority 3
years or more

Majority 2
years or less

N/A

N/A

Yes, but some
unsure

Length of time in
recovery

N/A

N/A

Majority 1-3
years

Majority 2
years or less

Perception of treatment
helpfulness

N/A

N/A

Most helpful

Most helpful

Good progress

Some progress

N/A

N/A

Length of time in
treatment
Medications used
How long on
medications

Majority
bup/nal
N/A

In Recovery?

Overall progress

Almost
everyone
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Effectiveness of
medications
Progress by
Medical providers
Progress by

Effective

Okay

Somewhat
effective
Okay

N/A

N/A

Okay

Well

Well

Well

Well

Very Well

Not very well

Not very well

Not very well

OK

OK

OK

Well

Well

OK

OK

Well

Very Well

Length time on
methadone

Long as
needed

Stabilize only

Long as needed

N/A

Length time on bup/nal

Long as
needed

Stabilize only

N/A

Long as needed

Length time on vivitrol

Long as
needed

Stabilize only

N/A

N/A

Length time on
buprenorphine

Long as
needed

Stabilize only

N/A

N/A

Medication
effectiveness
Methadone

Effective

Not effective

N/A

N/A

Medication
effectiveness Bup/nal

Very Effective

Somewhat
effective

N/A

N/A

Medication
effectiveness
Buprenorphine

Very effective

Somewhat
effective

N/A

N/A

Counselors
Progress by
Communities
Progress by
Clients
Progress by
Family and friends
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Medication
effectiveness Vivitrol

Somewhat

Effective

N/A

N/A

Agree

Agree

Somewhat
Agree

Agree

Somewhat
agree

Agree

Somewhat
agree

Agree

Agree

Somewhat
agree

Agree

Agree

Disagree

Disagree

Disagree

Agree

Helpfulness of
counseling

Helpful

Very helpful

Somewhat
helpful

Very helpful

Helpfulness of
medications

Very Helpful

Somewhat
helpful

Very Helpful

Very Helpful

Helpfulness of 12 step
support

Helpful

Helpful

Not to helpful

Helpful

Helpfulness of UA’s

Helpful

Helpful

Not to helpful

Helpful

Helpfulness of
combination
counseling and
medications

Helpful

Helpful

Somewhat
helpful

Helpful

Helpfulness of
combination of
counseling and
medications, UA’s and
12 step support

Helpful

Helpful

Not to helpful

Helpful

Involved in decision to
get off meds

effective

Physician
Involved in decision to
get off meds
Counselor
Involved in decision to
get off meds
Clients
Involved in decision to
get off meds
Family
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Suffer judgment

Agree

Agree

Strongly agree

Agree

Seen as chronic disease

Strongly
agree

Agree

Agree

Agree

Clients not motivated

Strongly
disagree

Disagree

Disagree

Disagree

Agree

Somewhat
agree

Agree

Agree

Disagree

Agree

Disagree

Disagree

Disagree

Agree

Somewhat
agree

Somewhat agree

Strongly agree

Somewhat
disagree

Strongly agree

Agree

Strongly agree

Somewhat
agree

Strongly agree

Agree

Disagree

Somewhat
disagree

Somewhat
disagree

Somewhat
disagree

Somewhat
agree

Agree

Somewhat
disagree

Somewhat
disagree

Challenge

A big challenge

Challenge

Somewhat
challenge

Issues about treatment
Consider clean
Issues about treatment
Time limited
Issues about treatment
Long term goal off
meds
Issues about treatment
Ok for life on
medications
Issues about treatment
Do you support
medication assisted
treatment
Issues about treatment
Clean only if off
medication
Issues about treatment
Chance to get clean
without medications
Challenges clients face
Dependent on
medications
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Challenges clients face
Shame

A challenge

A big challenge

Somewhat of a
challenge

Challenges clients face
Not being trusted

Not much of a
challenge
Somewhat of a
Challenge

A challenge

A challenge

Somewhat of a
challenge

A challenge

A challenge

A challenge

Somewhat of a
Challenge

A challenge

Less of a
Somewhat of a
Challenge

Challenges clients face
Not being understood

Challenges clients face
Being criticized

A challenge

A big challenge

Current views on
medication assisted
treatment

Total support

Halfway
support

N/A

N/A

Current views
encouraging clients to
get off medications

Don’t
encourage to
get off meds

Somewhat
encourage to
get off meds

N/A

N/A

Pressure to get off
medications

Feels pressure

N/A

Lots of
pressure

Lots of pressure
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Chapter V: Discussion of Findings
The field of medication assisted treatment has been around for over 60 years; however,
the practice was primarily limited to methadone clinics in the United States until 2004 when
buprenorphine/naltrexone, under the brand name Suboxone, was approved by the FDA for use in
the treatment of opioid dependence. In the subsequent years the adoption and use of medications
to assist in treatment services has jumped dramatically to an unprecedented level. The number of
clients being treated for opioid dependence has burgeoned from only 250,000 nationwide to over
700,000 today (United Nations Office on Drugs and Crime, 2010). Medical providers and
treatment programs have struggled to keep up with advancements in the field. This steep rise in
both the breadth and scope of the problem has left a gap in how clients are addressing their
opioid dependence and highlights the emergence of how both medical providers and CDPs
address the issues associated with medications. Medication assisted treatment outside of the
traditional methadone clinics was virtually unknown before this decade. Therefore counselor, or
CDP, knowledge and scope of practice with these clients was limited. There was also a shortage
of medical providers working outside of methadone clinics that fully understood the implications
and effectiveness of medication assisted treatment. Thus, this research study was designed to
collect, understand, summarize, and analyze the present attitudes, beliefs and practices within the
field from the perspective of the medical providers, CDPs, and opioid dependent clients.
Opioid dependence and addiction remains a threat to public health in the United States as
well as around the world. This public health crisis has been labeled as an “epidemic” by many of
our national leaders, including the President of the United States. The use of prescribed
pharmaceutical medications as well as illicit opioid related drugs (heroin, morphine, etc.)
continues to marginalize many in our society. These powerful drugs and medications that were
originally formulated to alleviate pain and suffering are now inflicting monumental amounts of
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pain and suffering for those affected, their communities, their families, and our modern day
society.
Much of the previous research in this field focused on the efficacy of available
medications utilized in medication assisted treatment for opioid dependence (Volkow, Frieden,
Hyde, & Cha, 2014a). Methadone is one of the most well-known and studied medications.
Bup/nal has undergone many research trials and double blind studies in order to more recently
gain FDA approval (Kosten, Schottenfeld, Ziedonis, & Falcioni, 1993). Naltrexone (Vivitrol) has
also been studied and all of these mediations continue to be evaluated by treatment professionals,
pharmaceutical companies, and researchers (Fram et al., 1989). This study was designed to
uncover issues that are not well studied and to add to the body of knowledge in the opioid
dependency treatment field by taking a deeper look into the complex dynamics that take place
with the three primary player groups in the treatment and recovery process. Medical providers,
CDPs, and the clients they serve make up the crux of the recovery platform and more research
focus on the beliefs and attitudes toward the treatment process for these parties could benefit
those who suffer. It is imperative that the process of change involved in the treatment and
recovery from opioid dependence be better understood and evaluated. It starts with identifying
the attitudes and beliefs that these three groups hold. In addition, the research design and data
are meant to add to the body of knowledge within the opioid dependence, recovery, and
treatment field especially as it relates to the new and widening best practice of medication
assisted treatment. Opioid replacement medications and the field of addiction medicine continue
to undergo important changes as medical science works to understand the physiology and
pharmacology of what the medical field calls a chronic brain disorder. The traditional paradigms
of both treatment and recovery continue to be challenged by the changing landscape of opioid
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dependence and recovery. This study examines professional and client views of length of time on
medications, decision on weaning off, effectiveness of the currently utilized medications,
benefits and drawbacks of each medication, helpful components of the treatment process,
defining recovery, as well as a variety of other important treatment issues.
The research questions were addressed and findings related to research questions 1, 2,
and 3 about the existence and nature of differences in opinions about medication assisted
treatment issues across provider and client groups were explored. Statistically significant
differences in attitudes were found on most issues, including length of time on medications,
effectiveness of medications, helpful components of the treatment process, decisions about
discontinuing medications, long term goals of medication assisted treatment, and the overall
progress of the field of medication assisted treatment showed different attitudes and beliefs
among the groups.

Research question 4 about what underlying beliefs and philosophies and

research question 5 about the implications of these differences were also explored and discussed
below.
Methods and Procedures
This research utilized a comparative mixed methods study with survey data collection
focused on attitudes, beliefs, and practices of the three participant groups—the “three legged
stool” in the field of medication assisted treatment for opioid dependence and recovery. Analysis
included descriptive and comparative t-test and ANOVA statistics with post hoc analysis.
Quantitative and qualitative data were collected via a survey.
This study was designed to identify differences and similarities across the three legs of
the stool in the field of medication assisted treatment—medical providers, CDPs, and clients. It
is well accepted practice in the opioid treatment field that any form of medication assisted
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treatment (Volkow et al., 2014b) is preferable to not receiving these services. It is important to
point out that “one size does not fit all” when it comes to treating this complex brain disease.
Participants and Sample Size
The study population included 45 medical providers, 199 CDPs, 199 methadone clients,
and 137 bup/nal clients. Medical providers included prescribing physicians, and physician’s
assistants that worked in opioid dependency and medication assisted treatment settings
throughout Washington State. CDPs, also known as addiction counselors, counsel and oversee
each opioid dependent client. Client respondents had been diagnosed as opioid dependent and
were participating in one of two opioid treatment programs in Washington State—one
methadone and one bup/nal clinic.
Demographics
Medical providers were on average older than both the CDP and client respondent
groups. The methadone and bup/nal client groups were younger than both of the professional
provider groups. The bup/nal group was the youngest of all participant groups, with the majority
of client participants between the ages of 21 and 40. Over half (55%) of the clients respondents
and about two-thirds of the CDPs were female, which was similar to the CDP gender distribution
statewide. The opposite was true for the medical provider group which was largely male. This
was somewhat higher than statewide, where 52% of practicing physicians are male (Washington
State Health Services Research Project Research Brief #66). The sample of medical providers
was a good cross representation of those working in the outpatient treatment practice field. There
are 22, primarily methadone, outpatient treatment practices in Washington State, whereas there
are several hundred doctors who engaged in office based bup/nal practices. The survey sample
reflects the current opioid treatment practices in Washington State.
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The CDPs are much like many other helping professions in that this work draws more
interested female professionals (i.e., nursing, social work, counselors). Interestingly, even though
statistics show that (Unger, Jung, Winklbaur, & Fischer, 2010) more males are diagnosed with
opioid dependence in the general population, the majority of those seeking help and enrolled in
opioid treatment programs are female participants. It can be theorized that females go for
professional help at higher levels than their male counterparts. This certainly holds true for
gender access to other medical services (Bertakis, Azari, Helms, Callahan, & Robbins, 2000) as
well. The medical provider group continues to be a male. Although this trend is changing (Allen,
2005) it appears to hold for the older group of medical providers surveyed in this research. The
length of time in the opioid treatment field for medical providers and CDPs appeared evenly
spread from one year to 21 years of service or more; however, the CDP group did have more
professionals with fewer years of experience.
The work setting of medical providers and CDPs was important to this research in order
to understand the context of experiential knowledge in the opioid dependence treatment field.
Medical providers were predominantly from bup/nal programs with inpatient, detox, and mostly
outpatient office based practice providers. Only a small group of the medical provider
respondents worked in methadone clinics. Medical providers in this study for the most part
perceived bup/nal as their medication of choice and only about one-fourth of providers treated
clients with methadone. Methadone is a tightly regulated schedule 2 narcotic and controlled
substance, so its use in the medication assisted treatment field is limited to federally and state
licensed opioid treatment programs. The majority of CDP respondents worked in outpatient
settings, with about half of each of those either having services that provide medications to assist
in the recovery process and half that did not offer medications. CDPs also had a range of other
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work settings that included detox, methadone clinics, and inpatient treatment programs. Overall
the CDP respondent group was a good representation of treatment settings across Washington
State. The CDP survey respondents were a very good cross sample of professionals currently
working in the field of substance abuse counseling. Their work settings, and time in the field
demonstrated a variety of settings where they practiced. These were not just professionals
working in primarily methadone outpatient treatment practices, or but represented a range of
CDP positions in Washington State. The clients were selected from two licensed and state
certified opioid treatment programs—a methadone clinic in the inner city of Seattle, Washington,
and a rural area bup/nal clinic located on a Native American reservation in the Northwest
Washington area. There were some distinctive cultural differences that could account for some of
the client research findings. The methadone group was from a large ethnically diverse urban,
primarily Caucasian and African American, in the Seattle, Washington area. The bup/nal clients
were representative of a smaller, more rural and tightknit Native American community. Ethnic
background was not collected in the survey; however, ethnic differences were clear given the
locations of the clinics and observation during the survey collection process. My research field
experience during clinic survey data collection in the methadone and bup/nal clinics represented
contrasting treatment delivery models. The methadone clinic had a more harried and sterile feel
toward the delivery of medicaitons, and the bup/nal clinic was smaller in nature and provided a
more nurturing environment.
The majority of methadone client participants had been participating in clinic services for
less than a year, and the majority of bup/nal clients had been participating in clinic services for
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two to three years. Bup/nal is a fairly new medication in the field of study as compared to
methadone. The bup/nal clinic participants have only had access to medication assisted treatment
since 2006 and their particular clinic setting has only been in operation since 2013.
Methadone clinic participants primarily self-reported themselves as being in recovery
from opioid dependence; however, some were ambivalent about their recovery status as nearly
one-fourth of them chose the yes, somewhat versus yes, definitely in recovery option. Bup/nal
clinic participants overwhelmingly had the self-perception that they were in recovery, with
almost all of them responding that they were definitely in recovery. Bup/nal clients also
self-reported being in recovery for longer periods of time than their methadone counterparts.
Both groups of client participants self-reported that the clinic services they were receiving were
helpful. This sample was a good cross representation of Washington State OTP clinic
participants that number 4,500 (SAMHSA—Substance Abuse and Mental Health Services
Administration brief 2015).
Survey Instrument
The data collection instrument used for this research project was a 21–29 question survey
that covered the topics related to medication assisted treatment.
Statements related to attitudes, beliefs, and practices about medication assisted treatment
had 6-point Likert-type response scales, including strongly disagree to strongly agree, not at all
effective to very effective, and not at all helpful to extremely helpful. Specifically, the issues
covered were: respondents’ attitudes toward medication assisted treatment; how strongly they
believe in the efficacy of current opioid treatments; effectiveness of medications; how long
treatment should last; the drawbacks of each therapy; long and short term treatment goals;
helpfulness of treatment approaches; and whether those receiving treatments experience shame,
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judgment, or continued marginalization. There were also several open-ended questions
designed to encourage respondents to share their stories related to their attitudes, beliefs, and
practices about medication assisted treatment for opioid dependence. Although the same core
questions were asked of survey respondents from all three respondent groups, additional
questions were also asked of each individual group. The survey also collected some demographic
information, including age, gender, length of time working in the opioid addiction field, type of
treatment modality, and length of time in recovery.
Major Findings
Three categories of major findings are discussed below. These include (a) differences
between provider groups (medical providers and CDPs, (b) differences between methadone and
bup/nal (buprenorphine/naloxone) clients, and (c) cross differences across all respondents
groups. There were statistically significant differences for almost all of the issues addressed by
the survey questions.
Overall progress and effectiveness of medication. The use of medications in the
treatment process for opioid dependence is a key advancement in the field and thus why, in
today’s opioid treatment field, best practice is noted as medication assisted treatment (Center for
Substance Abuse Treatment, 2005). With relapse rates noted as high as 95% with traditional
psychosocial treatments that involve cognitive behavioral approaches, the implementation of
adding medications to assist in the treatment and recovery for opioid dependent individuals has
been key. Medical providers and CDPs were asked about the overall progress in the field of
medication assisted treatment and the effectiveness of medications. They had significantly
different points of view. These results are consistent with findings patterned throughout this
study; the CDPs view the use of medications in a more skeptical and less supportive manner than
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the medical providers. These findings contradict current research that clearly demonstrates the
effectiveness of medications that are currently being used and accepted as best practice by the
medical professionals and leading researchers (Compton & Volkow, 2006a; Koob, 2009; Koob
& Le Moal, 2005; Koob & Volkow, 2010).
With the ever changing landscape, national focus, and advancements in medications, this
study first looked at how medical providers and CDPs perceived overall progress in the field.
Medical providers noted more progress being made in addressing the problem of opioid
dependence than did their CDP counterparts. What factors possibly account for these
differences? When one looks at the education and training differences between groups, it must be
noted that medical providers undergo extensive and rigorous training in order to get licensed as a
physician. They are traditionally trained to prescribe medication to assist them in the daily job
duties as a helping professional and are accustomed to utilizing medications for many different
forms of recovery from injuries and illnesses. CDPs have a much lower threshold of both
educational and internship/training requirements in order to obtain licensing. Chemical
dependency training programs are mostly conducted by two-year community college programs
where the curriculums require no classes in medication assisted treatment. Thus, these two
groups have different backgrounds, professional experiences, and educational requirements in
order to become licensed and considered experts in their fields. CDPs and medical providers not
seeing the same level of progress in the opioid treatment practice field has huge implications for
those who are undergoing treatments and working to get into recovery. CDPs have much more
face time and one-on-one contact with those in treatment, and by implication, greater influence
on their clients, and possibly a more in-depth view of how clients, their families, and
communities are affected and progressing.
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Medical providers and CDPs also had different views on the effectiveness of current
medications. Medical providers have the responsibility to understand the current research about
the effectiveness of each of the three primary medications studied. Methadone,
buprenorphine/naloxone (Suboxone®), and naltrexone (Vivitrol) are all medications that have
undergone double blind clinical trials in order to be shown as effective in the treatment of opioid
dependence. Medical providers must have firsthand working knowledge of these studies and
what is considered best practice in their fields. They undergo additional training in these
medications in order to certify themselves as opioid treatment providers. Workshops, trainings,
and continuing education all keep medical providers informed on the latest information about
this complex field and the challenges they face with clients who suffer from opioid dependence.
Utilizing medications to assist in the treatment and recovery process is part of the medical
providers’ scope of practice. It is for these reasons that medical providers are on the cutting edge
of how these medications are working or not working with the clients they are responsible to
serve. Do no harm is the Hippocratic Oath undertaken in medical school and played out in daily
practice. Many have studied and been exposed to the harm reduction model of addiction
treatment services and use this way of thinking and being as they navigate opioid treatment
services.
CDPs take a curriculum of courses that make up their chemical dependency educational
requirements, and participate in a 1500–2500 hour internship at a Washington State certified
treatment agency as trainees before they become fully licensed. Some CDPs have come into the
field because of personal firsthand experience as a recovering alcoholic/addict. Because of their
experience and training, the focus and goal of recovery has primarily been to be completely
abstinent from all mind and mood altering chemicals. This abstinence based mindset has
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influenced their attitudes toward medications. This mindset is in direct contrast to the medical
providers in the field. The burgeoning field of medically treating opioid dependence and the
rapid advancement that accompanied it left a gap for the CDPs to fill. They are professionals that
counsel and guide clients into the recovery process and typically have more one-on-one face time
and have developed a deeper level of trust, rapport, and discourse with affected clients. The
licensing process for CDPs has not changed in decades and remains in this state much the same
as it did when I was certified 28 years ago—all pre-medication assisted treatment. There are no
formal classes or educational requirements that are mandated as a part of CDP licensing for
medication assisted treatment. Many CDPs have had to learn this new paradigm of treatment by
workshops or firsthand experience and on the job training. CDPs approach their chosen
profession with a lot of heart and passion for what they do. They adhere to a guiding principle to
help others. They have their clients’ best interests in mind as they guide, teach, and counsel them
to rebuild their shattered lives. CDPs are very important and primary participants in the treatment
and recovery process since they spend the most time face to face with recovering clients in
opioid treatment programs and therefore have a lot of emotional equity and influence with opioid
treatment participants. CDPs are also asking the more difficult and far reaching questions that
many times are overlooked by the medical professionals as they take a wider and more holistic
approach to their work, helping clients navigate in the larger, not just physical, world.
Methadone and bup/nal client group differences. Originally this study was focused on
medical providers, CDPs, and clients who were active participants in opioid treatment programs
in Washington State. However, because of the design of the two clinics where I collected
surveys, I had two distinct opioid treatment respondent groups—199 surveys from methadone
clinic clients and137 surveys from bup/nal clinic clients. Several interesting between client
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group results emerged. These included views on the treatment components, their own feelings,
who should be involved in making the decision to get off medications, the long term goal of
medication assisted treatment, and the downsides and benefits.
Treatment components. When looking at components of treatment that were helpful,
methadone clients were less likely than bup/nal clients to view counseling as helpful. Methadone
clients also viewed the 12 step support self-help meetings as less helpful than did their bup/nal
counterparts. This pattern of differences continued when respondents were asked about
accountability via observed urine drug screens—methadone clients again saw this component of
the treatment process as less helpful than the bup/nal clients. In terms of the combination of
counseling and medications, once again methadone clients found these significantly less helpful
than did the bup/nal clients. Much of the previous literature does not break out the various
components of treatment as was addressed in this inquiry.
Client feelings. When it came to feelings of being marginalized (judged, criticized, seen
as not clean, feeling shame, being misunderstood, etc.) the methadone clients were significantly
more likely to agree that they felt negatively judged by others while they were on the
medications that were helping them gain and maintain recovery. Methadone clients viewed
feelings of shame more of a challenge than did bup/nal clients. There were similar findings for
feelings of being dependent on the medications, not being trusted, being criticized, and being
misunderstood.
Who should be involved in making decision about getting off medications. Bup/nal
clients were more likely than methadone clients to agree that family members could be involved
in the determination of their getting off medication. Methadone clients mostly disagreed with this
notion. This raises some interesting questions about why these two client groups have different
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perspectives. This was beyond the scope of this inquiry; however, the why could have important
implications for successful treatment.
Long term goal of medication assisted treatment. Methadone clients also were more
likely to disagree that the long term goal of medication assisted treatment was to get off all the
medications used for opioid treatment. Again, methadone clients were more likely than bup/nal
clients to agree that it is okay if they stay on medication assisted treatment for life if need be.
Downsides and benefits. On narrative responses that inquired about the positives and
downsides of both bup/nal and methadone, the methadone clients had a longer list of the medical
and physical issues related to methadone, including constipation, weight gain, and decaying
teeth. Overall they reported more complaints about the medication and did not report the level of
gratitude and positive effects of the medications and treatments as did their bup/nal counterparts.
Both methadone and bup/nal groups did report the treatment they were receiving as being
helpful.
Across providers (medical and CDP) and client (methadone and bup/nal) group
differences. There were several issues related to medication assisted treatment on which opinion
varied across both provider (medical and counseling) and client (methadone and bup/nal) groups.
Support. All respondent groups were asked how various supporting groups (physician
and medical providers, counselors, local communities, clients themselves, family and friends)
were doing in meeting the needs of people who suffer from opioid dependence. Bup/nal clients
were more likely than methadone clients and CDPs to respond that their physicians and medical
providers were doing well at addressing their needs.
Both the CDPs and the bup/nal clients perceived the counselors in a better light than the
medical providers and methadone clients. It stands to reason that CDPs would rate their part of
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the treatment process higher and bup/nal clients tended to agree. Bup/nal clients rated their
family and friends more positively than did all other groups, although methadone clients also
rated their family and friends as doing better than did the medical providers or CDPs did.
Both methadone and bup/nal clients were united with a higher assessment of how clients
themselves were responding than the paid professionals (medical providers and CDPs). Each
group rated themselves the highest in responding to the needs of those affected. Counselors felt
counselors responded better, medical providers thought medical providers responded better, and
clients felt they did better. A natural bias is demonstrated.
Helpfulness of treatment component. Opioid treatment programs have other components
besides just medication dosing and medication management, so respondents were also surveyed
about various components of the treatment process and asked how helpful they were. Those
components identified and surveyed included medication, counseling, accountability via
monitored urine drugs screens, 12-step support, and combinations of the four components listed.
All respondent groups were asked about the helpfulness of the various components of the
treatment process.
Counseling. Counseling was viewed as helpful by all respondent groups. However,
methadone clients and medical providers saw counseling as significantly less helpful than both
the bup/nal clients and CDPs.
Medications. All groups rated medications as helpful or very helpful. However, the
CDPs mean scores for helpfulness of medications were significantly lower than those of the
medical providers and both the methadone and bup/nal clients.
The 12-step support and accountability urine analysis. The 12-step support and
accountability urine analysis components were generally viewed as less helpful. Methadone
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clients viewed these two treatment components as less helpful than medical providers, CDPs,
and bup/nal clients. Methadone clients did rate accountability with urine drug screening as
somewhat helpful, but this was significantly lower than the medical providers, CDPs, and
bup/nal clients. These differences may be related to how methadone clients more frequently felt
judged, criticized or stigmatized at self-help support groups.
Urine drug screens and 12-step support both had methadone clients as lower in
helpfulness than the other three groups. Methadone clients felt urine drug screens and 12-step
support groups were less helpful than the bup/nal clients and the two professional groups.
Methadone clients in particular reflected a view that 12-step support groups were not helpful.
The traditional 12-step support groups of Alcoholics Anonymous, Narcotics Anonymous,
represent the primary self-help support that many clients in substance abuse treatment programs
attend as a part of their treatment program. Probation officers and the legal systems that clients
are involved with often mandate attendance at these AA/NA meetings. Even though clinicians
and providers see them as helpful components of recovery, methadone clients have reported
feeling negatively judged, criticized, and generally marginalized at these self-help meetings.
Component combinations. When the 12-step support and urine analysis accountability
were combined to include counseling and medications, all groups rated the pairing of these
components as helpful; however, the methadone group again differed from the other three groups
with a lower helpfulness rating. The last treatment option combined counseling, medication, and
accountability via urine drug screens, and these results indicated that both methadone and
bup/nal groups viewed this combination as less helpful than the CDP and medical provider
groups.
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Communities. The lowest ratings for all groups related to how respondents felt their local
communities were doing at responding to their needs. The two professional groups, medical
providers and CDPs, saw the local community response to this epidemic as not doing very well.
The methadone and bup/nal groups’ perception of community response was only slightly higher,
leaving a lot of room for improvement in their community’s response.
My experience has been that those outside the field of study continue to judge and
marginalize those who are afflicted, especially for clients in methadone. This is evidenced by
the lack of understanding of the disease process, and conservative approaches that tend to
moralize opioid dependence as a “choice.” Communities are resistant to allowing opioid
treatment programs to get licensed, and public hearings in this process bring out the opposition to
an expansion of services that are meant to help. Professionals in the field understand and
experience this lack of community support
Considered clean on medications. One statement asked if clients should be considered
“clean” or drug free if they were on opioid replacement medications like bup/nal and methadone.
While medical providers, methadone clients, and bup/nal clients agreed to this notion at mean
scores that were consistent with each other, the CDP group was less likely to agree that people
on these medications were clean. Although clients use these terms in responding to themselves,
narrative responses made the point that the clean and dirty terms were words that only
marginalized clients seeking treatment and recovery and that some thought these terms should be
abolished from use in the field of medication assisted treatment. Results were also consistent
with the thinking that medication assisted treatment participants were somehow not fully seen as
successful because of the use of medication to aid in this process. CDPs were, however, less
likely to agree with that statement as compared to medical providers, methadone, and bup/nal
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clients. People who are not in the substance abuse treatment field might agree with this
statement; however, for trained addiction treatment specialists to hold these beliefs and attitudes
toward clients on medication is troubling. Is this how clients are looked at while following their
approved treatment regimens? The results suggest that the substance abuse counselor continues
to agree to language that marginalizes and judges clients as they are trying to help in the
recovery from opioid dependence. If the CDPs do not believe in the efficacy of the medication
and continue to see their clients as not being in recovery when they are on medication, then one
has to wonder what impact this has on clients who are using their counselors as guides in the
recovery process.
Length of time and time limits. Medical providers and CDPs were asked whether opioid
dependent clients should be allowed to stay on medications as long as needed and this was
followed by a question about whether medication assisted treatment should be time limited.
Medical providers, methadone clients, and bup/nal clients disagreed with the statement that
medication use in opioid treatment should be time limited, whereas CDPs agreed with this
statement. These groups consistently appear to be on opposite ends of the spectrum—clients in
treatment and their medical providers voice strong sentiment that clients should be on
medications for as long as the need, while CDPs’ attitudes are the polar opposite and
demonstrate support for medications being strictly time limited.
Each medication was also addressed separately. The first was methadone. Bup/nal clients
were not asked their opinions on methadone, and methadone clients were not asked for input on
bup/nal as it was thought best for clients to respond only to the medications they were currently
utilizing in their treatment programs. Both methadone clients and their prescribers
overwhelmingly felt that clients should be on their approved medication for “as long as needed.”
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The opposite trend was noted by the CDPs; their responses generally indicated that methadone
was good for detox, stabilization, and periods of time up to two years. Only a minority of CDPs
saw the need to allow clients to be on methadone for as long as they needed.
The identical pattern of response was noted for bup/nal. Clients and medical providers
overwhelmingly responded “for as long as needed,” whereas CDPs were looking for the use of
bup/nal in a time limited fashion, for detox or shorter term stabilization. Buprenorphine, a third
medication which is a variant of bup/nal, recorded the same patterns of response. A fourth and
less frequently used medication, naltrexone (Vivitrol), was also put to the length of time inquiry.
A word of note here is that a naltrexone injection, which lasts for 30 days but can also be taken
as a daily oral medication, is a pure opioid blocker and possesses no opioid properties.
Methadone and bup/nal clients had little working knowledge of this medication and therefore
were not polled. Again a majority of medical providers supported naltrexone’s use for as long as
needed in the recovery process while CDPs continued their consistent response rates that
included stabilization. A good portion of CDPs had no working experience with naltrexone and
a small percentage even responded that it could be used for detox purposes, a use that naltrexone
is contra indicated for.
Responses to time limits highlight the biggest threat to successful client outcomes.
Narrative responses also were consistent as many CDPs continued expressing concern over
medications and their beliefs that clients over the long run needed to be off all medications in
order to properly and fully recover. I do understand the CDPs’ thinking process on this measure
as they want complete and full “recovery” from this disease. However they differ in their views
from clients and medical providers on how to accomplish this.
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This length of time issue represents the most controversial and often discussed question
from not only medical professionals, CDPs, and clients but other professionals, the general
public, and family members. Many times I have heard challenges and negative comments on
how long clients should be able to stay on the medications that many times are helping them gain
and maintain their recovery from opioid dependence. It seems everyone has a strong opinion on
this issue and are willing to express and give free and often times unsolicited advice. Many
analogies have been offered, but when was the last time anyone asked you how long you had to
be on insulin for your diabetes, or blood pressure medication? The issues about the length of
time clients should take their medication is complex and not easily solved. Clients in medication
assisted treatment are individuals that have different pathways into addiction as well as different
pathways into recovery. Medications and medication management fall under the licensure and
scope of practice of medical professionals, but that does not stop friends, family members,
spouses, and clients’ counselors from sharing their opinions and expertise.
This finding supports the need for CDPs to get additional training on available
medications that are currently being utilized in the field of opioid dependence treatment services.
Long term goal of medication assisted treatment. The statement that the long term goal
of medication assisted treatment should be that clients are free from illicit opioids and all
medications used in the treatment process had the least support from medical providers. Both
methadone and bup/nal clients as well as CDPs were significantly more likely to agree that the
long term goal should be for clients to be off all medications. The CDP group agreed with this
way of thinking at levels significantly above all other groups.
Support for medication assisted treatment. There was across the board support for
medication assisted treatment. However, the medical providers and their clients agreed with the
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concept of medication assisted treatment at significantly higher levels than the CDP group.
CDPs also had higher levels of agreement that clients should be given the chance to get clean
without the use of medication. These results are consistent with the lower level of CDP support
for medication assisted treatment.
Who should be involved in making decisions about getting off medication. Another
primary issue is related to the views about who should be involved in the decision for clients in
opioid treatment programs to get off their medications. One might initially think that this
decision should be solely between the medical provider and the clients who are taking the
medications; however, other views were clearly possible. When asked for their level of
agreement about who should be involved in the decision to discontinue mediations from the
standpoint of physicians, counselors, clients in treatment, and family members the results were
curious. Methadone clients were less likely than medical providers, CDPs, and bup/nal clients
that physicians should be involved in the decision. CDPs were significantly less likely to agree
that counselors should have a say in discontinuing their medication. Methadone clients
consistently answered lower on several scales related to time on medications, and decisions to
get off medications. It appears that methadone clients sought more control and less outside
interference (even with their prescribing physicians) when it came to these central issues related
to time on medications. Further inquiry into this dynamic is worth noting and is a
recommendation for further research.
The highest level of agreement between all respondent groups was noted when asked
about clients having a say about when they should get off their medications. The CDP group had
less agreement than the clients that clients should be involved in the decision. Why would
CDPs, even though they agreed with the notion of client input, have less agreement than their
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clients about their input into discontinuing medication? This appears to reflect the attitudes and
beliefs held by CDPs that clients should only utilize mediations for shorter time periods, such as
for detox and stabilization.
Medical providers, CDPs, and clients in opioid treatment programs did not support family
member input into the decision of when to get off medications, although curiously bup/nal clinic
participants were more agreeable to family input.
Client feelings. As expected, clients, medical providers, and CDPs indicated they
thought that clients who participated in medication assisted treatment for opioid dependence are
negatively judged until they discontinue the use of medications. All groups had high levels of
agreement, however methadone clients had higher levels of agreement that they felt negatively
judged and marginalized for being on methadone. There remains a lot of work to be done by
providers and professionals in the field to advocate and educate others to combat these pervasive
and divisive attitudes that remain a daily constant to clients who are attempting recovery from
opioid dependence. If opioid dependence is truly an epidemic in this country and other places in
the world, then solutions will certainly include a wide acceptance of what researchers and
providers consider best practice. All surveyed groups, especially medical providers, view opioid
dependence as a chronic disease. Chronic disease by definition lasts for long periods of time, if
not for the lifetime. However a very pervasive attitude and many analogies and metaphors
indicate beliefs that opioid dependence is an acute condition.
Motivation to change. Another popular belief held by many hinges on the change
dynamic and motivation to change. Respondent groups were posed a statement that people on
medications are not motivated to get clean. All groups demonstrated some level of disagreement
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to that statement with the medical providers indicating stronger disagreement. Interestingly
however the CDP group disagreed less heartily.
Long term goal. Medical providers highly disagreed while CDPs highly agreed that the
long term goal of mediation assisted treatment was to be free from both illicit drugs and all
medications that assisted them in the process. It is clear that the attitudes and beliefs of the
professionals involved do not align and have implications for the clients they serve are
concerning. Imagine yourself a client in this scenario where your prescribing physician
encourages and supports you to continue your course of treatment and consults with you about
how the medications are working, with no mention of stopping or titrating off, but then as you go
into your counseling session your CDP asks about your long term goals, and asks how long you
think you need to stay on the medication, or worse yet, encourages you to discontinue taking it.
Clients may find themselves confused and uncertain about their recovery status. This small
scenario highlights the dilemma of having two professionals with very different attitudes about
one’s treatment and recovery program.
All groups shared agreement that they supported medication assisted treatment. CDPs
demonstrated lower levels of agreement. When asked whether clients should be allowed to get
clean without the use of medications, there were moderate levels of agreement by all groups, but
again the CDP group was more likely to agree with this statement. The implications are
enormous since it is the CDPs who must first assess for opioid dependence and then discuss
treatment options with clients before they are referred to the medical providers. In order to be
eligible for medication assisted treatment clients must have an official diagnosis by their CDP;
however, if the CDP holds the belief that the client should first have the chance to go to a
non-medication assisted treatment program then it stands to reason that some clients will not
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receive the proper treatment. This in turn could have negative consequences and in some cases
cause more harm than good. Determining which client is a good candidate for medication is a
difficult task. I would not want to be the CDP responsible for this decision and would prefer to
consult with a medical provider who has more training in medications. Scope of practice
continues to be an important part of this critical dialogue, and “staying in your lane” is an
important teaching when dealing with decisions that can affect a person’s health and wellbeing.
Conclusion
Opioid abuse and dependence is a public health threat and epidemic here in the United
States and requires a dedicated focus and leadership among health care providers. One aspect of
this battle deals with the solution driven practices that attempt to help those affected to overcome
their dependence on opioids. Medication assisted treatment services are well researched and
documented and this body of knowledge in the field of opioid dependence has been adopted as
best practice by the leading practitioners and agencies that are experts in the field (Volkow et al.,
2014b). The American Medical Association, Substance Abuse and Mental Health Services
Administration, and The American Society of Addiction Medicine have all adopted medication
assisted treatment as cutting edge accepted treatment practices in today’s landscape.
This study sought to shed light on the complexities of the treatment practices that take
place between the three primary participants in this important work. Research designed to
unpack the underlying beliefs and attitudes that guide best practice is important. The deep and
complex treatment practices that help medical providers, CDPs, and opioid dependent clients
require inquiry to help aid in this epidemic. Research findings that add to the body of knowledge
in the field of medication assisted treatment can be beneficial to all involved and lead to changes
in both policy and practice.
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Findings of this study help open the dialogue and bring professional discourse into the
continued conversations about opioid dependence and recovery. The challenge lies in making the
study findings aid all participants in the opioid treatment and recovery process and to examine
and reflect on their approaches in treating this chronic medical disease.
Medical providers represent leaders in the field in the fight to achieve recovery. Their
experience and education continues to evolve as they advocate for the use of new and advancing
medications in the struggle to overcome insidious dependence on opioid drugs and the personal
and societal harm inflicted by misuse, abuse, and dependence of both prescribed pharmaceuticals
and illicit opioids. Medications are only one tool that medical providers have at their disposal,
and even though research validates medication effectiveness, it cannot be viewed as the panacea.
Complicated issues never come with easy solutions, and medical providers must continue to
remain open in their thinking to counseling, 12-step support, spiritual guidance, and other helpful
components that clients and CDPs identify as helpful pathways into recovery. Medical providers
as leaders in the field must continue to work with other professionals to communicate,
collaborate, and cooperate in the opioid treatment and recovery process. As long as they continue
the conversation in a professional and respectful manner they will lead by example and work to
be part of the solution.
CDPs and addiction counseling specialists across the United States also play a critical
role in the well documented struggle for viable opioid treatment services and recovery from the
disease. CDPs have a leadership role that cannot be minimized or downplayed as they have been
tasked as professionals in their chosen field of study to have a major impact with clients who
suffer. CDPs often times have the most “face time” through one-on-one counseling relationships,
building trust, rapport, and respect from clients who are engaged in opioid treatment services and
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medication assisted treatments. Their vital and important impact on clients and the recovery
process requires continued vigilance, study, and a way to keep updated to best practices and stay
on top of the ever changing landscape of valid and credible treatment practices. This study’s
findings point to adopting some changes in beliefs, attitudes, and practice for CDPs as they are
challenged to move forward with solution driven services. Understanding their own experiences
and bias that they have internalized is crucial to their advocacy for recovery with their clients and
how they communicate with other professionals in the field of medication assisted treatment.
Full recovery cannot take place without CDPs recognizing their strengths and limitations. CDPs
have been educated and trained philosophically toward abstinence based paradigms. These
traditional paradigms are undergoing strain and stretching the understanding of CDPs who
struggle to meet the challenges that the use of opioid based medications plays in the recovery
process adds to the recovery dynamic. There remains much work to be done for CDPs to fully
accept the new landscape of opioid dependence, medication treatment, and recovery. As with the
medical providers, CDPs must continue to work with an open mindset and stay engaged in
professional discourse in order to collaborate and cooperate with other addiction specialists and
especially with the clients that are the core focus of their chosen profession.
Clients who suffer from this debilitating disease can teach us a lot about the pathways
into and out of opioid dependence. It is their voices, beliefs, and attitudes that require intense
focus and understanding because they have the most to gain and lose in the process of treatment
and recovery. The importance of client driven data cannot be overstated. Clients make up a
group of affected individuals whose struggles impact families, communities, and the greater
society. They must continue to be seen and treated as individual human beings. As such they
deserve the respect and care that any person deserves from a health care system. Many personal
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experiences and voices from opioid dependent individuals point to the negative judgment,
labeling, criticizing, blame, and debilitating marginalization by society. Clients are in need of
effective and helpful treatment and recovery services, and have embraced medications as a part
of the solution to their personal dilemmas. It is time for all providers to listen carefully to client
experience and opinion as they seek solutions to rebuild the shattered spirits, personal dignity,
and worth that many times opioid dependency has taken from them. Clients have a personal
responsibility in this process and must be open to guidance by those that have both received
education and training and also “been there done that.” They must also continue to communicate,
collaborate, and cooperate with the treatment professionals and take an active role in their
personal recoveries. It is only through working together that all parties will experience the rich
and rewarding experience of freedom and recovery.
Study Implications
The current study findings have far reaching and serious implications for all involved in
the field of medication assisted treatment and opioid dependence recovery. Opioid use disorder
constitutes a national health problem and continues to represent a current epidemic in the U.S
and around the world. The implications for each of the study groups are discussed below.
Medical providers. Medical providers face many challenges as they treat this complex
and progressive brain disorder. As a group they are at the forefront of the treatment process for
opioid dependent individuals. This study demonstrated the challenges that they as medical
providers face in their daily work. They often times are criticized for not getting clients off
medications, feel pressure from addiction counselors to reduce dose amounts, or discontinue
medication if clients are not in compliance with counselor or other components of the treatment
process. They must take the lead in educating their clients and the addiction specialists they
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work with in order to justify current best practice. Medical providers need to understand that it is
up to them to educate others involved with the treatment process about the importance of
properly assessing the valid use of medications throughout the treatment and recovery process.
They need to recognize the amount of misinformation that others have about the use of
medications in the treatment process and the amount of resistance and skepticism that their
clients face when involved in medication-assisted treatment. The implications this study holds
for medical professionals as well as the clients they serve and the counselors who guide the
recovery process is a model of fully integrated care. All groups need to understand and be open
to their own bias and be willing to challenge themselves to set these aside for the best interest of
the clients who suffer. The importance of having these groups work collaboratively cannot be
overstated. Medical providers need to ask far reaching questions about long term recovery and
how that is defined with or without medications. Medications do have limitations and they are
only one component of successful recovery; they are not a sliver bullet and the only pathway into
recovery. Medical providers are in a leadership role in this important and often times life
threatening illness, and as such have a responsibility to educate, advocate, and work with clients
and all who are involved in the treatment and recovery process.
Chemical Dependency Professionals (CPDs). CPDs and other substance abuse
counselors providing direct psychosocial counseling and support services to opioid dependent
clients represent a huge piece of the puzzle for opioid dependent individuals who are seeking
relief and recovery. CDPs have a significant influence on the clients they serve and as such must
recognize their scope of practice, role, experience, and expertise in the recovery spectrum. This
study demonstrated the divergence in attitudes that CDPs have with regards to the medications
being utilized by the client’s medical providers. CDPs need a better understanding of the
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research indicating the neuroplasticity of this chronic brain disease to fully comprehend the
complexities of opioid dependence and the proper and legitimate use of medications that help
clients achieve recovery. Based on study findings, CDPs could benefit from additional training
and education about both the effects, and effectiveness of available medications, as well as on
the nature of the addicted brains and the damage created by opioid abuse. A focus toward the
best interest of their clients, possibly in some cases, less reliance on their own personal
experiences of recovery could help bridge the gap that is evident between CDPs and medical
providers. CDPs have a substantial impact with clients and much to offer the field of medication
assisted treatment. They must work toward a more integrated care model of treatment and
recovery. Their role needs to be better understood and respected by the medical field as they help
clients work toward long term goals, to cope with the negative responses they experience, and to
a full and successful recovery. CDPs are helpers and as such want the best for their clients, they
see recovery potential in each person they work with, and must recognize each individual’s
pathways into recovery vary. A possible fourth leg of the stool recognizes the importance of
family being involved in the education, treatment and recovery process and future research could
provide some focus and recommendations in this important arena. Full acceptance of medication
to assist and treat opioid dependence appears a lofty challenge to all CDPs, however continued
insistence on dogmatic approaches that include complete and total abstinence as the criteria for
recovery in the light of medical research findings are dangerous and destructive for some clients.
CDPs must challenge themselves to new ways of thinking and familiarize themselves with
current research literature on opioid dependence, in order to break free from the limitations of
their original training and experience that includes complete and total abstinence as the criteria
for recovery.
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Clients recovering from opioid dependence. Client voices and their recovery from opioid
dependence remain the most important single factor in this dialogue. This study demonstrated the
importance of giving clients their voice as it relates to their own individual recovery. They
literally are in the middle of the divergent approaches to help from the professionals. At the
same time they experience negative responses from their family members, friends, and others.
Clients who suffer from opioid dependence are clearly helped by medications, with the aim of
healing their damaged brains. They are the ones that need to be at the center of the discussion
about what works best for each individual’s success. Clients who have been and continued to be
negatively judged and marginalized for having this substance use disorder sometimes have
difficulty acting confidently or competently enough to act in their own best interest. However it
is in the clients’ best interests that they are factual and honest in their presentation to themselves,
providers, and friends/family. It remains a tall order for recovering people to take personal
responsibility in their recovery process, including their medications, counseling, and other forms
of support in order to fully recover. Diversion of medications, continued relapse with
pharmaceutical medications, and illicit drugs, are all issues that clients must face and overcome
in order to demonstrate integrity in their personal recoveries and gain the trust of their providers.
Study Limitations
There are several limitation to this study. It was difficult to identify, contact and get
medical providers to respond to the survey. Thus, the sample size of N = 43 fell short of the
study goal. Medical providers’ work settings were primarily outpatient bup/nal providers and
more methadone clinic providers could have made results more robust, providing for the
possibility of comparing bup/nal and methadone medical providers. The survey instrument had
not been used in a previous study and data were self-reported and thus subject to bias. Results
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reflect a particular demographic area of the United States and may not generalize to other areas,
countries, or cultures.
The sample population was from the Pacific Northwest geographic region of the United
States, specifically, Washington State, and thus might not be representative of other geographical
areas. Since the survey was designed and first tested in this study, reliability and validity are yet
to be established until the current study is replicated. There also remains the possibility of
missing data as some participants carefully considered and answered all questions while others
may have been hasty in their responses.
Future Research
Future research is indicated in several key areas of medication assisted treatment for
opioid dependence. Clinical trials of medications continue to dominate the landscape of research
in the field; however, what is lacking is deeper understanding of clients, CDP, and medical
provider attitudes and bias as they relate to opioid treatment and recovery. What is indicated is
further inquiry into how the clients and providers (both medical and psychosocial) view the
process of treatment solutions and define what recovery means and what it looks like in today’s
landscape. An additional and important area of inquiry would be to study family members,
friends, and community attitudes about medication assisted treatment. Families and communities
can play an important role in supporting and contributing to clients’ treatment and recovery.
More qualitative inquiry could enhance deeper understandings of both the challenges and
solutions by any of these three groups. Each supported finding is worthy of independent study.
Issues related to length of time on medications, goals of opioid treatment and recovery, helpful
components of the treatment process, and especially negative attitudes held about opioid based
medications that assist the recovery process, are all directions for future researchers to conduct
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studies in order to add to the ever growing body of knowledge in the mediation assisted
treatment field.
Families and community members also have a role to play in addressing the opioid
dependency epidemic. Survey research for these groups, similar to the study of medical
providers, CDPs, and clients would also add to the conversation and help in the search for
solutions.
Recommendations
The recommendations that come from the current study are not confined to a simple set
of criteria; however, the complexities of both the process that leads to a very negative impulsive
and compulsive use of opioids and the process leading to change and recovery are evident. It is
important that each of these three important groups that is involved in solution based activities
come together to practice integrated care. No groups have the one right answer, but collectively
they possess the power, knowledge, and experience necessary to overcome this devastating
conditions that effects millions. Easy solutions to complex problems rarely exist, and in the field
of opioid dependence recovery utilizing medications to assist in the process constitutes the
biggest advancement in the field over the past 60 years. With the addition of newer medications
recently approved and adopted for practice, the recommendations for continued study, analysis,
and shifting of paradigms for the “old” way of doing things in the addiction treatment field is
paramount. We must keep focus on best practice and successful client outcomes to truly inform
how providers, clients, and substance abuse counselors continue to move forward in the field of
medications assisted treatment. This will only happen through treatment outcome data as
providers and the programs they work for track client success and the components of care that
were both helpful and not helpful.
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Scientists and researchers also need to help in this challenge by continuing their
dedicated work in the fields of pharmacology, neurobiology, and brain chemistry in order that
they lead the way and inform the field of addiction medicine as to best practices.
Recommendations going forward from this research study include but are not limited to:
x

Mandated education classes as part of any core curriculum for the certification of
chemical dependency licensing on “medication assisted treatment”;

x

Required continuing education (CEUs) for medical providers, chemical dependency
counselors, and other professional working in the social science fields on opioid
dependence, recovery, and medication assisted treatment;

x

More research focused on the deeper qualitative dynamics of the opioid treatment and
recovery process;

x

Continued advocacy and voice at the policy level for substance abuse prevention and
treatment, especially as it relates to opioid abuse and dependence;

x

Community education campaigns that help educated the general public about the field
of medication assisted treatment, overcoming myths and misconceptions, and
advocating for the expansion of opioid treatment programs and services for those that
suffer from this chronic disease process;

x

Work to mandate a true “integrated care” model of medication assisted treatment
between medical provides, CDPs, and the clients they both serve; and

x

Continue the medical and scientific work and research in order to understand the
neuropathways involved in the addiction process, and how the brain is in effect
hijacked by our use of pharmaceutical medications, and illicit drugs.
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Epilogue
My role as a leader in the area of substance abuse treatment and counseling was evident
to me from the very first year that I entered personal recovery from substance abuse over 29
years ago. My journey was to not only help myself overcome the demons and life shattering
experiences that I encountered but also to leave the treatment and recovery field better than I
found it. I felt that sharing my story, and personal experience, strength, and hope would
demonstrate leadership by modeling. I knew through personal experience that leadership in those
I admired, respected, and followed was a style that was more modeled by example than by
words. Respect is a huge part of leadership and being able to gain that with family members,
peers, and other leaders was how I carried myself. At the time I did not realize what I know
today and that is the journey to both my personal healing and recovery and my leadership ability
and focus represented a side-by-side process of change. During my life’s darkest time, something
others describe as an emotional, physical, and spiritual bottom, I was consoled by a future
mentor and leader who reassured me that change was simple and that all I would have to do was
change ONE thing, and I thought what a relief I can do that, but after a long pause he said
“everything.” A change in my thinking, my feeling, and my entire way of being was indicated if
I was to undergo the transformation from a broken drug addict to a true leader. The leadership
potential was a value system that was embedded in me from my early upbringing in a small rural
Nebraska community. Those that came before me taught and inspired me to be an independent
thinker, to never give up, and to be interested in others, to give back, and to be a lifelong learner.
My PhD in Leadership and Change began not as a professional goal and a stepping stone
to enhance my professional career, but rather as a deep personal goal to validate my potential and
resilience as a person. I entered into this program very familiar with the change process because
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as stated above I had undergone a personal transformation over the previous 20 years and as a
result experience the personal freedoms associated with the promises of recovery. A personal
mantra that ensued was taken directly from one of my guiding references, the Big Book of
Alcoholics Anonymous, which stated:
If we are painstaking about this phase of our development, we will be amazed before we
are halfway through. We are going to know a new freedom and a new happiness. We will
not regret the past nor wish to shut the door on it. We will comprehend the word serenity
and we will know peace. No matter how far down the scale we have gone, we will see
how our experience can benefit others. That feeling of uselessness and self-pity will
disappear. We will lose interest in selfish things and gain interest in our fellows.
Self-seeking will slip away. Our whole attitude and outlook on life will change. Fear of
people and economic insecurity will leave us. We will intuitively know how to handle
situations which used to baffle us. We will suddenly realize that God is doing for us what
we could not do for ourselves. (pp. 83–84)
And so the promises were personally manifested in my life, which led me to pursue my doctoral
degree in this program at Antioch University in leadership and change.
While working in the substance abuse field I occupied many important leadership
positions within a local Native American reservation as the Lummi people adopted me into their
ways and practices. They allowed me to humbly direct youth leadership treatment and recovery
programs, help build and enhance residential programs like the Lummi youth academy and the
Se>eye>chen youth residential treatment program, as well as my current position as Director of
the Lummi Healing Spirit Clinic. I have been allowed the honor of supervision and leading staff
teams that included from 20–45 professionals. In my certification as a CDP I also aspired to
leadership roles in my educational and scholarly pursuits. Most CDPs do not go beyond a two
year associate degree in their training and certification process. I set my goals in leadership to
gain a PhD as a CDP, which is something very few do. I felt that this would position me to be
able to make the most impact in my field on inquiry and place me in a leadership role and
continue my advocacy in the helping field. This PhD program in leadership and change has
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afforded me all of those opportunities and more. My hopes and dreams as I graduate from this
program is to humbly and respectfully carry the message to those who still suffer from not only
substance abuse problems but life challenges as well. There is strength in change, and personal
fulfillment in leadership. Many thanks for those individuals that inspired, motivated, supported,
and guided me in my journey.
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Appendix D: HSC Permission

LUMMI COUNSELING SERVICES
Dr. Adam Kartman M.D. Medical Director
2616 Kwina Road, BELLINGHAM, WA 98226
(360) 380-7121

Antioch IRB

FAX: (360) 384-2350

August 11, 2015

RE: Healing Spirit clinic OTP Survey

Dear Sir or Madam:

Opiate dependence is a local, state and national problem. The number of opiate related deaths has
tripled over the past 3 years. In Washington State it represents the number one cause of death for the
age group 21-39.

I have been working in the opiate treatment field for the past decade and have personally witnessed the
devastation the affliction of opiate dependence causes individuals, their families and the community

Traditionally Opiate Treatment Program (OTP) clinics have utilized the medication methadone, however
with the recent approval of other medications the field of opiate dependence treatment has been
expanding. Buprenorphine/Naloxone (Suboxone) was approved by the FDA in 2004 for OTP clinics and
office base practice as well. Lummi’s OTP providing Buprenorphine/Naloxone and Naltrexone, but not
methadone is unique.

Many past and current research designs have documented positive outcomes due to the use of
medications in opiate treatment programs. It is now considered best practice to utilize medications to
assist opiate addicts in their recovery process. The addition of medication to counseling therapy is
referred to as Medication Assisted Treatment (MAT).
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However in the field of opiate treatment there still remains controversy and concern among patients,
their families and counselors about medication assisted treatment. There is work to be done to inform
and educate people to the benefits of combining patient accountability through drug testing, counseling
and medication assisted treatment.

I fully support conducting a survey of opiate dependent clients in our clinic in order to learn more about
underlying attitudes and beliefs about treatment services and medication. This information can be a
benefit in improving services. As long as the information collected is anonymous and confidential, there
should be no risk of harm to anyone. Clinic counselors will be available to talk with any survey
participants as the need arises in case of any negative feelings or reactions.

Thanks for your attention in this important matter. Please feel free to contact me if you have any further
questions.

Dr. Adam Kartman M.D
Lummi Healing Spirit Medical Director
360-739-5168 (cell & voice mail)
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